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Summary 
 
Introduction: Tuberculosis (TB) is a leading cause of morbidity and mortality in South Africa. 
Whilst clinical parameters are important objective outcomes in TB, they are often not directly 
correlated with the subjective well-being of the patient which can be assessed using patient- 
reported outcome (PRO) measures. Health-related quality of life (HRQOL) is a specific PRO 
of multi-dimensional nature, which includes physical, mental and social health domains. 
Furthermore, HRQOL may be associated with medication adherence. The thesis evaluates 
HRQOL and its association with medication adherence in TB in South Africa. 
Methods: A systematic review on HRQOL and adherence in TB was conducted. Based on the 
findings, a conceptual framework for HRQOL in TB was developed as a basis for identifying 
PRO measures, and to generate an endpoint model. The two generic measures SF-12 and 
EQ-5D-5L, the respiratory-specific measure St. George´s Respiratory Questionnaire (SGRQ), 
the condition-specific measure Hospital Anxiety and Depression Scale (HADS) for HRQOL 
and  well-being  assessment  and  the  Morisky  Medication  Adherence  Scale  (MMAS)  for 
adherence  assessment  were  finally  selected.  All  these  measures  were  applied  in  an 
observational, longitudinal, multicentre study at five data collection time points during the six- 
month standard TB treatment. Eligible patients were older than 18 years, new TB cases and 
were diagnosed without HIV co-infection. Change over time in the Physical Component Score 
(PCS-12) of SF-12 was defined as primary endpoint. Sample size estimation based thereupon 
has led to a recruitment target of 96 patients. Statistical analysis included significance testing, 
correlations, univariable and multivariable analysis, and repeated measures ANOVA. 
Results: A total of 131 patients participated in the study. Whilst HRQOL was impaired in all 
physical, mental and psycho-social health domains at the start of standard TB treatment, it 
improved significantly, and in a clinically meaningful manner, during the course of treatment. 
The greatest improvement in average mean score from baseline to six-month treatment 
(+95%)  was  observed  in mental health.  Younger  patients with  higher  education  and  in 
employment  reported  a  better  HRQOL.  Adherence  mean  scores  stayed  constant  with 
participants attaining a medium average level throughout the treatment course. Associations 
between HRQOL and adherence were mainly weak, and included a positive relationship with 
improvements in anxiety and depression, pain and discomfort, and psycho-social health 
aspects after six months of treatment. 
Discussion: This was the first longitudinal study in South Africa which evaluated HRQOL and 
its association with medication adherence in TB following a patient-centred and integrative 
approach. The study demonstrated the need for an integrative understanding of TB with 
HRQOL as one of the core elements to inform gaps in current TB management. In addition to 
an adequate drug treatment, the management of TB should also include services that focus 
on mental and psycho-social needs of the patient. 
 
x 
Conclusion: An understanding about patient-reported HRQOL in TB treatment should support 
the identification of sustainable health innovations in TB, help determining the value of new 
products, and support decision making with regard to health policy and pricing. In addition, an 
integrative patient-centred approach can contribute towards supporting the Sustainability 
Development Goal 3 target and the End TB strategy of the World Health Organization. 
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Preface 
 
In 2016, the United Nations (UN) introduced the Sustainable Development Goals (SDGs) to 
replace the Millennium Development Goals (MDGs) (WHO, 2015d). The MDGs were 
established during a Millennium Summit at the turn of the century to address global inequalities 
in wealth, health, gender, and education and promote environmental stability and greater 
global partnership for development, with the target to reach these goals by 2015. The SDGs 
comprise 17 goals, among them the third SDG (SDG3), a specific goal with focus on health 
including 13 targets. SDG3 aims to ensure healthy lives and promote well-being for all at all 
ages and aims to reach this goal by 2030 (WHO, 2015d). One of the ambitious targets within 
SDG 3 is to end the epidemic of tuberculosis (TB) by 2030 (WHO, 2015d). Another equally 
ambitious target focuses on universal health coverage, including access to safe, effective, 
quality and affordable essential medicines. Providing access to affordable medicines requires 
an understanding of the efficacy and cost-effectiveness in order to allow efficient decision- 
making in a health system. Evidence of both efficacy and cost-effectiveness are required for 
the evaluation of the benefit of treatment for the patient which should also consider the 
patient´s perspective. Further to this, the World Health Organization (WHO) has stated that 
patient involvement in their health care is a social, economic and technical necessity (Doward 
et al., 2010). 
The disciplines of Pharmacoeconomics and Outcomes Research engage in the evaluation of 
patient-reported perspectives of disease. They contribute to a comprehensive understanding 
of the burden of disease and the effectiveness of treatment. One specific patient-reported 
outcome is health-related quality of life (HRQOL). The concept of HRQOL is applied in 
developed countries such as the UK to assess the performance of the National Health Service 
(NHS) (Appleby, 2005). The improvement in HRQOL is an important outcome for the NHS 
patient-centred approach to monitor performance. Furthermore, the concept of HRQOL is often 
considered in cost-effectiveness analysis. A challenge in applying a patient-centred approach 
in healthcare is the lack in standardization of the application of patient-reported outcomes. 
However, knowledge of HRQOL assessment can support the health system with information 
on health needs, quality of care, effectiveness of healthcare products under real-life conditions, 
and clinical thresholds. For developing countries such as South Africa, efficient health system 
performance is essential in order to handle the burden of diseases. With the introduction of a 
National Health Insurance (NHI) system in South Africa providing universal health coverage 
for all there is a need for an evidence-based approach to evaluate cost-effective and patient- 
valued medical interventions to be included in the NHI. 
This work is structured in eight chapters. Chapter 1 introduces the topics of patient-reported 
16  
outcomes, HRQOL and adherence in general, followed by information on tuberculosis and its 
treatment. The overall research aim and specific research objectives are presented in chapter 
2. Chapter 3 provides a brief overview on South Africa as country this work is focused on. 
Chapter 4 presents a systematic review on HRQOL and adherence in TB. Based on the 
findings from the systematic review, the study design and methodology of a longitudinal study 
were developed as described in chapter 5. Chapter 6 and 7 report the results of the longitudinal 
study. A chapter summarizing all references and an appendix including supplementary 
information complete the thesis. 
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1. Introduction 
 
 
1.1 Patient-reported outcomes measures – an evidence- 
based tool 
 
1.1.1 Introduction and definition 
 
Demonstrating clinical efficacy, safety and quality of new treatments have been the three 
hurdles in the pharmaceutical drug development process in order to gain regulatory approval 
and market authorization. They have also been the basis for pricing and reimbursement 
discussions. Although clinical endpoints, such as arterial blood pressure in hypertension and 
blood sugar in diabetes, are informative they may not clearly translate to patient meaningful 
outcomes such as symptom benefit, improved emotional functioning, improved health-related 
quality of life (HRQOL) and overall well-being (Deshpande, 2011). Outside of the clinical trial 
environment, comprehensive healthcare and disease management should not only include 
physiological indicators but also an assessment of subjective well-being. Disease and 
treatment of disease influence the perception of health and well-being (Dhuria et al., 2009). 
Different stakeholders of a health system such as regulatory agencies, payers, pharmaceutical 
companies and healthcare professionals have realized this issue and have added a focus on 
real-world effectiveness and cost-effectiveness. These additional requirements are directly 
related to a patient-centered approach in healthcare. The difference between efficacy and 
effectiveness is that efficacy observes a treatment under artificial and controlled clinical 
conditions while effectiveness assess a treatment under real-life circumstances; therefore, 
effectiveness often leads to different outcomes compared to efficacy results. The patient 
perspective is observed with patient-reported outcomes  (PRO) measures which provide 
evidence that the outcome is important to the patient with regard to survival, function and 
feelings (Patrick, 2013). The data obtained from PROs generate value propositions beyond 
clinical, physiological, and biochemical data to inform about disease and treatment impact on 
functioning and overall well-being (Deshpande, 2011, Doward et al., 2010, Acquadro C, 
2003b). This follows a humanistic approach in health. The terminology PRO was first 
introduced in 2000 at the US Food and Drug Agency (US FDA); the term was later formalised 
in 2006 when the FDA released draft guidance on PROs and later in 2009 with the final 
guidance which provided their definition of PROs: 
"Any report of the status of a patient’s health condition that comes directly from the patient, 
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without interpretation of the patient’s response by a clinician or anyone else.” (FDA, 2009) 
However, earlier than the U.S. FDA, the European Medicines Agency (EMA) provided following 
definition of PROs: 
"Any outcome based on a patient’s perception of a disease and its treatment(s) scored by the 
patient himself is called a Patient-Reported Outcome (PRO). PROs are a large set of patient- 
assessed measures ranging from single item (e.g., pain VAS, overall treatment evaluation, and 
clinical global improvement) to multi-item tools. Multi-item tools can be mono-dimensional 
(e.g., measuring a single dimension such as physical functioning, fatigue, and sexual function) 
or multi-dimensional questionnaires measuring several of the following: symptoms, functional 
status, satisfaction, well-being, or health-related quality of life (HRQL). In general terms, PROs 
provide information on the patient’s perspective of a disease and its treatment." (European 
Medicines Agency, 2005). 
 
 
1.1.2 Application of PROs 
 
PROs can be applied at many different stages in the drug development process and 
evaluation. For example, PROs are often included in clinical trials and real world evidence 
studies to assess efficacy, effectiveness and efficiency in order to evaluate the benefit and 
utility of medical treatment from the patient perspective. The evidence from PRO data can 
therefore be used for regulatory approval, pricing and reimbursement discussions and post- 
marketing. 
 
Drug Development 
 
PROs are often used during drug development and in particular during the clinical phase, to 
evaluate efficacy. During the translational or pre-investigational phase of the development of 
a new drug they can  be used to  gain better understanding of the natural history and 
characteristics of a disease and of disease symptoms; to define sub-populations, as well as to 
support the planning of clinical trial design and data analysis and interpretation of trial data 
(Patrick, 2013). Before PROs are applied in clinical trials, they can be used to support the 
recruitment process of eligible participants for clinical trials (Patrick, 2013). 
 
Clinical trials (Phases I-III of clinical drug development) 
 
Although PROs can be implemented in any of the three phases of clinical drug development, 
they are generally reserved for Phase II and Phase III clinical trials. During the clinical trial 
design and development phase, PROs can be incorporated into the endpoint strategy as 
clinical endpoint to support efficacy and safety. Some studies include PROs as primary or co- 
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primary endpoint. However, most studies implement PROs as a secondary or exploratory 
endpoint to generate evidence for the added value of a drug or device and to support 
biochemical endpoints (Doward et al., 2010). Information obtained from clinical studies is 
mainly used to define a medical need, meaningful treatment benefit, to demonstrate superiority 
against a comparator treatment or current standard care; and to gain more information on 
adverse events related to the intervention (Doward et al., 2010). Therefore, PROs are often 
applied in comparator studies rather than in placebo controlled trials, where the investigational 
treatment is compared against an active comparator/standard care rather than against 
placebo. Active comparator studies are known as comparative effectiveness research (CER). 
 
Regulatory Approval 
 
The clinical data and results obtained from clinical trial efficacy evaluation are compiled in a 
pharmaceutical dossier for regulatory evaluation and approval for market authorization, and 
act thereby as an evidence-based approach for labeling claims. Some countries such as 
Germany require clear definition of superiority of new drug application (NDA) compared to 
standard care in order to grant market approval (Ruof et al., 2014). Guidance on the use of 
PRO instruments to support product label claim has also been issued by U.S. FDA (FDA, 
2009). Unlike the U.S. FDA, the European Medicines Agency (EMA) has not issued a formal 
guidance but has released a reflection paper providing recommendations on the use of 
HRQOL PRO instruments and supplementary guidance in context of disease-specific 
guidance documents (European Medicines Agency, 2005); best practice and industry 
guidelines on the development and use of PRO instruments (Rothman, 2009, SACMOT, 2002) 
are also available  (Patrick, 2007, Acquadro C, 2003b, Doward et al., 2010). 
 
In 2011, the U.S. FDA introduced the term clinical outcome assessment (COA) to underline 
the importance of PROs but also of clinician (ClinRO) and observer reported outcomes 
(ObsRO) and performance outcome (PerfO) measures (Patrick, 2013). Regulatory 
qualification of clinical outcome assessments (COA) has been undergone at U.S. FDA known 
as U.S. FDA Clinical Outcome Assessment Qualification Program. The COA qualification 
program concludes if the COA is reliable and well-defined and if it measures a specific concept. 
The EMA has introduced the European Regulatory Issues on Quality of Life Assessment 
(ERIQA) (Acquadro C, 2003b). Both agencies  are currently attempting to have greater 
harmonization in their process of qualitative review of clinical outcomes assessments (COAs) 
(Patrick, 2013). In 2013 the U.S. FDA has further expanded the role of the patient in the drug 
development process by the term patient-centered outcome and committed to the Patient- 
Centered Drug Development Initiative (Patrick, 2013). Between 2013 - 2017 the agency will 
obtain patient perspective on different therapies and disease areas (Patrick, 2013). 
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Post-marketing Phase (IV) 
Effectiveness is usually assessed in post-marketing studies under real-life conditions and is 
often used to inform treatment guidelines (Acquadro C, 2003b). However, efficiency can be 
evaluated during efficacy studies by including self-reported utility PROs capturing the 
economic aspects of a treatment and  modeling the economic effects resulting in cost- 
effectiveness outcomes. Evidence-based PRO data inform healthcare providers and payer 
about qualitative effective and affordable treatment options and support them in their decision 
making e.g. in pricing & reimbursement (FDA, 2009, European Medicines Agency, 2005). 
 
 
1.1.3 Value of PROs for Key Stakeholders 
 
PROs are of interest to a variety of different stakeholders within the health system. Each 
stakeholder applies and/or draws different information out of PRO data. The pharmaceutical 
industry uses PRO information for differentiation strategies and for label claims (Gnanasakthy, 
2013). Regulatory agencies apply PRO data for granting approval and market authorization of 
healthcare products which show an added benefit to the patient. Based on adequate PRO 
data, health technology assessments (HTA) agencies can determine benefits and added value 
of medical interventions for health policy making as well as for establishment of medical 
guidelines (Bresnahan and Rundell, 2014); Australia, Canada and a number of European 
countries such as Germany and UK have local HTA agencies and a number of emerging 
countries are considering the introduction of formal HTA bodies to support health policy 
decisions. PRO data are considered in reimbursement decisions with regard to cost- 
effectiveness and inform payers. On a global level, 65% of the payers see data derived from 
peer-reviewed publications as more critical in their decision making process than PRO label 
claims (Reasner, 2015). In addition, the validation of PRO measures in country specific 
populations is of importance for payers. For example, in Germany, a new healthcare product 
has to show an additional benefit to achieve a price premium (Reasner, 2015). Physicians and 
health care professionals interpret treatment efficacy and effectiveness differently than a 
patient, as physicians and health care professionals may underestimate severity and 
overestimate treatment improvement. PRO allow an understanding of level of impairment, 
disability and patient satisfaction (Doward et al., 2010). 
 
 
1.1.4 Psychometric properties of PROs and their conceptual 
framework 
The impact of disease and treatment on a patient´s daily life can only be observed when PROs 
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reflect meaningful aspects which are relevant to the patient (Acquadro C, 2003b). Such 
information goes beyond counting of events and in combination with clinical data it provides 
valuable and unique information about disease and treatment impact (Acquadro C, 2003b). 
These meaningful aspects reflect the face and content validity, as well as the psychometric 
properties of the PRO instrument within a specific concept and context of use. The underlying 
concept measured in the PRO covers different health-related domains, dimensions and items 
in a conceptual framework. The conceptual framework is a graphical description of 
relationships among concepts, domains and items (Burke, 2008, Doward et al., 2010), as 
shown in figure 1. An example for a conceptual framework is given in 1.2: 
 
 
 
Figure 1: General conceptual framework of PRO measures. The general conceptual 
framework consists of concept, domains and items. 
 
The conceptual framework of a PRO instrument is mirrored in the endpoint model of clinical 
studies by mapping endpoints to treatment benefit and appropriate claims (Burke, 2008). 
Depending on the type of instrument, the concept of interest may vary. Such concept of interest 
may comprise physical functioning, symptoms, psychological well-being, social well-being, 
cognitive functioning, role activities, work productivity, personal constructs, patient satisfaction, 
patient preferences, adherence to treatment, clinical trial outcomes, and health-related quality 
of life (PROQOLID, Deshpande, 2011, Doward et al., 2010, Acquadro C, 2003b). 
 
 
1.2 Health related Quality of Life (HRQOL) as PRO concept 
 
The concept of health-related quality of life (HRQOL) is strongly related to the definition of 
health by the World Health Organization (WHO) defining health as “a state of complete 
physical, mental and social well-being and not merely the absence of disease or infirmity” 
(WHO 1948). A health system should aim to improve health and HRQOL of a population 
22  
(eunethta, 2013). One specific PRO concept which is more widely applied in clinical trials is 
HRQOL. 
HRQOL is a multi-dimensional concept which may include physical, psychological and social 
domains (figure  2). Each domain consists of dimensions (such as physical functioning, 
emotional distress, and social interactions). Each domain being measured may comprise of 
single or multiple items (single question, statement or task). These domains, individually and 
collectively, evaluate the impact of a health condition and its treatment in daily life as well as 
health perception by the patient (eunethta, 2013, Apalone, 2001). It is thereby also a patient- 
relevant endpoint (eunethta, 2013). HRQOL assessment allows thereby an integrated 
evaluation of treatments beyond clinical parameters; physical health includes physical 
functioning, mobility, self-care, and usual activities; psychological health comprises cognitive 
functioning, emotional distress and anxiety and depression; social health focuses on the quality 
and quantity of social interactions and contacts (eunethta, 2013). 
 
 
 
Figure 2: Health-related quality of life (HRQOL) concept. HRQOL concept comprises physical, 
mental, social domains and a domain for the health care intervention. 
 
 
Clinical parameters, such as mortality and morbidity, are seen to delivery insufficient 
information about the full impact of a medical intervention (Aggarwal et al., 2013, eunethta, 
2013). The integration of health perception through the patient respects the subjective health 
status perceived independently from objective disease parameter (Apalone, 2001). When a 
medical intervention does not target survival, an intervention-related improvement in HRQOL 
may have comparable importance as efficacy endpoints (eunethta, 2013). Health-related 
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emotional and social burden can be equal or even exceed the physiological impact of a disease 
(Dhuria et al., 2009). Consequently, HRQOL allows a benefit assessment (gains and losses) 
during clinical and epidemiological studies (eunethta, 2013). According to the European 
Network for Health  Technology Assessment (eunetHTA) and its published guideline on 
HRQOL and utility  measures (2013), the objectives of HRQOL  assessment include (1) 
epidemiology of HRQOL (description of health status of a population), (2) assessment of 
relative effectiveness of a product, (3) cost-utility assessment of a product, and (4) informing 
clinical decision making (eunethta, 2013). 
Together with morbidity and mortality, HRQOL is one of the patient-relevant endpoints in 
clinical trials and pharmacoeconomic evaluations (eunethta, 2013). Both the USA (through US 
FDA) and the UK (through the National Institute of Health and Care Excellence / NICE) 
incorporate  HRQOL  as  a  PRO  in  their  decision-making  process  when  appraising  new 
technologies. The EMA disease-specific guidelines frequently request PRO endpoints ranging 
from symptoms to quality of life data to be included as key secondary end-points. From 81 final 
clinical guidance documents, available from EMA in 2010, 39 guidelines specified PRO 
inclusion as either primary (n=5), secondary (n=22) or both (n=12) trial endpoints (Doward et 
al., 2010, European Medicines Agency, 2005). The U.S. FDA approved 11 drug products and 
EMA 18 drug products based on HRQOL as primary endpoint, only 3 products used HRQOL 
as non-primary PRO label claim in the US (Gnanasakthy, 2013). A majority of these products 
were approved prior to the release of the PRO guidance through the U.S. FDA. 
HRQOL measures have to be based on an appropriate framework which includes relevant 
health-related domains (Bottomley et al., 2009). This approach ensures that clinical variables 
are linked to HRQOL outcomes in an a priori hypothesized manner (Apalone, 2001). The 
conceptual framework of HRQOL includes physical, mental and social domains, which consist 
of single items depending on the respective HRQOL instrument. Figure 3 shows the general 
conceptual framework of HRQOL. 
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Figure 3: Conceptual framework of health-related quality of life (HRQOL) based 
on the definition of health by WHO. 
HRQOL can be applied as tool for public health surveillance systems. The U.S. Department of 
Health and Human Services has implemented the initiative Healthy People 2020 and uses 
HRQOL to monitor the public health surveillance in order to reach their goals for Healthy 
People 2020 (CentersforDiseaseControlandPrevention, 2016). HRQOL can be applied to 
generate a spectrum of information to support health systems in their performance. It is an 
indicator for health service needs and for intervention outcomes. HRQOL supports  the 
measurement of health insurance coverage and of the quality of health services and health 
care, and supports the identification of health policy and legislation needs. HRQOL facilitates 
the allocation of healthcare resources based on unmet needs. Using HRQOL for 
monitoringeffectiveness of different interventions can guide the development of strategic plans 
and can track efforts to promote equity in health (CentersforDiseaseControlandPrevention, 
2016). 
 
 
 
1.2.1 Critical aspects about HRQOL 
 
There are some critical aspects about HRQOL. HRQOL reflects the subjective perception of 
health. Since patients with the same health status value their HRQOL differently, there may be 
high inter-individual variability within a defined group of patients. Furthermore, different 
HRQOL measures may give different results and make a comparability of outcomes between 
different instruments not always possible. Additionally, outcomes vary with different population 
groups. One of the methodological issues is that a number of different HRQOL measures have 
been developed, evaluated and applied with little standardization. Different types of HRQOL 
measures differ in their objective of application such as generic, disease-specific and utility 
measures. 
 
 
1.2.2 Types of HRQOL measures 
 
Different types of HRQOL measures are known: profile and summary measures, generic, 
disease-specific or condition-specific, and utility measures. Profile or summary measures are 
descriptive and apply a scoring system in form of a scale: binary (yes/no), ordinal (7 point- 
Likert) or continuous (visual analogue scale) (eunethta, 2013). Generic HRQOL instruments 
are applied to a broad range of indications and health problems, since they cover general 
aspects of HRQOL (eunethta, 2013, Deshpande, 2011, Doward et al., 2010). Generic HRQOL 
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measures allow comparison of HRQOL across different disease populations and general 
population norms (where they exist) and are often applied to inform health policy maker about 
allocation of resources (eunethta, 2013). Disease-specific or condition-specific measures are 
applied in a specific disease or health condition and thereby allow comparison within a specific 
indication. A systematic use of generic HRQOL instruments in all diseases supports consistent 
value judgment and transparency, for example in reimbursement decisions (eunethta, 2013). 
Disease-specific measures are more sensitive to changes than generic instruments and of 
greatest interest for patients and clinicians because of their increased relevance. Disease- 
specific HRQOL information is complementary to generic HRQOL measures, also when no 
effect was observed with generic measures. 
A specific type of generic or disease-specific measures is used for health state preferences 
(utility) measurement. Such measures generate utilities by preference-based or choice-based 
methods representing patient or general population preferences for a health state. Utilities can 
be generated directly or indirectly; direct methods generate utilities from patients directly using 
time-trade off (TTO, choice-based), standard gamble (SG, choice-based) or visual analogue 
scale (VAS, preference-based). Utilities generated are used to calculate common-used utility 
outcomes such as quality-adjusted life years (QALYs) for cost-effectiveness and cost-utility 
evaluations. A commonly used basis for the calculation of utilities measure is the European 
Quality of Life-5 Dimensions instrument (EQ-5D) (eunethta, 2013). 
 
 
1.3 Medication adherence 
 
The World Health Organization has defined inadequate medication as a major problem for 
management of chronic diseases (WHO, 2003). Non-adherence to treatment of chronic 
diseases has a negative effect on clinical effectiveness, morbidity, causes medical and psycho- 
social complications, increases health care costs (direct and indirect costs) and reduces 
HRQOL (Cramer, 2008, WHO, 2003). The WHO have stated that increased medication 
adherence might have a greater impact on a populations health than any improvement in 
specific medical treatments (WHO, 2003). 
Medication adherence is a complex, multi-dimensional, dynamic phenomenon comprising the 
patient behavior with regard to taking a drug at the prescribed interval, dose, and dosing 
regimen as  well as  quality of how medication  is taken  (Cramer, 2008, Hughes, 2007). 
Medication adherence is “the process by which patients take their medications as prescribed” 
(Vrijens et al., 2012). It comprises the initiation of the treatment (first dose), implementation of 
the prescribed dosing regimen, discontinuation of the therapy (end of therapy), and persistence 
(time from initiation  until discontinuation) (Vrijens  et al., 2012, Lam and Fresco, 2015). 
Medication adherence is crucial to reach clinical targets and the causes of non-adherence are
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multi-factorial (Lam and Fresco, 2015, Fairman, 2000). Since adherence affects the 
effectiveness of medical interventions and their outcomes, effective and efficient treatment 
requires the identification of factors that contribute to non-adherence (Saleem, 2012). Major 
factors impacting medication adherence behavior are known (figure 4); these factors include 
therapy-, condition-, health system- and patient-related factors (Wilke et al., 2011, WHO, 
2003). 
 
 
 
Figure 4: Causal factors impacting medication adherence. These factors comprise patient- 
related, therapy-related, condition-related and health system-related factors. 
 
 
All six factors described in figure 4 can influence medication adherence. The direct 
associations between medication adherence and some factors have already been studied in 
German patients with chronic diseases taking regular medication and with patients taking 
thromboprophylaxis after orthopedic surgery (Wilke et al., 2011). This study showed that 
medication non-adherence was lower when people have positive medication beliefs, positive 
mood and a positive doctor-patient relationship (Wilke et al., 2011). 
An ideal measure to assess overall adherence to medication including initiation, persistence, 
implementation and discontinuation does not exist; therefore a multi-measure approach may 
be considered where direct and indirect adherence measures are combined (Fairman, 2000). 
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Direct measures such as drug determination in biological fluids or direct patient observation 
are often regarded as being the most reliable and accurate approaches. However, individual 
changes in drug metabolism and multidrug intake affect monitoring of plasma levels, and 
patient observation is limited to inpatient settings and clinical trials (Fairman, 2000, Nguyen et 
al., 2014, Lam and Fresco, 2015). Indirect measures comprise medication monitoring (such as 
pill counting) and self-reported measures; however, medication monitoring is cost intensive 
and self-reported measures may be less reliable due to patient recall, underreported non- 
adherence and memory bias issues (Fairman, 2000, Lam and Fresco, 2015, Stirratt et al., 
2015). On  the other hand, self-reported adherence measures  are cost-effective, with a 
minimum burden to the patient, and easy to administer. Each adherence measure has its 
advantages and disadvantages and the selection of adherence measures depends on the 
attributes, research objectives and available resources of each study (Lam and Fresco, 2015). 
 
 
1.4 Tuberculosis 
 
 
1.4.1 Disease characteristics of Tuberculosis 
 
Tuberculosis (TB) caused by the mycobacterium tuberculosis is an infectious disease (Bauer 
et al., 2013, Kittikraisak et al., 2012, WHO, 2016). Transmission of TB between humans is 
through airborne route by droplet nuclei, usually through coughing, sneezing, talking or singing 
(NDoH, 2014). TB affects mainly the respiratory system involving the lung parenchyma 
(pulmonary TB), but can also attack the remaining body known as extrapulmonary TB (e.g. 
pleura, lymph nodes, abdomen, genitourinary tract, skin, joints and bones, meninges). 
Individuals with diagnosed latent TB are not infectious. Suppressed immunity such as in HIV 
increases the probability to develop active TB (NDoH, 2014). Symptoms of pulmonary TB 
include a persistent cough of more than two weeks that brings up phlegm, which may be 
bloody, breathlessness, which is usually mild to begin with and gradually gets worse, lack of 
appetite and weight loss, a high temperature of 38ºC or above, night sweats, extreme tiredness 
or fatigue, unexplained pain for more than three weeks (NDoH, 2014). 
 
 
1.4.2 Global disease burden of tuberculosis 
 
TB remains one of the top 10 causes of death worldwide. One third of the world population is 
infected with mycobacterium tuberculosis, having a latent TB, and 10.4 million people felt ill 
from TB in 2015 (WHO, 2016). About 1.8 million died from TB including 400,000 cases with 
HIV co-infection, and 60% of the TB cases occur in six countries worldwide: China, India, 
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Indonesia, Nigeria, Pakistan, and South Africa (WHO, 2016). More than 50% of all HIV co- 
infections in TB are found in Southern African countries. The rate of new TB cases has slowly 
remained at 1.5% from the year 2014 to 2015. In the year 2015, about 450,000 cases had a 
multi-drug resistant TB (MDR-TB). The End TB Strategy of the WHO targets to reduce the 
prevalence and mortality rate of TB by 50 percent by 2015 and to achieve a prevalence of 1 
case in 1 million population per year by 2050 (Mamani et al., 2014, WHO, 2016). 
 
 
1.4.3 Diagnosis of Tuberculosis 
 
Diagnosis of TB relies mainly on self-presentation of individuals with TB symptoms to a health 
care facility which requires awareness about TB as disease among communities. Diagnostic 
tests applied include smear microscopy, culture, and polymerase chain reaction (PCR) based 
assays such as Line Probe Assay and Xpert, as recommended in South Africa (NDoH, 2014). 
X-rays may be applied in diagnostic testing of TB. However since many diseases mimic TB on 
x-rays, they are only applied in patients who cannot produce a sputum sample or who may 
have a negative sputum but are HIV positive (NDoH, 2014) Usually, patients have to provide 
sputum smear for first diagnosis; sputum smear microscopy determines acid-fast bacilli (AFB), 
the most common of which is M. tuberculosis. This microscopy testing is quick compared to 
AFB culture which can take days or weeks. A sputum smear positive outcome confirms the 
existence of AFB, most probably tuberculosis. A smear negative test result can either mean 
symptoms are not related to mycobateria including M. tuberculosis or it may mean 
mycobacteria were not present in sufficient concentration for detection. Treatment is initiated 
after sputum smear confirmation. 
 
 
1.4.4 Treatment and monitoring of Tuberculosis 
 
The aim of disease treatment is to improve patient functioning by reducing disease progression 
and severity (Chassany, 2002). About 87 percent of TB patients can be cured with appropriate 
and effective treatment (WHO, 2016, Kittikraisak et al., 2012). Without treatment, 70 percent 
of pulmonary TB cases die within 10 years. Standard treatment of new TB cases is a six-month 
drug regimen with four antibiotics (rifampicin, isoniazid, ethambutol and pyrazinamide). All four 
antibiotics are administered orally during the first 8 weeks of treatment (intensive phase), 
followed by rifampicin and isoniazid for additional four months (continuous phase). Different 
from standard TB treatment is the treatment of MDR-TB. Patients with MDR-TB who show 
resistance against rifampicin and isoniazid have to undergo at least 20 months of treatment 
with expensive and toxic drugs (e.g. amikacin, kanamycin). Mismanagement of individuals 
receiving MDR-TB treatment may lead to extensively drug-resistant TB (XDR-TB) (NDoH, 
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2014). 
Side effects may develop under standard TB treatment. Side effects may comprise following 
symptoms: burning, numbness and tingling sensation in the feet, joint pains, anorexia, nausea, 
abdominal pains, skin rash with/ without itching, changes in the colour of urine, impaired vision, 
yellowing of eyes, confusion (NDoH, 2014). Monitoring of tuberculosis is essential to observe 
the treatment response. As no molecular TB tests have been validated  for monitoring, 
pulmonary TB is monitored clinically by body weight control and bacteriological by sputum 
smear probes. Cure from TB is determined by a negative sputum smear. 
 
 
1.5  HRQOL, medication adherence and tuberculosis 
 
Medication adherence can be associated with a patient´s self-perceived health status (physical 
and social functioning  as  well as  general health) as shown  in  patients who underwent 
percutaneous coronary intervention (Coehlo, 2013). Given a potential relationship between 
poor HRQOL and non-adherence, a better understanding of HRQOL and how to improve 
HRQOL of patients with specific diseases  may support the improvement of medication 
adherence (Kruijshaar et al., 2010). There are expectations that a strong medical adherence 
is associated to a good HRQOL and vice versa (WHO, 2003). The association between 
HRQOL and medication adherence has been studied rarely. One meta-analysis about 
qualitative studies examining adherence to TB treatment reported the association between 
well-being and adherence in TB to be based on two mechanisms (Munro S, 2007). The first 
mechanism is that TB patients stopped their treatment because they felt better in terms of their 
health and well-being. The reason behind is that patients perceived the improvement in well- 
being as a cure of TB. The second mechanism is that patients stopped treatment when they 
experienced no improvement in their health status and well-being or experienced a worsening 
in TB. Both mechanisms were based on qualitative studies examining medication adherence 
in TB patients. Still, only a few published studies assessed adherence to TB treatment in South 
Africa (Louw et al., 2012, Corless et al., 2009, McInerney et al., 2007, Munro S, 2007) and only 
one study observed an association between TB treatment adherence and HRQOL outside of 
South Africa in HIV co-infected people (Deribew A, 2013). It has been recommended to 
observe the relationship between HRQOL and medication adherence by applying a self- 
reported PRO measure (Saleem, 2012, WHO, 2003). 
 
 
1.6 Identified research gaps 
 
A literature review about HRQOL and adherence in TB was conducted in order to gain a 
comprehensive understanding of the current research in the field (Appendix Figure 1). 
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Including literature until February 2014 research gaps were identified and have led to the 
formulation of specific research objectives. According to the findings of the literature review, 
only two studies (Louw et al., 2012, Bauer et al., 2013) evaluated HRQOL in TB patients in 
South Africa. However, none of these studies included the Western Cape Province, which has 
the highest TB burden in South Africa. A study evaluating HRQOL during the course of 
standard TB treatment in the Western Cape Province of South Africa is lacking. The majority 
of identified studies evaluating HRQOL in TB patients followed a cross-sectional design (Atif 
et al., 2014a, Bauer et al., 2013); only a few studies followed a prospective longitudinal design 
to evaluate HRQOL in TB (Atif et al., 2014a, Marra et al., 2008, Kruijshaar et al., 2010, Maguire 
et al., 2009). However, a prospective study design evaluating HRQOL in active TB patients 
would allow insights into changes of HRQOL during different treatment phases (Bauer et al., 
2013) and might provide valuable information to the South African health setting. Only one 
study (Dhingra and Rajpal, 2005) worldwide developed a TB-specific HRQOL measure (DR- 
12) for the Indian health setting. However this TB-specific HRQOL measure has no proven 
validity and reliability. A validated TB-specific HRQOL instrument is lacking. According to a 
meta-analysis about HRQOL in TB by Bauer et al (Bauer et al., 2013) qualitative evaluations 
of HRQOL are not available but would provide valuable information to health care providers 
about patients' experiences and needs in specific health care settings. Although studies of 
medication adherence in TB are available, none have evaluated the association with HRQOL 
aspects. 
 
 
 
2. Research aims and objectives 
 
Specific research questions were elaborated based on the identified research gaps. The 
research gaps comprised factors including  the need for further research on the patient 
perspective and patient´s HRQOL, lack of a TB-specific PRO instrument, and the need for 
quantitative research on medication adherence in TB patients. Furthermore, despite the fact 
that South Africa is one of the 22 high TB burden countries with one of the highest prevalence 
and incidence rates in TB worldwide, there is a lack in research about HRQOL and adherence 
in TB. Based on these factors, following research questions were elaborated: 
• How does pulmonary TB affect patients HRQOL in the South African health setting, 
with focus on the Western Cape Province, which has the highest TB burden in South 
Africa? 
• What outcomes would provide a longitudinal study design of HRQOL evaluation? 
• Since no TB-specific HRQOL measure is available, can HRQOL in TB be evaluated 
with other available generic and disease-specific measures? 
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• Is there an association between HRQOL and medication adherence in TB? 
• Does a combination of different PRO measures applied reflect a potential conceptual 
framework for pulmonary TB and do they comprise TB relevant psychometric 
properties? 
 
The research questions based on identified research gaps lead to the following research topic: 
Health-related Quality of Life and its association to medication adherence in active pulmonary 
TB patients in South Africa – an integrated patient-centred outcomes approach. 
 
 
2.1 Aim 
 
The overall aim of this PhD research program was to understand the impact of pulmonary TB 
on HRQOL, considering physical, social and mental health dimensions, and the association 
between HRQOL and medication adherence in TB in South Africa. 
 
 
2.1.1 Specific research objectives 
 
Thereby the PhD program intended to develop a comprehensive understanding on how 
changes in HRQOL during TB treatment affect the health status of a patient by following 
hypotheses and hypothesized relationships: 
• To understand the current state of knowledge regarding the impact of TB on HRQOL 
and medication adherence to TB treatment (Table 1) 
• To evaluate HRQOL in active pulmonary TB patients, receiving standard TB treatment, 
using a combination of generic and disease- and condition-specific HRQOL measures. 
These HRQOL measures have shown validity and reliability in TB or in a disease with 
characteristics that are closely related to TB (most preferably chronic obstructive 
pulmonary disease (COPD)). Hypothesized relationships between HRQOL and socio- 
demographic data and  clinical data (sputum smear results) were planned to be 
assessed (Table 1). 
• To evaluate adherence to anti-TB standard treatment in active pulmonary TB patients, 
using a patient-reported adherence measure with shown validity and reliability in TB. 
Hypothesized relationships between medication adherence and clinical data (sputum 
smear results) were planned to be assessed (Table 1). 
• To investigate hypothesized relationships between HRQOL and medication adherence 
in active pulmonary TB patients receiving standard anti-TB treatment (Table 1). 
 
Table 1 presents the research objectives as research hypothesis. 
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Table  1:  Overview  of  main  research  objectives.  Research  objectives  are  presented  as 
research hypothesis and sub-hypothesis. 
 
 
 
Hypothesis Sub-hypothesis 
Patients  suffering  from  pulmonary   TB  •  Patients suffering from pulmonary TB experience a 
experience a decreased HRQOL in a physical, decreased HRQOL in a physical, social and mental 
social   and   mental   health   manner   which health manner. 
improves as clinical TB data improve due to anti- • HRQOL improves as clinical TB improves due to anti- 
TB treatment over time. There is a hypothesized  TB treatment over time. 
relationship between improvement in HRQOL 
and improvement in clinical TB data over time. 
Socio-demographic background of the patient HRQOL  is  different  in  socio-demographic  subgroups  as 
with regard to gender, age, education, work following: 
status and co-morbidities impacts the HRQOL 
in TB. • Women experience a worse HRQOL than men 
There is a hypothesized relationship between • Older people tend to have poorer HRQOL in TB than 
HRQOL and socio-demographic characteristics  younger people 
in TB patients. • Patients with higher education experience less impact 
on HRQOL in TB 
• Patients working and receiving a financial income have 
a better HRQOL 
• Patients suffering from co-morbidities report a worse 
HRQOL subgroup 
As  medication  adherence  to  TB  treatment Patients with high medication adherence have a better 
decreases treatment effectiveness declines with treatment effectiveness which is reflected in improved 
regard  to  clinical  data.  Patients  with  high clinical data of sputum smear results. Adherence to anti- 
medication adherence have a better treatment TB treatment decreases over time. 
effectiveness which is reflected in improved 
clinical data. Adherence to anti-TB treatment 
decreases over time. 
There is a hypothesized relationship between 
medication adherence and clinical data in TB 
patients. 
HRQOL and medication adherence affect each There is an association between HRQOL and medication 
other. There is an association between HRQOL adherence  in  TB  patients,  with   two   underlying 
and medication adherence in TB patients. mechanisms: 
• As HRQOL   improves medication   adherence 
decreases 
• as  HRQOL  worsens  or  has  no  change  since 
treatment start medication adherence decrease 
Patients with depression and anxiety are hypothesized 
to have lower medication adherence 
 
 
33  
3. Country where the research was performed: 
South Africa 
South Africa is one of the largest and most advanced economies on the African continent. It is 
a middle-income country with a population of 54.96 million people and a GDP of US$ 312.8 
billion (TheWorldBank, 2016). The growth of the GDP expected for 2016 is 0.4% 
(TheWorldBank, 2016). South Africa has one of the highest inequality rates in the world, with 
a Gini index (dispersion of income or wealth in a country) of 0.66 to 0.7 as reported by the 
World Bank in 2016 (TheWorldBank, 2016). The country faces a quadruple burden of diseases 
including perinatal and maternal health disorders, communicable diseases, non- 
communicable diseases (NCDs), and violence-related injuries (Mayosi et al., 2009). 
Communicable diseases such as HIV/AIDS, TB and malaria cause the highest burden among 
the disease burden in South Africa, with TB being a health problem with epidemic proportions 
(WHO, 2016, Cramm JM, 2010, McInerney et al., 2007). The national mortality rate in TB was 
133 per 100,000 population in 2015 (WHO, 2016). The case fatality ratio (estimated mortality 
/ estimated incidence) in TB in South Africa was 0.22 in 2015 (WHO, 2016). In international 
comparison, the incidence rate is highest in South Africa with 834 new cases per 100,000 
population and a total of 454,000 official cases in 2015 (WHO, 2016) (figure 5). 
 
 
 
 
 
Figure 5: Incidence rate of TB in South Africa between 1990 and 2015 (WHO, 2015c). 
 
 
 
About 20,000 MDR-TB cases out of 580,000 new MDR-TB cases worldwide were recorded in 
2015 in South Africa (WHO, 2016). TB treatment is a challenge since the presence of HIV and 
related antiretroviral (ARV) treatment exacerbate the risk for TB as a result of 
immunosuppression (McInerney et al., 2007). Approximately 73% of all TB patients are also 
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diagnosed HIV positive. South Africa is one of the countries with a relative high rate of missed 
TB cases; either not diagnosed or diagnosed but not reported. About 90% of all new and 
relapsed TB cases have a pulmonary TB manifestation (WHO, 2016) Universal health 
coverage covered treatment of 63% of all TB patients in South Africa. 
Based on the latest epidemiological data provided by City Health, City of Cape Town, the 
highest TB incidence in Cape Town (Western Cape Province) is found in the sub district 
Khayelitsha. 
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4. Health-related quality of life and its association 
with medication adherence in active pulmonary 
tuberculosis– a systematic review of global 
literature with focus on South Africa 
 
This article has been published in the BMC Journal Health and Quality of Life Outcomes 
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4.1 Abstract 
 
Introduction: Tuberculosis (TB) is a leading cause of morbidity and mortality in South Africa. 
Clinical parameters are important objective outcomes in TB; however they often are not directly 
correlated with subjective well-being of the patient, but can be assessed using patient-reported 
outcome (PRO) measures. Health-related quality of life (HRQOL) is a specific PRO generally 
multi-dimensional in nature and includes physical, mental and social health domains. The 
inclusion of HRQOL PROs in trials and clinical practice can provide additional information 
beyond clinical and microbiological parameters. Furthermore, HRQOL may be associated with 
medication adherence. This review focuses on patient-reported HRQOL and its association 
with medication adherence in TB patients in South Africa. 
Methods: A comprehensive search strategy was developed focusing on the impact of TB on 
patient-reported HRQOL, the existence of a conceptual framework of TB-specific HRQOL, 
determinants of medication adherence, and the association of HRQOL with medication 
adherence. Data were extracted from all identified articles and additional data extraction was 
performed by two independent reviewers with special focus on longitudinal studies in order to 
understand changes of HRQOL and adherence over time. Research gaps were identified with 
regard to patient-reported HRQOL and medication adherence. 
Results: A total of 66 articles met the  eligibility criteria. Ten HRQOL  studies  and one 
adherence study used a longitudinal design, none of these in South Africa. A variety of different 
generic and disease-specific HRQOL measures were identified in the articles. In South Africa 
four HRQOL and five adherence studies (non-longitudinal) were published. Similar factors 
(socio-demographic, socio-economic, disease-related, therapy-related, and psycho-social 
aspects) affect HRQOL and adherence. Although standard TB treatment improved all health 
domains, psychological well-being and social functioning remained  impaired in 
microbiologically cured patients after treatment.  
Conclusion: While evidence of TB impact on HRQOL and medication adherence and their 
association exists, it is very limited for the South African situation. No valid and reliable TB-
specific HRQOL measures were identified in this systematic review. An assessment of 
HRQOL in TB patients in South Africa is required as this may assist with improving current 
disease management programmes, medication adherence and national treatment guidelines. 
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4.2 Introduction 
 
The global burden of tuberculosis (TB) is still a major public health concern although the 
United Nation´s Millenium Development Goals (MDGs) target to reverse TB incidence by 2015 
has been achieved. Around 9.6 million new TB cases and 1.5 million TB deaths were estimated 
to occur in 2014 worldwide (WHO, 2015c). Twenty-two high-burden countries defined by the 
World Health Organization (WHO) account for 80% of all TB cases. Despite the availability and 
affordability of effective TB medication South Africa has the highest prevalence and incidence 
rates (696 and 834 cases per 100,000 population) among these countries (WHO, 2015c) TB 
is South Africa´s leading cause of mortality (134 cases per 100,000 population). TB is known 
to impact health-related quality of life (HRQOL) (Bauer et al., 2013, Chang B, 2004, Guo et al., 
2009). Effective treatment, relapse and the emergence of multi-drug resistant TB (MDR-TB) 
are closely related to TB treatment adherence and consequent HRQOL (Munro S, 2007). The 
assessment of an association between both, HRQOL and medication adherence in TB, would 
provide valuable information on treatment effectiveness, optimal disease management and 
health policy making. 
Patient-reported outcomes (PRO’s) provide unique evidence of different aspects of the 
experience of living with a disease or condition and how important these aspects are to 
patients. In this sense, they go beyond clinical parameters and respect the integrated nature 
of health, ideally encompassing physical, mental and social well-being. The measurement of 
HRQOL using PRO’s allows for a multidimensional understanding of health, an evaluation of 
disease and treatment impact on the health condition and the patients’ daily life. It is strongly 
related to the World Health Organization's (WHO's) definition of health as “a state of complete 
physical, mental and social well-being and not merely the absence of disease or infirmity” 
(WHO, 1948). A comprehensive knowledge of HRQOL in TB patients can allow for 
identification of treatment gaps. Addressing these gaps will lead to improvement of health care 
services and disease prevention strategies, and support health policy making. A number of 
countries such as the UK, Germany and Australia rely on PRO data about medical 
interventions for pricing, reimbursement and health policy decision-making about medical 
interventions. South Africa is becoming increasingly aware of the importance of such outcome 
evaluations and has released its first guidance on pharmacoeconomic submissions in 
February 2013 (NDoH, 2013). The aim of this systematic review was to understand HRQOL 
and medication adherence during TB treatment and how both concepts are associated based 
on international literature. Longitudinal studies were of particular interest to understand 
changes in HRQOL and adherence during the course of TB treatment. The focus of this 
research lies on active pulmonary TB and not on latent TB (LTBI), MDR-TB, XDR-TB, TB in 
children or TB with HIV co-infection, as these types of TB show different HRQOL outcomes 
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(Brown et al., 2015). As South Africa suffers from a major TB burden, we put a specific focus 
on HRQOL and adherence to TB treatment in the South African health setting. 
 Keywords 
 
Health-related quality of life, medication adherence, tuberculosis, patient-reported outcomes, 
South Africa 
 
 
4.3 Review 
 
 
4.3.1 Methods 
 
Search Strategy for identification and selection of relevant studies 
A systematic literature search has been performed in PubMed, EMBASE and PsychINFO, with 
the last search conducted on 22 February 2015. Search terms applied included tuberculosis, 
health related quality of life, HRQOL, quality of life, South Africa, patient-reported outcomes, 
outcome assessment, life quality, well-being, adherence, non-adherence, and compliance; 
different combinations were used (Table 1 in the Appendix). Each search term combination 
resulted in different initial hits which were screened by title and abstract. Articles were excluded 
if they were not related to the pre-defined search terms or were published in a language other 
than English. Duplicates were removed. The full texts of all remaining articles were reviewed. 
References cited by the identified publications were additionally scanned for relevant studies. 
Data on TB and adherence was additionally taken from the WHO and the Department of Health 
of the Republic of South Africa. Data from articles with a longitudinal study design were 
separately extracted and included when psychometric validity and reliability were reported for 
HRQOL or adherence measures, when changes in HRQOL during TB treatment including at 
least baseline and end of treatment were reported, and when the study population consisted 
of new TB cases treated as outpatients. 
 
Data Quality and Data Extraction 
Data from all identified articles was extracted and structured according to physical, mental and 
social health aspects of HRQOL; data on medication adherence was summarized. Research 
on HRQOL and medication adherence in South Africa was described separately. In addition, 
studies with a longitudinal design were subject to a separate; subsequent data extraction 
performed by two independent reviewers. This additional extraction covered the PICOS 
elements (P = population, I = intervention, C = comparator or control, O = outcome, S = study 
design), with additional items covering major research topic, study objective, study setting, 
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sample size, PRO measure applied, and measurement time points. Prior to data extraction, all 
longitudinal studies underwent quality assessment. As longitudinal studies were observational 
in nature, quality of reporting was evaluated using the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) statement (Bauer et al., 2013). A STROBE 
quality checklist with 8 items was applied, with scores ranging from 0 (no quality) to 16 (best 
quality) (Bauer et al., 2013). 
 
 
4.3.2 Results 
 
Our literature search in PubMed, EMBASE and PsychINFO yielded 988 initial hits. After 
screening by title and abstract and after removal of duplicates, 61 articles remained. An 
addition of three WHO reports, two guidelines from the South Africa´s Department of Health 
and one article identified by hand search of citations resulted in 67 eligible articles for this 
systematic review. One article was excluded, yielding 66 eligible full-text articles (Figure 6). A 
detailed description of the literature search is available in the Appendix. The 66 articles 
comprised 22 cross-sectional studies, 17  longitudinal studies, 7  (systematic) reviews, 8 
qualitative studies and 12 articles including editorials, comments and letters. Nine studies were 
performed in South Africa (four HRQOL and five medication adherence studies; Table 4 in the 
Appendix). All final 66 articles underwent extraction of information about HRQOL and 
adherence in TB. The 17 identified longitudinal studies were potentially eligible for separate 
data extraction; 11 of them actually met the eligibility criteria for separate data extraction, while 
6 studies were excluded as eligibility criteria were not met (Table 3 in the Appendix). 
Application of the STROBE quality of reporting checklist to the 11 longitudinal studies resulted 
in a median score of 7 for HRQOL studies, with scores ranging from 5 to 11 out of 16 (the 
greater the score the higher the quality of reporting). The adherence study had a score of 10 
(Table 3 in the Appendix). 
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Figure 6: Flow diagram of literature search. Literature search process was conducted in the 
databases PubMed, EMBASE and PsychINFO; additional articles were obtained from World 
Health Organization and Department of Health Republic of South Africa. 
 
TB impact on HRQOL 
The systematic review found that TB has a negative impact on patients' HRQOL and overall 
wellbeing (Masumoto et al., 2014, Aggarwal et al., 2013, Babikako et al., 2010, Rajeswari et 
al., 2005, Chang B, 2004, Hansel NN, 2004). Factors associated with HRQOL in TB included 
socio-demographic (age, gender) and socio-economic (income, education, housing, social 
security) factors, disease-related (symptoms) and therapy-related (side effects, adverse 
events) factors, and psycho-social aspects (isolation and stigmatization, psycho-social burden) 
(Adeyeye et al., 2014, Masumoto et al., 2014, Aggarwal et al., 2013, Bauer et al., 2013, 
Deribew A, 2013, Dias et al., 2013, Ralph et al., 2013, Awaisu et al., 2012, Balgude and 
Sontakke, 2012, Chung et al., 2012, Kittikraisak et al., 2012, Louw et al., 2012, Othman, 2011, 
Aggarwal, 2010, Guo et al., 2010, Dhuria et al., 2009, Guo et al., 2009, Guo N, 2008, Marra et 
al., 2008, Chamla, 2004, Hansel NN, 2004, Marra et al., 2004). There was some evidence to 
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suggest that amongst TB patients, psycho-social burden may have a greater impact than 
clinical symptoms (Chang B, 2004, Hansel NN, 2004). The results of this literature review 
identified that TB treatment resulted in a significant improvement in HRQOL, especially in 
physical and psychological dimensions (Aggarwal et al., 2013, Bauer et al., 2013, Ralph et al., 
2013, Awaisu et al., 2012, Balgude and Sontakke, 2012, Louw et al., 2012, Othman, 2011, 
Guo et al., 2009, Guo N, 2008, Chamla, 2004). The improvement in HRQOL was greatest 
during the first 2-3 months (intensive treatment phase) (Bauer et al., 2013, Othman, 2011). 
The results also revealed that although a patient was defined as microbiologically cured 
following successful treatment, morbidity still existed due to anatomic and functional changes 
of the lung at treatment completion (Ralph et al., 2013, Pasipanodya et al., 2007b, Weis and 
Pasipanodya, 2010, Muniyandi et al., 2007). Specifically, a state of chronic morbidity continued 
which resulted in health quality loss that differed for developing countries with regard to their 
socio-demographic and -economic situation (Diel and Lampenius, 2014, Miller et al., 2009, 
Pasipanodya et al., 2007a). It was also noted that the assessment of HRQOL has currently not 
been integrated into the WHO guidelines for TB treatment, national guidelines or TB control 
programmes (Atif et al., 2012a). An important consideration from the results of the review was 
that patient-reported HRQOL outcomes may differ after the end of treatment depending on the 
HRQOL measures applied as different measures may measure different concepts (Aggarwal 
et al., 2013, Chung and Li, 2013, Balgude and Sontakke, 2012, Kruijshaar et al., 2010, Guo et 
al., 2009, Dion et al., 2004). 
 
TB impact on Physical Health 
TB impacts physical health, resulting in impaired physical functioning, development of fatigue, 
adverse events of treatment and increased use of health care services. Major physical 
impairment was reported through somatic symptoms and other TB related physiological 
outcomes (Awaisu et al., 2012, Guo et al., 2009, Chang B, 2004, Hansel NN, 2004). The 
impairment in HRQOL was worse in patients with HIV co-infection (Deribew A, 2013). Impaired 
physical functioning was closely related to the development of fatigue (Chang B, 2004, Hansel 
NN, 2004). The literature revealed that fatigue was triggered through sleep disturbances, 
coughing and malnutrition, and TB medication (Hansel NN, 2004). Drug-based treatment of 
TB impacted HRQOL in two ways. Whilst the TB treatment resulted in a significant 
improvement in HRQOL (Aggarwal et al., 2013, Bauer et al., 2013, Ralph et al., 2013, Awaisu 
et al., 2012, Balgude and Sontakke, 2012, Louw et al., 2012, Guo et al., 2009, Chamla, 2004), 
the drugs taken often resulted in adverse drug reactions which negatively affected HRQOL 
(Hansel NN, 2004). The greatest physical impact on HRQOL was caused by the large quantity 
of pills and the treatment duration, and a reduction in both was expected to improve HRQOL  
(Hansel NN, 2004). Health care services may have a negative effect on HRQOL through the 
relationship between healthcare worker and patient, especially due to a lack of knowledge and 
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misunderstanding about TB. This relationship was not only important for the degree of 
compliance with the current TB treatment guidelines, but also comprised emotional support 
and disease-related information through nurses (Dias et al., 2013, Atif et al., 2012b). 
 
TB impact on Mental Health 
The impact of TB on mental health related to psychological, emotional and spiritual wellbeing, 
and patients perception of their health. Psychological distress was commonly reported among 
TB patients (Peltzer K, 2012, Naidoo and Mwaba, 2010), with depression and anxiety being 
the most frequently reported mental disorders (Peltzer K, 2012, Aamir and Aisha, 2010), 
especially in TB patients diagnosed with post-traumatic stress disorder (PTSD) (Peltzer et al., 
2013). Besides depression and anxiety, feelings of anger were also reported (Hansel NN, 
2004). Psychiatric co-morbidity may increase the distress of physical illness, prolong recovery 
time, and may also lead to poor treatment compliance (Naidoo and Mwaba, 2010). 
Psychological distress may be caused by social stigmatization followed by social isolation 
during TB treatment and impacted financial situation (Peltzer K, 2012, Issa BA, 2009, Hansel 
NN, 2004). Mental disorder in TB patients was  associated with socio-demographic  and 
economic factors and in HIV co-infected TB patients also with stigmatization and perceived 
health status (Peltzer K, 2012, Deribew A, 2013); a misconception about TB including fear of 
dying, disease transmission, disease symptoms and treatment leads to lower cure and survival 
rates as the patient may act according to this misconception (Dias et al., 2013, Hansel NN, 
2004). Prevalence rates of depression and mental disorders among TB patients in low income 
countries ranged between 46% to 80% (Peltzer K, 2012, Aamir and Aisha, 2010). About 20% 
of non-adherent TB patients in Pakistan reported depression and anxiety after treatment 
completion and developed a multi-drug resistance (Aamir and Aisha, 2010). TB can also have 
an impact on caregivers. In Malaysia caregivers reported poor mental health and an increased 
risk of depression (Atif et al., 2013). TB may affect spiritual wellbeing. Patients in the USA 
experienced TB as a wake-up call which changed their lifestyle in a positive way. These 
patients stopped drinking alcohol, adopted a healthier lifestyle and became more concerned 
about their health (Hansel NN, 2004). 
 
TB impact on Social Health 
Diagnosis and treatment of TB can have an impact on social health including reduced social 
functioning and an increased financial burden as a result of stigmatization (Hansel NN, 2004). 
Social functioning often comprises roles at the workplace, in the community and within the 
family (Chang B, 2004, Hansel NN, 2004). The infectious nature of TB can lead to a stigma 
and disruption of social interaction with others, resulting in social isolation (Dhuria et al., 2009). 
TB-related stigmatization was often associated with stigma of HIV and AIDS (Naidoo and 
Mwaba, 2010, Van Rie et al., 2008). Many TB patients were unable to work due to the travel 
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distance between a health clinic they get the treatment from and workplace, but also due to 
the disease induced worsening of their physical condition (Dias et al., 2013, Chang B, 2004, 
Hansel NN, 2004). This may affect the financial and economic situation of TB patients in terms 
of limited work capacity or inability to work which could lead to a decrease in income or even 
a total loss of income (Hansel NN, 2004, Dias et al., 2013). Saving travel expenses to reduce 
the financial burden may lead to medication non-adherence (Chang B, 2004). Some studies 
indicated that a better financial empowerment could improve TB-related depression, 
medication adherence and HRQOL (Peltzer K, 2012, Issa BA, 2009). Often family members 
needed to get involved as caregivers leading to a loss of income by either through reducing 
their own work (Chang B, 2004) or by providing financial support to the patients (Hansel NN, 
2004). TB induced fatigue may impair the sexual function of the patient (Hansel NN, 2004). 
 
South African studies on HRQOL in TB 
In this review four studies which evaluated HRQOL in TB patients in South Africa were 
identified. All of them applied a cross-sectional design and had a strong focus on psychological 
distress and mental health (Peltzer et al., 2013, Peltzer K, 2012, Louw et al., 2012, Naidoo and 
Mwaba, 2010) (Table 3 in the Appendix). The evidence shows that TB impacted physical 
functioning and mental health domains of HRQOL. Mental disorders and psychological distress 
were present in TB and TB/HIV co-infected patients (Peltzer K, 2012). Depression was most 
prevalent (64%), followed by PTSD (30%), feeling of helplessness and a lack of social support 
(Peltzer et al., 2013, Naidoo and Mwaba, 2010). It was proposed that the integration of 
screening, treatment and mental health care services for TB patients (Peltzer et al., 2013, 
Peltzer K, 2012) would improve the quality of health and health outcomes of TB and HIV co- 
infected patients in South Africa (Louw et al., 2012). 
 
Adherence to Treatment 
Medication adherence is a complex, multi-dimensional, dynamic phenomenon comprising 
patient behavior with regard to the prescribed interval, dose, and dosing regimen as well as 
appropriateness of how the medication is taken (Cramer, 2008, Hughes, 2007). In the absence 
of drug resistance, TB is a curable disease with a six month treatment of antibiotics (Chirwa T, 
2013). Medication adherence is a key factor for treatment success (NDoH, 2014), and might 
have a greater impact on a population´s health than any improvement in specific medical 
treatments (WHO, 2003). Adherence during the intensive treatment phase (first two months) 
increases the chance for cure in newly diagnosed patients (Chirwa T, 2013). In contrast, non-
adherence leads to spread of free TB bacteria in the community; this may impact the patient 
by resulting in disability, drug resistance, relapse and risk of death and the community by 
increased health costs (NDoH, 2014, Chirwa T, 2013, Cramm JM, 2010, Husain MO, 2008). 
There is no gold standard on how to measure medication adherence. Conventional ways of 
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adherence control in TB include pill counting and Directly Observed Treatment (DOT); under 
DOT medication intake is directly observed and thereby it is a surveillance tool to control 
adherence. A Cochrane systematic review (Volmink and Garner, 2007) compared DOT with 
self-supervised TB medication treatment. While DOT is an objective mechanism to control 
adherence, self-supervised treatment depends on the subjective adherence behavior of the 
patient. The Cochrane review showed no differences in adherence between the two 
approaches; further clinic based DOT and community based DOT showed no differences. DOT 
is a key element of DOTS (Directly Observed Therapy, Short course), a TB management 
programme from WHO that comprises five elements: government control, detection, 
medication supply, supervised treatment, and monitoring of TB (Naidoo P, 2009, Volmink and 
Garner, 2007). Although DOTS is commonly practiced, the cure rates in some countries are 
still low due to poor adherence (Naidoo P, 2009). A number of studies (14, 40, 41, 43, 47, 48, 
50, 54-57) identified qualitatively different factors affecting adherence based on behavioral 
sciences: therapy-related (adverse events), condition-related (TB symptoms, psychological 
stress and depression), socio-economic and demography-related (gender, age, food access, 
education, marital status), health system related (inadequate relationship between health care 
provider and patient, poor health infrastructure), and patient-related  (forgetfulness, drug 
abuse). Adherence may also be influenced by family pressure, insufficient social support, a 
fear of disclosure, migration within the country or to neighboring countries. Health beliefs of 
the patient play a major role in adherence (Cramm JM, 2010, Husain MO, 2008) and may 
impact adherence positively (Dujaili et al., 2015, Aamir and Aisha, 2010, Husain MO, 2008, 
McInerney et al., 2007, Rowe KA, 2005). or negatively (Cramm JM, 2010, Naidoo P, 2009). 
Material incentives and enablers promote and assist adherence to TB treatment through 
higher clinic attendance (Lutge EE, 2012, Rowe KA, 2005). Material incentives include cash 
or non-cash vouchers and promote adherence in form of a positive reward of the patient´s 
adherence behavior. Enablers assist adherence by directly acting to overcome financial 
barriers to treatment such as transport vouchers or food; it is unknown whether incentives and 
enablers will improve adherence in the long-term (Lutge EE, 2012). 
 
South African Studies on Adherence 
Four studies assessed adherence to TB medication in South Africa: two cross-sectional 
studies (Lutge E, 2013, Corless et al., 2009) and two qualitative studies (Cramm JM, 2010, 
Naidoo P, 2009) (table 3 in Appendix). These studies indicated that TB patients were more 
adherent during the first two months of treatment (intensive phase) when symptoms were more 
present. Patients believed that they could be cured through effective treatment and through a 
good health alliance with their health care professional (Cramm JM, 2010, Naidoo P, 2009). A 
qualitative study by Naidoo et al (Naidoo P, 2009) identified a number of themes in a DOTS 
environment in South Africa which affect adherence behavior. Non-adherence was related to 
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poverty, HIV co-infection, stigmatization, an unsupportive social and work environment, and 
feelings of helplessness and hopelessness (Naidoo P, 2009). Although the psycho-social 
burden in TB was higher than in HIV patients, adherence to both treatments was comparable 
and the psycho-social burden did not impact adherence (Corless et al., 2009). Non-adherence 
was mainly affected by limited food access, a lack of public transport to clinics, the cost of 
transport, and through social stigmatization (Cramm JM, 2010, Naidoo P, 2009). The two 
cross-sectional studies observed adherence by economic incentives and by patient reported 
outcomes. One study revealed that material incentives such as monthly vouchers of US$15 
given during treatment did improve treatment completion; 35% of patients receiving no material 
incentives completed treatment while 43% of patients receiving vouchers did complete the 
treatment (Lutge E, 2013). However the study was affected by a low fidelity to the delivery of 
vouchers in public health clinics and further research into this is required. The other study 
compared medication adherence between TB and HIV patients by applying the patient- 
reported Morisky Medication Adherence Scale and by counting missed appointments (Corless 
et al., 2009). On average TB patients missed 1.85 days of treatment and had a good self- 
reported adherence in this study. 
 
The Association between HRQOL and Adherence during TB 
Our systematic review identified one study which addressed the association between well- 
being and adherence in TB. This study was a meta-analysis of 44 qualitative studies including 
8 studies from South Africa about adherence to TB treatment by Munro et al (Munro S, 2007). 
The systematic review indicated two underlying mechanisms for the association between well- 
being and adherence. The first mechanism related to TB patients prematurely stopping their 
treatment because they felt better. The reason was that patients perceived the improvement 
in well-being as a cure of TB. On the other hand, the second observed mechanism referred to 
patients stopping treatment when they experienced no improvement or a worsening in their 
health status and well-being (Munro S, 2007, WHO, 2003). 
 
HRQOL and adherence in longitudinal studies 
Ten observational studies with a longitudinal design evaluating HRQOL in new smear-positive 
TB cases receiving TB treatment were eligible for separate data extraction as shown in table 
2 (Atif et al., 2014a, Mamani et al., 2014, Aggarwal et al., 2013, Ralph et al., 2013, Balgude 
and Sontakke, 2012, Kruijshaar et al., 2010, Dhuria et al., 2009, Maguire et al., 2009, Marra et 
al., 2008, Chamla, 2004). Three studies took place in India (Aggarwal et al., 2013, Balgude 
and Sontakke, 2012, Dhuria et al., 2009), two in Indonesia (Ralph et al., 2013, Maguire et al., 
2009), and one each in Canada, China, Malaysia, the UK and Western Iran (Marra et al., 2008, 
Chamla, 2004, Atif et al., 2014a, Kruijshaar et al., 2010, Mamani et al., 2014). Studies 
evaluated HRQOL at diagnosis or before treatment, after 4 weeks of treatment, at switch from 
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intensive to continuous phase at two months following treatment initiation, after three months 
and at the end of treatment after six month. Only one study did not include HRQOL data for 
the end of treatment time point (Kruijshaar et al., 2010). Sample size varied from 30 (Balgude 
and Sontakke, 2012) to 1034 (Aggarwal et al., 2013) with a mean sample size of 206. Seven 
different HRQOL measures indentified in this review; three were generic (SF-36, WHOQOL- 
BREF, EQ-5D), three were dimension-specific measures, either for depression (BDI and 
Center for Epidemiologic Studies Depression Scale), or for anxiety (State-Trait Anxiety Short 
Form), and one was respiratory-specific (St. George´s Respiratory Questionnaire (SGRQ)). 
Independent from HRQOL measure and health setting, all studies reported impaired HRQOL 
before TB treatment and an improvement in HRQOL due to TB treatment. However, it was 
noted that residual impairment in HRQOL remained in some patients after successful 
treatment (Aggarwal et al., 2013, Atif et al., 2014a, Dhuria et al., 2009, Marra et al., 2008). 
Variables which were shown to predict lower HRQOL prior to treatment initiation included low 
socio-economic status and depression (Atif et al., 2014a, Kruijshaar et al., 2010). It was also 
identified from the studies included in the review that HRQOL is most affected in physical and 
psychological or mental domains (Chamla, 2004, Mamani et al., 2014). The greatest 
improvement observed in HRQOL due to treatment was in the physical domain (Kruijshaar et 
al., 2010, Dhuria et al., 2009). 
In terms of adherence, there was only one study identified that followed a longitudinal approach 
(Chirwa T, 2013). This study assessed medication adherence by counting missing days from 
patient medical record cards. About 35% of patients were non-adherent to TB treatment, with 
the majority missing less than 15 days of treatment. No longitudinal study addressed the 
association between HRQOL and adherence in TB. 
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Table 2: Data Extraction of longitudinal studies evaluating HRQOL and adherence in TB 
 
Reference 
 
Study 
Objective 
 
Study 
Setting/ 
Sample 
Size 
 
Population 
 
Comparator 
Group 
 
HRQOL 
Measure 
 
Application time 
point of HRQOL 
Measure 
 
Overall Outcome in 
HRQOL 
 
Outcomes in HRQOL Domains 
 
Aggarwal 
et al 2013 
(Aggarwal 
et al., 
2013) 
 
To quantify 
impairment 
in HRQOL 
and to 
evaluate 
the utility 
 
India 
N=1034 
 
Newly 
diagnosed 
PTB patients 
 
None 
 
WHOQO 
L-BREF 
 
Hindi 
version 
 
1st time point: 
within 2 weeks of 
initiating intensive 
phase 
2nd time point: 
within 2 weeks of 
switching to 
continuation 
phase 
3rd time point: 
within 2 weeks of 
stopping 
treatment 
 
Impaired HRQOL 
improves significantly 
with anti-tuberculosis 
treatment. Residual 
impairment is noticed in 
some patients at the 
end of treatment 
 
Patients in urban areas and those with 
higher socioeconomic status (SES) have 
higher domain scores and better HRQOL. 
The WHOQOL-BREF physical and 
psychological domain scores are 
significantly lower and more affected than 
other domains. 
 
Atif et al 
2014 (Atif 
et al., 
2014a) 
 
To 
evaluate 
the impact 
of TB 
treatment 
on HRQOL 
 
Malaysia 
 
 
n=216 
 
New smear 
positive PTB 
patients; no 
HIV co- 
infection 
 
None 
 
SF-36 v2 
 
Tamil, 
Malay 
and 
Mandarin 
version 
 
1st time point: 
start of treatment 
2nd time point: 
end of intensive 
phase 
3rd time point: 
end of treatment 
 
Impaired HRQOL 
improves significantly 
with anti-tuberculosis 
treatment. Scores in the 
physical and mental 
health components 
were still impaired after 
end of treatment 
 
Health domains improve between baseline 
and end of the intensive phase, and end of 
treatment, except for bodily pain and 
vitality. At the start of treatment, 67.1% of 
patients are at risk of depression, 
compared to 35% at end of intensive phase 
and 23.5% at end of treatment. Patients 
aged <45 years and/or non-smokers have  
a better mean physical component 
summary (PCS) score. Lower and affected 
mental health is related to smoking, low 
income and presence of more than three 
TB symptoms. 
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Balgude et 
al 2012 
(Balgude 
and 
Sontakke, 
2012) 
 
To assess 
the impact 
of TB and 
treatment 
on HRQOL 
India 
n= 60, 
(30 
patients 
and 30 
controls) 
 
Newly 
diagnosed 
smear 
positive TB 
patients 
 
Healthy 
control from 
the general 
population 
 
WHOQO 
L-BREF 
plus 2 
items 
examine 
d 
separatel 
y 
 
1st time point: 
baseline 2nd time 
point: after 2 
months 
3rd time point: 
after 4 months 
 
At baseline, HRQOL is 
significantly affected 
with physical and 
psychological domains 
most affected. All 
domains improve after 
2 and 4 month 
treatment. 
 
Mean scores of patients' physical and 
psychological domains are lower than 
controls at all 3 time points of assessment. 
There is significant improvement in the 
scores at 2 & 4 months of treatment. The 
mean scores of patients' environmental 
and social domains are lower than control 
at baseline, but improve at 4 months of 
treatment and are comparable to control 
 
Chamla 
 
To assess 
 
China 
 
TB patients 
 
General 
 
SF-36 
 
1st time point: 
 
HRQOL is impaired at 
 
Treatment improves all domains; at end of 
2004 impact of  population  before treatment baseline with physical treatment physical functioning, role- 
(Chamla, 
2004) 
TB and 
treatment 
on HRQOL 
n= 205, 
(102 
patients 
and 103 
controls 
without TB 
Chinese 
version 
2nd time point: 
after 2 months 
3rd time point: 
end of treatment. 
scales most affected 
and improves due to 
treatment. 
emotional, bodily pain, social functioning, 
and general health are not different from 
control.  Physical scales are more 
commonly affected than mental health 
scales. 
 
Dhuria et 
al 2009 
(Dhuria et 
al., 2009) 
 
To assess 
impact of 
TB and 
treatment 
on HRQOL 
 
India 
 
n=180, 
(n=90 
patients 
and 90 
controls) 
 
TB patients 
 
General 
population 
matching for 
age, gender, 
and 
socioecono 
mic status 
 
WHOQO 
L-BREF 
 
Hindi 
version 
 
1st time point: 
baseline 2nd time 
point: 3 months 
3rd time point: 
end of treatment. 
 
TB patients have an 
impaired HRQOL with 
significant improvement 
in all domains except 
social domain after 
treatment. 
 
The highest improvement is in physical 
domain, followed by psychological domain. 
The mean score of overall HRQOL and 
physical domain at completion of treatment 
is better in females than males. Males 
score better in psychological, social and 
environmental domains. After end of 
treatment HRQOL is still affected in 
physical domains compared to healthy 
controls. 
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Kruijshaar 
et al 2010 
(Kruijshaar 
et al., 
2010) 
 
To assess 
the impact 
of TB and 
its 
treatment 
on patients' 
health 
status 
 
UK 
 
 
n=61 
 
TB patients 
 
None 
 
SF-36 v2 
UK 
version 
 
 
EQ-5D 
STAI-6 
CES-D 
 
1st time point: 
diagnosis 
2nd time point: 2 
months 
 
Impaired HRQOL 
improves already after 
2 month treatment, but 
is still below the UK 
norm score 
 
SF-36 v2 scores improve significantly 
except for physical functioning, general 
health perceptions, and physical summary 
score. Vitality, mental health, and mental 
health summary scores are comparable to 
the UK norm. EQ- 
5D: pain/discomfort and problems with self- 
care improve while a borderline decrease  
is seen for mobility, except for self-care. 
Depression and anxiety improved due to 
treatment (CES-D and STAI-6 scores). 
51% report economic burden due to TB. 
 
Maguire et 
 
To quantify 
 
Indonesi 
 
smear 
 
None 
 
SGRQ 
 
1st time point: 
 
Impaired HRQOL 
 
Although HRQOL improves due to 
al 2009 the impact a positive PTB   baseline 2nd improves with treatment treatment (Maguire of TB  patients   time point: 2 at 2 and 6 months 24.6% of patients still have significant lung 
et al., HRQOL n=115    months 3rd time  function impairment after at end of 
2009)      point: 6 months  treatment 
 
Mamani et 
 
To assess 
 
Iran 
 
Pulmonary 
 
Healthy 
 
SF-36 
 
1st time point: 
 
Impaired HRQOL 
 
All domains of SF-36 are significantly 
al 2014 the QOL  and control from  baseline 2nd improves due to impaired and improve after 2 month 
(Mamani among TB  extrapulmon general  time point: 2 treatment compared to treatment; improvement between two and 
et al., patients n=184 ary TB population Persian months 3rd time controls six months is not significant. Physical 
2014)  (64 patients  version point: 6 months  functioning and energy are most affected. 
  patients       
  and 120       
  controls)       
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Marra et al 
2008 
(Marra et 
al., 2008) 
 
To identify 
areas of 
HRQOL 
affected by 
latent and 
active TB; 
treatment 
impact on 
HRQOL 
 
Canada 
 
 
n=206 
(104 
active TB 
and 102 
latent TB) 
 
Active and 
latent TB 
patients 
(LTBI) 
 
LTBI defined 
as a positive 
TST result 
without 
radiographic 
or clinical 
evidence of 
active TB 
 
SF-36 
v2 
BDI 
 
1st time point: 
baseline 
2nd time point: 3 
months 3rd time 
point: 6 months 
 
At baseline HRQOL is 
more affected in active 
than latent TB patients. 
Treatment improves 
HRQOL in active but 
not in latent TB. 
Patients with active TB 
have still impaired 
HRQOL after treatment 
completion compared 
to US norms. 
 
All domains of SF-36 improve over 
treatment in active and latent TB except 
bodily pain in active and except social 
functioning and vitality in latent TB. BDI 
shows no improvement in LTBI 
participants, but significant improvement 
for those with active TB. 
 
Ralph et al 
 
To 
 
Indonesi 
 
smear 
 
Healthy 
 
SGRQ 
 
1st time point: 
 
Impaired HRQOL 
 
After treatment 27% of TB patients have 
2013 investigate a positive TB control from  baseline   2nd improved over moderate to severe pulmonary function 
(Ralph et 
al., 2013) 
morbidity 
over TB 
treatment 
period 
n=240, 
(200 
patients 
and 40 
controls) 
the general 
population Indonesi 
an 
version 
time point: 4 
weeks 3rd time 
point: 8 weeks 
4th point time: 24 
weeks 
treatment time. impairment. HIV -positive status was 
significantly associated with worse HRQOL 
 
Reference 
 
Study 
objective 
 
Study 
Setting 
 
Population 
 
Comparator 
Group 
 
Adheren 
ce 
Measure 
 
Application time 
point of 
Adherence 
Measure 
 
Overall Outcome in 
Adherence 
 
Specific Outcome in Adherence 
 
Chirwa et 
al 2013 
(Chirwa T, 
2013) 
 
To 
estimate 
cure rates, 
and their 
association 
with 
adherence 
to TB 
treatment 
 
Malawi 
n=524 
 
TB patients 
 
None 
 
Retrospe 
ctive 
counting 
of 
missing 
days 
during 
treatment 
 
Retrospective 
review of records 
 
Adherence to TB 
treatment had a 
significant effect on 
cure of TB 
 
Overall, 35.1% of patients did not fully 
adhere to TB treatment. Of these, 86.4% 
missed < 15 days and 23.4% missed at 
least 1 day of treatment Overall, 92.7% of 
patients were cured from TB and 33.7% of 
these missed at least 1 day of treatment. 
Patients who missed <15 days and 15 to 
29 days of treatment were less likely to be 
cured compared with those who fully 
adhered. 
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4.4 Discussion 
 
This systematic review addressed the issues relevant to understand the impact of TB on 
HRQOL and medication adherence from a global perspective and specifically for South Africa 
using an integrative health approach. TB impacts the physical, emotional, psychological, social 
and economic dimensions of HRQOL, and residual impairment may be still present after 
treatment. We identified thirty-six studies evaluating HRQOL in TB of which twenty-one studies 
took place in WHO´s high-burden TB countries. Atif et al (Atif et al., 2014b) reported that most 
HRQOL studies in TB so far applied a cross-sectional design and our systematic review 
confirms this finding. Thirteen studies across high-burden countries had a cross-sectional 
design while only eight studies evaluated longitudinal changes (Table 3). To date, very few 
studies have followed changes in HRQOL longitudinally over time in TB patient populations. 
No longitudinal study has been conducted in South Africa even though South Africa has the 
highest prevalence and incidence among the 22 high-burden TB countries worldwide. Our 
understanding of the long-term impact of TB on HRQOL, covering the time of treatment and 
after treatment, is limited. There is a need for further research assessing changes in HRQOL 
longitudinally, specifically in high-burden countries like South Africa. Most studies on 
medication adherence during TB treatment employed a qualitative approach observing 
psychometric aspects of adherence. One systematic review of qualitative studies reported an 
association between HRQOL and adherence TB (Munro S, 2007). We found that similar factors 
affect HRQOL and adherence including TB therapy, health condition, socio-economic and 
demographic factors as well as quality of health care services. Studying the association 
between HRQOL and medication adherence during TB treatment will allow for a better 
understanding of how treatment effectiveness can be improved and care for TB patients 
optimised. 
 
Table 3: Eligible Studies included in Data Extraction Representation of eligible studies included in 
the systematic review and listed according to their WHO high-burden country status. 
WHO high-burden 
country 
Total Number of HRQOL studies Cross- 
sectional 
Design 
Longitudinal 
Design 
China 2 (Yin et al., 2012, Chamla, 2004) 1 1 
India 6 (Dhingra and Rajpal, 2005, Dhuria et al.,    1 
2009, Balgude and Sontakke, 2012, 
Aggarwal et al., 2013, Muniyandi et al., 
2007, Rajeswari et al., 2005) 
5 
Indonesia 2 (Maguire et al., 2009, Ralph et al., 2013) 2 
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Nigeria 2 (Issa BA, 2009, Adeyeye et al., 2014) 2 
Pakistan 1 (Husain MO, 2008) 1 
Philippines 1 (Masumoto et al., 2014) 1 
South Africa 6  (Louw  et  al.,  2012,  Peltzer  K,  2012, 6 
 Peltzer et al., 2013, McInerney et al., 2007,  
 Naidoo and Mwaba, 2010, Corless et al.,  
 2009)  
Uganda 1 (Babikako et al., 2010) 1 
Other countries Total Number of HRQOL studies Cross- Longitudinal 
  sectional Design 
  Design  
Canada 3 (Dion et al., 2004, Guo N, 2008, Marra et 2 1 
 al., 2004)   
Iraq 1 (Dujaili et al., 2015)  1 
Malaysia 4 (Atif et al., 2013, Atif et al., 2014b, Atif et 3 1 
 al., 2014a, Awaisu et al., 2012)   
Taiwan 1 (Chung et al., 2012)  1 
Thailand 1 (Kittikraisak et al., 2012) 1 
UK 1 (Kruijshaar et al., 2010)  1 
USA 2 (Pasipanodya et al., 2007a, Pasipanodya 2 
 et al., 2007b)  
Western Iran 1 (Mamani et al., 2014)  1 
Yemen 1 (Othman, 2011) 1 
 
Table 3: Representation of eligible studies included in the systematic review and listed 
according to their WHO high-burden country status. 
 
The studies included in this systematic review revealed similar HRQOL outcomes with a 
number of different measures, but a TB-specific measure is lacking. Although two studies 
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reported developing TB-specific measures, FACIT-TB in Iraq (59) and DR-12 in India (68), 
neither provides adequate evidence for validity or reliability. Measures applied during 
longitudinal HRQOL studies were generic (SF-36, WHOQOL-BREF, EQ-5D) and dimension- 
specific measures, either for depression (BDI and Center for Epidemiologic Studies 
Depression Scale) or for anxiety (State-Trait Anxiety Short Form), one measure was specific 
for respiratory diseases (SGRQ). All measures reported similar HRQOL outcomes for TB and 
confirmed that physical health domains were more affected than mental health domains. All 
health domains for each measure improved during TB treatment. However, physical 
impairment was still present after treatment. The measures only capture parts of the health 
domains relevant to TB or may not be sensitive enough to observe the actual impact of TB on 
HRQOL. This implies the need for a TB-specific PRO measure which captures all relevant 
health domains and health aspects of TB including the physical, psychological, and social 
domains. Such a measure will need to consider socio-demographic and cultural differences 
between patients with TB, taking into account the stigma of HIV and how the social standing 
of the patient within his or her community is affected. The development of such a specific 
measure will also allow a deeper understanding of MDR-TB, TB/HIV co-infection and 
extrapulmonary TB. Future studies should also include the identification of minimal clinically 
important difference (MCID), i.e. the smallest difference in a domain which patients perceive 
as an improvement or a worsening; this is unknown for TB patients and will allow 
understanding meaningful changes in HRQOL. 
Current evidence regarding the association between HRQOL and adherence in TB is lacking 
globally. Future research about the association between HRQOL and adherence in TB specific 
will help to optimize existing treatment programs, understand the limitations in TB control and 
targeted interventions and improving the health status of high-burden TB populations. The 
WHO´s End TB Strategy targets a TB free world by 2035. One of the three strategic pillars to 
reach this goal focuses on integrated, patient-centred TB care and prevention. HRQOL 
assessment allows an integrative understanding of TB from a patient perspective. Resulting 
knowledge supports an understanding of TB-related physical, mental and social needs and 
addresses diverse barriers. This patient-centred approach may support quality assessment 
and rationale use of medicines, which fall under the pillars of the End TB Strategy. 
This systematic review had several strength and limitations. It combined qualitative and 
quantitative research on HRQOL and adherence and this mixed method may be viewed as 
strength as it ensures capturing all relevant information on the topic. The methodological 
quality of the eligible studies varied and might have an effect on the reported outcomes. We 
only applied the STROBE Statement for quality reporting to longitudinal studies; we observed 
a moderate reporting quality with a median of 7 out of 16 points, indicating that the quality of 
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the articles included in this review were fairly poor. This might affect the reported information. 
Most studies applied different PRO measures at differing time points during treatment at 
different study sites, making any general conclusions regarding the impact of TB on HRQOL 
difficult. Studies had an observational nature rather than a controlled trial design as mostly 
applied in systematic reviews; however, observational studies might be more reliable as they 
observe patients in real life rather than under controlled ideal conditions. Publication bias may 
be present in this systematic review although our findings were consistent across different 
settings; we selected peer-reviewed literature from three different databases and included grey 
literature to control for publication bias. We did not include unpublished information and studies 
published in a different language than English. 
 
 
4.5 Conclusions 
 
The relevance and importance of HRQOL assessments is growing and HRQOL has become 
an important tool for the understanding of health outcomes adopting a patient-centred 
approach to care and treatment. Further research is required in a country-specific context to 
contribute to efficient decision making with regard to TB related strategies; product approval, 
pricing and reimbursement as well as health policy making; A number of new anti-TB drugs, 
vaccines and diagnostics have recently achieved marketing approval or are in late clinical 
development. Assessment of longitudinal changes in HRQOL and its association to medication 
adherence in TB in a high TB burden country such as South Africa are not yet available. Such 
data would support the identification of sustainable health innovations in TB by providing 
information on benefits and gaps in current treatment strategies tailored for a specific patient 
population. This  will be useful to  determine  the value of new products  and to  perform 
appropriate cost-effectiveness analyses to optimize the allocation of societal resources 
specifically for South Africa. This is of high relevance as a number of new TB drugs, vaccines 
and diagnostics have recently achieved marketing approval or are in late clinical development. 
A longitudinal study assessing HRQOL and medication adherence in active TB in South Africa 
applying valid and reliable measures  that capture all relevant aspects of TB would be 
necessary to assess the achievement of the WHO´s End TB Strategy pillars. 
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5.1 Abstract 
 
Introduction: Health-related quality of life (HRQOL) has become an important measure to 
identify and shape effective and patient-relevant healthcare interventions innovations through 
outcomes. Adherence to tuberculosis (TB) treatment is a public health concern. The main 
objective of this research is to develop a study design for evaluation of HRQOL and its 
association with medication adherence in TB in South Africa. 
Methodology: A conceptual framework for HRQOL in TB has been developed to identify 
patient-reported outcome (PRO) measures for HRQOL and adherence and to generate an 
endpoint model. Two generic (SF-12 and EQ-5D-5L), one disease-specific (St. George´s 
Respiratory Questionnaire (SGRQ)) and one condition-specific (Hospital Anxiety and 
Depression Scale (HADS)) measure for HRQOL and Morisky Medication Adherence Scale 
(MMAS) for adherence assessment were identified. All measures are applied in a longitudinal 
multicentre study at five data collection time points during standard TB treatment. Statistical 
analysis includes multivariable analysis. Change over time in the physical component score 
(PCS) of SF-12 is defined as primary endpoint. Sample size estimation based thereupon has 
led to a recruitment target of 96 patients. This study is on-going. 
Discussion: This is the first longitudinal study in South Africa which evaluates HRQOL and its 
association with medication adherence in TB in a comprehensive manner. Results will help to 
improve current treatment programmes and  medication adherence and will support the 
identification of sustainable health innovations in TB, determining the value of new products, 
and supporting decision making with regard to health policy and pricing. 
 
 
Keywords 
 
Health-related quality of life, adherence, tuberculosis, study design, South Africa 
 
 
5.2 Introduction 
 
According to the World Health Organization (WHO), health has a multi-dimensional nature and 
comprises physical, mental and social health domains (WHO, 1948). Health-related quality of 
life (HRQOL) is a patient-reported outcome (PRO) parameter which refers to the multi- 
dimensional nature of health directly from the patient perspective. Tuberculosis (TB) places a 
significant burden on the health system of South Africa, which has the highest prevalence and 
incidence rates of all 22 high-burden TB countries worldwide (WHO, 2015c). Treatment is 
available in South Africa, however the incidence rate is only slowly decreasing and the relapse 
rate is high. Both epidemiological parameters may be influenced by HRQOL in TB. They may 
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also be additionally affected through inadequate treatment adherence although Direct 
Observed Treatment (DOT) has been introduced for supervised treatment monitoring. To study 
these associations, further research is required. The study presented here intends to evaluate 
HRQOL and its association with medication adherence in TB in South Africa. To understand 
the impact of HRQOL in TB and determinants of medication adherence, we first conducted a 
systematic review of the available literature (Kastien-Hilka et al., 2016). In brief, active TB 
impacts HRQOL significantly across different health settings; the impairment affects physical, 
emotional, psychological and social as well as economical aspects. Although standard TB 
treatment improves all health domains, psychological well-being and social functioning 
remained impaired in microbiologically cured patients after treatment (Ralph et al., 2013, 
Pasipanodya et al., 2007b, Weis and Pasipanodya, 2010, Muniyandi et al., 2007). Most 
published studies on HRQOL in TB had a cross-sectional design (Atif et al., 2014b), however 
to fully understand the impairment of HRQOL, TB impact needs to be assessed over the 
complete treatment period (Brown et al., 2015). In our systematic review we identified only ten 
studies which have  followed a longitudinal approach; none  of them in a  South African 
environment (Aggarwal et al., 2013, Atif et al., 2014a, Balgude and Sontakke, 2012, Chamla, 
2004, Dhuria et al., 2009, Kruijshaar et al., 2010, Maguire et al., 2009, Mamani et al., 2014, 
Marra et al., 2008, Ralph et al., 2013). Similar factors as for HRQOL impact medication 
adherence (Kastien-Hilka et al., 2016, WHO, 2003). Medication adherence “the process by 
which patients take their medications as prescribed” (Vrijens et al., 2012). It comprises the 
initiation of the treatment (first dose), implementation of the prescribed dosing regimen, and 
discontinuation of the therapy (end of therapy), and the persistence (time from initiation until 
discontinuation) (Vrijens et al., 2012, Lam and Fresco, 2015) Medication adherence is crucial 
to reach clinical targets and the causes of non-adherence are multi-factorial (Lam and Fresco, 
2015, Fairman, 2000). WHO stated that “increasing the effectiveness of adherence 
interventions may have a far greater impact on the health of the population than any 
improvement in specific medical treatment” (WHO, 2003). Both HRQOL and adherence are 
related to the patient (Cote, 2003). A change in adherence is followed by a change in HRQOL 
and a relationship between adherence and HRQOL is existing (Cote, 2003, Kastien-Hilka et 
al., 2016). 
We perform a longitudinal study for evaluating patient-reported HRQOL and its association 
with medication adherence in TB in South Africa. This study is specific to TB and transferability 
to other diseases are beyond the scope of this research. The study will provide information on 
the health status of TB patients and their HRQOL; HRQOL outcomes will allow understanding 
which health domains are most impacted by TB. Adherence behaviour will be observed from 
a patient perspective. This will allow us to identify which health aspects of TB are influencing 
adherence and which health domains are impacted by non-adherence. Since the study is 
61  
taking place among patients from South Africa, the cultural and socio-demographic impact on 
TB are respected. This article describes the study design and rationale. 
 
 
5.3 Materials and stepwise procedures 
 
 
5.3.1 Study aim and outcomes 
 
The main aim of the study is to evaluate HRQOL and medication adherence in active TB 
patients in South Africa. Specific study outcomes comprise following: to assess TB impact on 
HRQOL and its longitudinal changes during standard TB treatment; to understand patient- 
reported medication adherence and its longitudinal changes during standard TB treatment; to 
evaluate any influence of socio-demographic aspects on HRQOL and adherence with regard 
to gender, age, education, work status and co-morbidities in sub-group analysis; to assess any 
association between changes in HRQOL and changes in adherence and sputum smear 
results; to understand if an association between HRQOL and adherence during standard TB 
treatment is existing and which health domains are involved. 
The following preparatory steps were undertaken during the design phase of the study and are 
described in detail below: conceptualization of HRQOL in TB; identification of patient-reported 
measures applied in HRQOL evaluation and in studies of adherence to anti-TB standard 
treatment; selection of HRQOL and adherence measures capturing all relevant health aspects 
of TB; definition of data collection points for HRQOL and adherence; identification of a primary 
endpoint on basis of HRQOL and development of an endpoint model; selection of study setting; 
definition of study participant inclusion and exclusion criteria; development of a rationale for 
sample size determination; definition of statistical analysis. 
 
 
5.3.2 Conceptualization of HRQOL in TB 
 
The results of the literature review identified that TB impacts physical, emotional, 
psychological, social and economic domains of HRQOL, with residual impairment still present 
in each of these domains even after treatment. Based on these results, a conceptual 
framework of HRQOL in TB has been developed (figure 7). 
  
 
 
 
Figure 7: Conceptual framework of HRQOL in TB, developed based on systematic review results. 
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The physical health domain is mainly described by TB-related physical and physiological 
aspects which comprise disease symptoms, health status, fatigue and physical functioning. 
There are also influences of TB treatment due to side effects, pill burden and duration of 
treatment. The mental health domain is mainly impacted by the psychological and emotional 
aspects related to TB which include depression and anxiety, fear of spreading TB, feelings of 
anger, health perception of the patient, and patient´s spirituality. The social health domain we 
defined by the social functioning of the patient and the economic burden related to TB. Social 
functioning is mainly impacted by social role, social support, sexual functioning, stigmatization 
and social isolation. The economic burden is influenced by a loss in salary and any financial 
burden related to being ill. 
 
 
5.3.3 Identification of HRQOL and adherence PRO measures in 
TB 
The systematic review yielded 38 studies which applied patient-reported outcome (PRO) 
measures in HRQOL and adherence: two systematic reviews, 21 cross-sectional studies, 14 
longitudinal studies, and one qualitative study (table 1 in appendix). 
Based on the identified studies, 43 HRQOL and three adherence PRO measures were 
extracted, including 34 reported measures from the systematic reviews of Bauer et al (Bauer 
et al., 2013) and 17 different HRQOL instruments from Guo et al (Guo et al., 2009) (tables 2 
and 3 in appendix). Overall, the most frequently applied HRQOL instrument in TB was the 
generic Short-Form 36 (SF-36), followed by World Health Organization Quality of Life - BREF 
(WHOQOL-BREF), EuroQol-5D (EQ-5D) and disease-specific instruments, namely the Beck 
Depression Inventory (BDI), Kessler-10 (K-10) and St. George´s Respiratory Questionnaire 
(SGRQ). Our systematic review identified ten studies applying a longitudinal design in HRQOL 
evaluation in TB (Aggarwal et al., 2013, Atif et al., 2014a, Balgude and Sontakke, 2012, 
Chamla, 2004, Dhuria et al., 2009, Kruijshaar et al., 2010, Maguire et al., 2009, Mamani et al., 
2014, Marra et al., 2008, Ralph et al., 2013). Consistent with the results of the current review, 
the SF-36 was applied more often than other PROs to observe longitudinal changes. Next in 
frequency were the WHOQOL-BREF, SGRQ, EQ-5D, BDI, as well as the State-Trait Anxiety 
Short Form (STAI-6) and Center for Epidemiologic Studies Depression Scale (CES-D). In 
addition to our literature search, we accessed the database PROQOLID for HRQOL 
instruments which are applied in pulmonary and psychiatric illnesses and linguistically 
validated for application in English language in South Africa (PROQOLID). This identified 17 
measures (table 4 in appendix). 
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5.3.4 Rationale for selection of HRQOL and adherence PRO 
measures 
A systematic use of generic HRQOL measures in all diseases supports consistent value 
judgments and transparent reimbursement decision making (eunethta, 2013). Two types of 
PRO measures are applied in HRQOL evaluations: generic measures and disease- or 
condition-specific measures. Generic measures have the advantage of allowing comparison 
of quality of life outcomes across different diseases and can accommodate effects of co-morbid 
conditions; they are often applied to inform health policy maker about allocation of resources 
(eunethta, 2013). In contrast to generic measures, disease-specific instruments comprise 
disease specific health aspects (eunethta, 2013, Doward et al., 2010, Deshpande PR, 2011). 
Disease- and condition-specific measures may be more sensitive to changes in HRQOL and 
may better detect important disease-related changes over time. Disease- and condition- 
specific HRQOL information may be complementary to generic HRQOL measures, specifically 
when no effect is observed with generic measures. However a recognized and validated TB- 
specific HRQOL instrument currently does not exist. We therefore followed the approach to 
select generic and disease- and condition-specific measures which capture all major HRQOL- 
related aspects of TB based on our conceptual framework. 
All 43 measures applied in HRQOL studies and 3 adherence instruments identified by our 
literature search as well as all 17 instruments from the PROQOLID database search were 
reviewed. Measures were selected in order to capture physical, mental and social health issues 
of TB. In addition to consistency with our conceptual framework, selection required that the 
respective measures had been validated in TB and linguistically validated for English in South 
Africa. Based on these criteria, we finally selected the St. George´s Respiratory Questionnaire 
(SGRQ) as a disease-specific measure and the Hospital Anxiety and Depression Scale 
(HADS) as a condition-specific measure. The SGRQ is recommended as a preferred 
instrument by the European Medicines Agency (EMA) for evaluating quality of life in COPD 
patients (EMA, 2012). As a measure specifically for respiratory diseases, it captures important 
health aspects which can be applied to TB. HADS was selected as it allows evaluation of 
anxiety and of depression. As a preference-based and a profile measure, we selected the EQ- 
5D-5L and SF-12. Notably, the SF-12 has previously been used in pulmonary TB patients in 
South Africa for HRQOL assessment (Louw et al., 2012). 
An ideal adherence measure to assess overall adherence to medication including initiation, 
persistance, implementation and discontinuation does not exist; therefore a multi-measure 
approach may be considered where direct and indirect adherence measure are combined 
(Fairman, 2000). Direct measures such as drug determination in biological fluids or direct 
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patient observation are often regarded as being the most reliable and accurate. However, 
individual changes in drug metabolism and multidrug intake affect monitoring of plasma levels, 
and patient observation is limited to inpatient settings and clinical trials (Fairman, 2000, Nguyen 
et al., 2014, Lam and Fresco, 2015). Indirect measures comprise medication monitoring (such 
as pill counting) and self-reported measures; however, medication monitoring is cost intensive 
and self-reported measures may be less reliable due to patient recall, underreported non- 
adherence and memory bias issues(Fairman, 2000, Lam and Fresco, 2015, Stirratt et al., 
2015). Vrijens et al defined adherence measures for the quantitative assessment of initiation, 
persistance, and implementation (Vrijens et al., 2012). Both, initiation and persistance are time- 
to-event variables and should be assessed by Kaplan-Meier curves, median persistence or 
proportion of persistent patients at a given time point. Implementation is assessed by a 
summary statistic such as the proportion of prescribed drug taken or longitudinally by electronic 
databases of drug dosing histories. Each adherence measure has its advantages and 
disadvantages and the selection of adherence measures depends on the attributes, research 
objectives and available resources of each study (Lam and Fresco, 2015). The present study 
focuses on the measurement of HRQOL and adherence in a real life middle-income setting in 
a township of South Africa. The study is purely observational, with no influence on treatment 
and follows patients during their TB care. The available resources of the study and the study 
environment do not allow application of direct adherence measures although they would in 
principle be the best instruments to measure patient´s medication taking behavior (Nguyen et 
al., 2014); Since DOT is established in South Africa, we decided to apply a self-reported 
measure as it allows to identify specific reasons for being non-adherent (Nguyen et al., 2014, 
Lam and Fresco, 2015). Further, a self-reported measure is best applicable to the study 
environment and study settings as it is cost-effective, with a minimum burden to the patient, 
easy to administer and flexible in timing and mode of administration. Self-reported adherence 
measures have additional advantages; they inform about non-adherence before adverse 
clinical outcomes develop and about adherence determinants such as psychosocial factors 
(Stirratt et al., 2015). A gold standard for self-reported, questionnaire-based adherence 
measurement does not exist (Nguyen et al., 2014, Fairman, 2000). The Morisky Medication 
Adherence Scale (MMAS) is widely used, reliable and valid and has been applied in TB before 
(Lam and Fresco, 2015, McInerney et al., 2007, Corless et al., 2009, Stirratt et al., 2015). 
MMAS allows the evaluation of the concept of medication-taking behaviours, barriers to 
adherence, and beliefs associated with adherence (Lam and Fresco, 2015) including 
forgetfulness and adverse events (Nguyen et al., 2014). Based on the taxonomy of adherence 
by Vrijens et al MMAS covers the implementation and discontinuation phase of adherence. 
The assessment of self-reported scales includes the correlation with an objective adherence 
measure, and MMAS was correlated with pharmacy records and clinical outcomes (blood 
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pressure control) as comparison measure of adherence (Nguyen et al., 2014). 
All four HRQOL measures and the adherence measures are reliable and validated 
(PROQOLID, Morisky, 2008b, Lam and Fresco, 2015), and the HRQOL measures were 
linguistically validated for English in South Africa (St George´s University of London, 2012, 
Euroqol, PROQOLID). All selected measures are described in detail in the appendix. 
 
 
5.3.5 Rationale for study endpoint model 
 
An endpoint model for the present study was based on measurement concepts as reported by 
Burke from the US FDA (Burke, 2012). Treatment benefit measurements comprise four 
different concepts: disease-defining concepts, proximal disease and distal disease impact 
concepts, and disease impact on general life concepts. 
Disease-defining concepts describe clinical signs of a disease. The impact of these disease- 
specific clinical signs is reflected in proximal disease impact concepts of disease symptoms 
and somatic sensation. Both disease-defining and proximal disease impact concepts reflect 
some aspects of the physical health domain of the conceptual psychometric framework of 
HRQOL. Mental, social and psychosocial domains of HRQOL are represented through the 
distal disease impact concepts. Distal disease impact concepts include physical, psychological 
and social functioning, thereby reflecting additional aspects of the physical health domain. The 
disease impact on general life concept comprises aspects which result from impairment in 
distal disease impact concepts, such as impairment of social role functioning, economic burden 
and quality of life in general. Based on the benefit treatment measurement concept of Burke 
(Burke, 2012) and based on the psychometric concept of TB-specific HRQOL, we developed 
following endpoint concept for TB (figure 8): 
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Figure 8: Endpoint concept for TB based on major HRQOL health domains and on 
benefit treatment measurement concepts. 
 
 
The selected HRQOL and adherence measures were integrated into the endpoint 
concept. The physical health domain of HRQOL is evaluated by the physical component 
score of the SF-12 (PCS-12). The change between end of treatment and baseline in the 
PCS-12 score is defined as the primary study endpoint. The EQ-5D-5L physical domain and 
SGRQ symptoms domain scores represent secondary endpoints. The mental health 
domain of HRQOL is assessed by the mental component score of the SF-12 (MCS-
12), the EQ-5D-5L mental domain, SGRQ activities domain, and HADS. The (psycho-) 
social health domain of HRQOL is evaluated by SGRQ impacts on social activities domain. 
Other endpoints comprise clinical data (sputum smear) for presence of active TB and 
treatment monitoring as well as medication adherence by application of MMAS-8. Table 4 
provides an overview of endpoints selected and related instruments applied. The final 
endpoint model for evaluation of HRQOL and adherence in TB is presented in figure 9. 
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Endpoint (mean difference EOT minus BL) PRO Measure 
Primary endpoint SF-12 PCS-12 
Secondary endpoint SF-12 MCS-12 
 EQ-5D-5L 
SGRQ 
 HADS 
Other endpoint Clinical data (sputum smear) 
 MMAS-8 
 
 
Table 4: Primary, secondary and other endpoints applied in HRQOL evaluation 
 
 
 
 
 
Figure 9: The final endpoint model for evaluation of HRQOL and treatment adherence in PTB, 
respecting HRQOL domains and disease-defining as well as proximal and distalmeasurement 
concept. 
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5.3.6 Study design and study setting 
 
The study is observational in nature with a longitudinal design including repeated measures of 
HRQOL and adherence per study participant. Multiple health facilities are included and the 
study has thereby a multi-centre design. The highest TB burden in Cape Town is recorded in 
the Khayelitsha sub-district. Six health facilities with the highest TB caseloads per month were 
selected. Each health facility has an outpatient TB department. The caseloads of TB cases for 
each selected health facility were provided through the Western Cape Province. 
 
 
5.3.7 Patient population and participant recruitment 
 
The patient population comprises patients diagnosed with active pulmonary TB. TB patients 
are eligible if their age is 18 years or older and if they have not received standard TB treatment 
prior to this study. Patients are excluded if they are diagnosed with multidrug-resistant TB 
(MDR-TB) and extensively drug-resistant TB (XDR-TB), and/or with HIV co-infection. The 
eligibility status of each patient is subject to verification by the responsible TB nurse of each 
health facility. Based on a patient information document, eligible patients are informed about 
nature, purpose, potential risks and benefits of the study. Patients have the opportunity to 
decline their participation or to withdraw from the study at any time point. If an eligible patient 
agrees to participate in the study, a written informed consent is obtained before study start. 
The sample population is reached by pooling eligible patients from all study sites. 
 
 
5.3.8 Study procedure 
 
Eligible participants receive a six month standard TB treatment with rifampicin, isoniazid, 
ethambutol and pyrazinamide at each health clinic or health centre. The drug treatment is local 
standard care according to the national TB guideline and DOT is applied (NDoH, 2014). The 
treatment is not influenced by this non-interventional research study. The study evaluates 
HRQOL and adherence based on questionnaires completed by patients, who are treated and 
managed in the health facility independently from this study. Most studies evaluating HRQOL 
longitudinally included data collection before treatment or at treatment start, at the switch from 
the intensive to continuous treatment phase and at end of treatment. (Aggarwal et al., 2013, 
Atif et al., 2014a, Balgude and Sontakke, 2012, Chamla, 2004, Dhuria et al., 2009, Kruijshaar 
et al., 2010, Maguire et al., 2009, Mamani et al., 2014, Marra et al., 2008, Ralph et al., 2013). 
We decided on a tighter data collection regimen to monitor changes in HRQOL more closely 
and included five different time points over the 6 month treatment period: beginning of 
treatment (baseline) and follow-up visits 1-4 after 1, 2, 4 month and 6 month (end of treatment). 
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Data collection starts when TB treatment is initiated; the four HRQOL measures and a socio- 
demographic questionnaire are applied at baseline (treatment start). The four HRQOL 
measures are repeatedly applied at all follow up visits 1-4 together with the MMAS. Data are 
collected based on combined completion of paper questionnaires and face-to-face interviews 
through trained field workers. Training of field workers is based on a Standard Operating 
Procedure (SOP) specifically written for this study. Questionnaires are scanned by the field 
worker for any missing responses. The patient is asked to provide an answer for the missing 
response unless the question was intentionally left unanswered. TB-related clinical data 
(sputum smear results) are collected from TB nurses when available during the treatment 
period for each patient. 
 
 
5.3.9 Data management 
 
All paper-based documents including the questionnaires and informed consent forms are 
stored at the University of Cape Town for a period of ten years. The HRQOL, adherence and 
socio-demographic measures, and sputum smear results data are transferred to an electronic 
database independently by two research team members. Every third questionnaire is entered 
into a second database. Both databases are reconciled to minimize errors related to data entry. 
All questionnaire responses are scored according to each questionnaire´s manual instructions. 
Scored data are prepared for statistical analysis applying SPSS software. 
 
 
5.3.10 Rationale for sample size determination 
 
The primary endpoint is the Physical Component Score (PCS) of SF-12. Walter (Walters, 2004) 
compared four different methods for sample size estimation using SF-36 as primary endpoint. 
Since SF-12 has shown comparable results with SF-36, both measures are seen as similar 
and comparable and the methods discussed applicable to SF-12. We decided to select a 
method for sample size determination which is based on the mean difference. The estimation 
of mean difference in PCS-12 scores is defined as average mean difference score between 
end of treatment (EOT) and baseline (BL). We therefore performed a literature search for 
studies applying SF-12 or SF-36 as an outcome measure during TB treatment, and found 10 
studies presenting SF-12 and SF-36 scores (Babikako et al., 2010, Dion et al., 2004, Guo N, 
2008, Kruijshaar et al., 2010, Marra et al., 2008, Atif et al., 2014a, Louw et al., 2012, Bauer et 
al., 2013). Only two studies reported PCS-36 scores over the 6 month long TB treatment, and 
observed a change in mean score over time (baseline to end of treatment) with a mean 
difference of 4.0 (Babikako et al., 2010) and of 4.1 (Atif et al., 2014a). The minimal important 
difference (MID) for SF-36 and SF-12 is reported with > 3 points by the questionnaire manual 
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(Maruish ME, 2009). We therefore assumed a mean difference of 4.0 for our study. A standard 
deviation (SD) for PCS-12 was defined with the value 7 at end of treatment for PCS-36 (Atif et 
al., 2014a). Final sample size was calculated based on a mean difference of 4.0 and a SD of 
7 for mean PCS-12, resulting in a standardized effect size of 0.57. Using the standardized 
effect size with a two-sided 5% level of significance and a 95% power yielded in an estimated 
sample size n = 80 subjects. We estimated an attrition rate of 20% leading to a final sample 
size n = 96 patients. 
 
 
5.3.11 Anticipated results 
 
Based on published HRQOL studies in TB, we expect an improvement in HRQOL during the 
course of treatment; especially physical health aspects are expected to improve. However, 
some residual physical impairment has previously been reported after treatment end, although 
patients' were microbiologically cured. Reported mental and psychosocial health aspects 
included depression and anxiety, and social isolation and stigmatization. We expect to find 
these aspects of health impairment reflected in HRQOL outcomes at the beginning of 
treatment. As TB treatment requires a long-term dosing regimen, we expect a decreasing 
adherence behaviour over the treatment course, although DOT is established and a 
requirement in South Africa. Potential pitfalls of our study are mainly driven by the infrastructure 
of the health setting in the township Khayelitsha, which, however, reflects South African reality. 
Patients have no regular access to mobile phones and interview dates for HRQOL and 
adherence interviews are difficult to organize; follow up with the patients is also difficult for the 
health facilities. We expect a number of missing interviews and interviews taken not at the 
required time points, albeit around the target interview dates. Our HRQOL and adherence 
measures are self-reported measures and reflect a subjective patient view. Related bias 
including over- and under-reporting of both concepts can be expected. This will be consistent 
with the individual patient’s TB condition. Experienced pitfalls for future studies will be 
discussed as lessons learned from our study. 
 
 
5.3.12 Statistical analysis 
 
All statistical analyses are conducted using IBM SPSS Version 22®. Descriptive statistics are 
calculated for socio-demographic descriptors of the patient population and all study outcomes. 
Study outcomes comprise the means of all HRQOL domain and total scores, adherence scores 
and sputum smear results, and related changes over time. Categorical variables are described 
by frequencies, proportions (%) and number of missing values. Continuous variables (HRQOL, 
adherence) are described by the mean and median as measures of central tendency, first and 
72  
third quartiles, standard deviation (SD), minimum (Min) and maximum value (Max), and 
number of missing values. Continuous variables are checked for non-normality with q-q plots 
and histograms. Outliners are observed via boxplots; if applicable 5% trimmed means may be 
calculated. Ordinal variables representing responses to questionnaire items are described in 
the same way as categorical and/or continuous variables, depending on their properties. For 
example, responses to an item with 3 answer levels would be described in the same way as a 
categorical variable whereas responses to an 11 step (0-10) rating scale would be described 
in the same way as a continuous variable. 
Change of each HRQOL measure and of the adherence measure between baseline and each 
follow up visit is calculated based on mean scores. Changes in mean scores between baseline 
and end of treatment are presented as boxplots. Differences between baseline and each follow 
up are examined based on significance testing; choice of tests considers the distribution of the 
variables involved. For distributions with no or only limited deviations from normality, the paired 
t-test is used, otherwise the Mann-Whitney U test. The level of statistical significance is set at 
5%, two-sided for both the paired t-test and Mann-Whitney U test. Change in HRQOL mean 
scores over time (BL, visit 1-4) is further examined by two-way repeated measure analysis of 
variance (ANOVA), for all HRQOL instruments. 
Responsiveness of HRQOL measures refers to their ability to detect important change over 
time in the concept measured, even if this change is small. Each change in mean score for 
each measure is compared with its reported MID. When the change in mean score is equal or 
above the MID, the change is interpreted as meaningful. Further, the effect size is calculated 
by dividing the change in mean score through the standard deviation at baseline (0.2, 0.5 and 
0.8 represent small, medium and large effect size) (Cohen, 1988, Aggarwal et al., 2013). It is 
further observed which health domains improve, worsen, or remain unchanged over time 
based on change in mean scores. Hypothesis testing is applied to HRQOL, adherence and 
sputum smear outcomes. The hypotheses testing comprises following assumptions: HRQOL 
improves, adherence declines, and sputum smear results improve over time from baseline to 
end of treatment. Hypothesis testing is performed by repeated measures ANOVA if data are 
normally distributed or with the Kruskal-Wallis test for non-normally distributed data. Sub-group 
analyses are performed additionally, by gender, age, ethnicity, marital status, educational and 
work status, and co-morbidities. 
Additional relationships are assessed for HRQOL, adherence, and sputum smear results, 
including sub-groups analyses according to socio-demographic data. First, the correlations 
between all health domains of all HRQOL measures at baseline are assessed by applying 
Pearson´s correlation coefficient or Spearman´s rho coefficient. A correlation matrix is 
presented. Second, it is examined how changes in HRQOL and changes in adherence are 
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associated with changes in sputum smear results over time. Correlation coefficients are 
calculated and linear mixed regression models are estimated. Third, it is examined how 
changes in both HRQOL and adherence are linked with the socio-demographic variables by 
applying linear mixed regression models. A final analysis assesses how HRQOL and 
adherence are associated with each other, from baseline to end of treatment, by applying linear 
mixed regression models. Adjustments for multiple testing will be made where sensible. 
Related issues will be discussed. 
 
 
5.4 Discussion 
 
The impact of TB on patients' HRQOL has been reported in international studies including 
some conducted in high-burden TB countries but its longitudinal changes have not been 
assessed in South African TB patients. South Africa is the country with the highest prevalence 
and incidence rate in TB among all 22 high-burden countries (WHO, 2015c). Limited 
knowledge about adherence behaviour during TB treatment is available, most from qualitative 
studies. Both outcomes, HRQOL and adherence, are assumed to impact each other but this 
association has not been studied longitudinally so far. The objective of this research is to 
perform a study evaluating HRQOL and its association with medication adherence in patients 
with active pulmonary tuberculosis in South Africa. We developed a conceptual framework for 
HRQOL in TB capturing all TB related physical, mental and psycho-social health aspects; 
based on a systematic literature search we found a total of 43 different HRQOL and three 
adherence measures which were applied in TB. Based on these findings we selected HRQOL 
and adherence  measures which capture all HRQOL constructs in  TB according to our 
conceptual framework. The rationale of PRO measure selection respected the use of generic 
HRQOL measures which allow comparison between different diseases and thus support 
consistent value judgment and transparency e.g. in reimbursement decision making (eunethta, 
2013). Further, we included disease- and condition-specific instruments which are more 
sensitive to change than generic instruments. This ultimately led to the selection of two generic 
measures (EQ-5D-5L and SF-12), one disease-specific (St George Respiratory Questionnaire) 
and one condition-specific measure (Hospital Anxiety and Depression Scale). As a patient- 
reported adherence instrument, we selected the Morisky Medication Adherence Scale 
(MMAS). Validity and reliability of these selected PRO measures, including their linguistic 
validation for English for South Africa, is given. MID was identified from literature for each 
HRQOL measure to understand meaningful changes over time. Based on the conceptual 
framework and selection of PRO measures, an endpoint model with the change between end 
of treatment and baseline in the physical component score (PCS) of SF-12 defined as primary 
endpoint was developed. PCS score of SF-12 is selected as primary endpoint since TB has a 
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major impact on the physical health. Based on the primary endpoint, the required sample size 
was determined to be 96 participants. The described protocol is specific to TB, however the 
rationale for selection of HRQOL and adherence measures may be transferred to other studies 
applying PRO measures and might be useful for the development of a general approach for 
future studies. Patient-reported HRQOL reflects the patient perspective, and is an information 
source for health service quality and treatment effectiveness which could support the decision 
making during reimbursement, access to medicines and health policy process (McKenna, 
2011, Calvert, 2014). A number of clinical trials include PRO measures for assessing efficacy 
as endpoint to generate an added value and to support biochemical endpoints (Doward et al., 
2010). Post-marketing studies apply PRO measures for evaluation of effectiveness to inform 
treatment guidelines (Acquadro C, 2003a). To ensure data quality and evidence reporting, the 
study design and methodology of PRO trials are of importance. PRO-specific rationale and 
objectives, PRO endpoint specification, timing of PRO assessment, sample size determination 
for HRQOL studies, PRO data collection, and statistical analysis are key aspects of study 
design and methodology (Calvert, 2014). We developed our study design according to these 
aspects. It is hoped that this study will provide important information about physical, mental 
and psycho-social health aspects of TB in the South African socio-demographic context. This 
additional knowledge about TB, which goes beyond well-known physiological and clinical 
parameter, should inform current treatment guidelines for South Africa. Currently, a number of 
new TB drugs and diagnostic devices are under development or in a clinical phase. An 
integrative knowledge about HRQOL should assist with evaluating the added value of newly 
developed TB drug products and treatment procedures in comparative effectiveness research 
(CER) studies. Outcomes from CER will support resource allocation, reimbursement decisions, 
access to medicines and health policy making in TB in the context of the implementation of 
National Health Insurance for South Africa. The evaluation of HRQOL and its association with 
adherence in TB using  the selected PRO measures could support future research and 
development of a TB-specific measure by reviewing the different health domains and their 
items for TB-relevant aspects. Such TB-specific measure may be integrated into standard care 
to monitor TB treatment with an integrative patient-centred approach. 
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6. Health-related quality of life in South African 
patients with pulmonary tuberculosis 
This manuscript has been submitted for publication to PLOS ONE on 24 September 2016 
and is currently under review. 
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6.1 Abstract 
 
Background: The evaluation of patient-reported health-related quality of life (HRQOL) in 
pulmonary tuberculosis (TB) contributes to a comprehensive understanding of the burden 
associated with this disease. The aim of this study was to assess the overall impact of TB on 
the health status and on single health domains identified in the WHO definition of health, 
including physical, mental and social health aspects. 
Methods: Four instruments for HRQOL evaluation were applied in a longitudinal multicentre 
study during six-month standard TB treatment in South Africa. These included the generic SF- 
12 and EQ-5D-5L, the disease-specific St. George´s Respiratory Questionnaire (SGRQ) and 
the condition-specific Hospital Anxiety and Depression Scale (HADS). Statistical analysis 
included significance testing, univariable and multivariable analysis, and repeated measures 
ANOVA. Change over time in the physical component score (PCS) of SF-12 was defined as 
primary endpoint. A target sample size of 96 patients was estimated. 
Results: HRQOL of the study participants was impaired in all physical, mental and psycho- 
social health domains at treatment start. HRQOL improved significantly and in a clinically 
meaningful manner during the course of standard TB treatment, over the period of the study. 
The greatest improvement (95%) was observed in mental health. Younger patients with higher 
education and who were employed had a better HRQOL. 
Discussion: This study demonstrates the need for an integrative understanding of TB with 
HRQOL as core element to inform gaps in current TB management. Improvements in the 
management of TB following an integrative patient-centred approach will contribute towards 
meeting the United Nations Sustainable Development Goal 3 (SDG3) target and will support 
the End TB strategy of the WHO. 
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6.2 Introduction 
 
At the beginning of 2016, the United Nations (UN) introduced the Sustainable Development 
Goals (SDGs) to replace the Millennium Development Goals (MDGs) established in 2000 
(WHO, 2015b). The third goal of the SDGs (SGD3) aims to ensure healthy lives and promote 
well-being at all ages (WHO, 2015b). One target of SGD3 focuses on universal health 
coverage, including access to safe, effective, high quality and affordable essential medicines 
(WHO, 2015d). Access to medicines requires sponsors to demonstrate that the medicine is 
safe, effective and affordable. The evidence of the real benefit of a treatment is usually 
evaluated based on clinical trials and real world data evidence. Only after this evidence has 
been provided, can medicines be made accessible through healthcare organizations. The 
World Health Organization (WHO) claims that patient involvement in their healthcare is a 
social, economic and technical necessity (Doward et al., 2010). The evaluation of a patient- 
reported perspective of a disease and treatment contributes to a comprehensive 
understanding of the benefit and risk associated with that disease. This is important as some 
concepts cannot be measured objectively. One specific patient-reported outcome (PRO) is 
health-related quality of life (HRQOL). HRQOL is a PRO which refers to the multi-dimensional 
nature of health, and usually includes physical, mental and social health domains (WHO, 
1948). 
A further target of the UN SDG 3 includes an end to the epidemic of tuberculosis by 2030 
(WHO, 2015a). Tuberculosis (TB) places a significant burden on the health system of South 
Africa, which has the highest prevalence and incidence rates of all 22 countries with a high 
burden of TB worldwide (WHO, 2015c). 
The impact of TB on HRQOL has been reported in a systematic literature review (Kastien-Hilka 
et al 2016). This systematic review found that TB had a negative impact on patients' HRQOL 
and overall wellbeing. The review further identified several factors associated with HRQOL in 
TB which included socio-demographic (age, gender) and socio-economic (income, education, 
housing, social security) characteristics, disease-related (symptoms) and therapy-related (side 
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effects, adverse events) factors, and psycho-social aspects (isolation and stigmatization, 
psycho-social burden) (Adeyeye et al., 2014, Masumoto et al., 2014, Aggarwal et al., 2013, 
Bauer et al., 2013, Deribew A, 2013, Dias et al., 2013, Ralph et al., 2013, Awaisu et al., 2012, 
Balgude and Sontakke, 2012, Chung et al., 2012, Kittikraisak et al., 2012, Louw et al., 2012, 
Othman, 2011, Aggarwal, 2010, Guo et al., 2010, Dhuria et al., 2009, Guo et al., 2009, Guo N, 
2008, Marra et al., 2008, Chamla, 2004, Hansel NN, 2004, Marra et al., 2004). Significant 
physical impairment caused by somatic symptoms and consequences of TB has also been 
reported (Awaisu et al., 2012, Guo et al., 2009, Chang B, 2004, Hansel NN, 2004). 
Although TB treatment results in a significant improvement in HRQOL, especially in physical 
and psychological dimensions (Aggarwal et al., 2013, Bauer et al., 2013, Ralph et al., 2013, 
Awaisu et al., 2012, Balgude and Sontakke, 2012, Louw et al., 2012, Othman, 2011, Guo et 
al., 2009, Guo N, 2008, Chamla, 2004) the treatment regimen can be difficult for patients due 
to adverse drug reactions, the quantity of pills and treatment duration. This may have a 
significant impact on levels of adherence in this patient population. There is also some 
published evidence to suggest that amongst TB patients, psycho-social burden may have a 
greater impact than clinical symptoms. Specifically, anxiety and depression are the most 
frequently reported mental disorders reported in TB patients (Peltzer K, 2012, Aamir and Aisha, 
2010). It is believed that psychological distress may be caused by social stigmatization 
because of public misconception that a TB patient suffers from HIV co-infection (Naidoo and 
Mwaba, 2010, Van Rie et al., 2008). This association with HIV/AIDS may lead to a perception 
of social isolation during TB treatment and further impacted by the poor financial situation of 
many patients (Peltzer K, 2012, Issa BA, 2009, Hansel NN, 2004). 
The impact of TB on HRQOL in South African populations was assessed in two studies only, 
(Louw et al., 2012, Westaway, 2001). As most other published studies addressing HRQOL in 
TB patients, both studies followed a cross-sectional study design. Longitudinal changes in 
HRQOL assessed in South African TB patients were not available when our study was initiated. 
Since information on HRQOL contributes to efficient decision making, product approval, pricing 
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and reimbursement as well as health policy making, HRQOL data will support the identification 
of sustainable health innovations in TB. A recognized reliable and validated TB-specific 
HRQOL measure has not been available, however all relevant HRQOL aspects of TB need to 
be captured to assess the achievement of the WHO´s End TB Strategy pillars. 
The aim of this research was to evaluate patient-reported HRQOL in pulmonary TB in South 
Africa. The study sought to understand the overall impact of TB on the health status and on 
single health domains identified in the WHO definition of health, including physical mental and 
social health aspects. The study addressed the impairment in HRQOL associated with TB, 
prior to treatment and longitudinal changes in HRQOL over the course of a six-month standard 
TB treatment. 
 
 
6.3 Methods 
 
A detailed description of the study design and methodology has been published previously 
(Kastien-Hilka et al 2016). Briefly, the study followed an observational longitudinal design 
including prospective, repeated measures of HRQOL per study participant. 
 
 
6.3.1 Patient population and participant recruitment 
 
Study participants were recruited between November 2014 and May 2015 at six selected 
primary health care clinics with the highest TB caseloads per month in Cape Town. Four of 
these facilities are run by the local government, and two by the provincial government, and are 
located in the Khayelitsha sub-district of the Cape Town Metro district. The sub-district has the 
highest TB burden in Cape Town, based on latest available case loads from 2012 provided 
through the Western Cape Province. The study population comprised of patients diagnosed 
with active pulmonary TB. TB patients who were 18 years or older and were not diagnosed 
with TB before were eligible. Patients were excluded if they were diagnosed with multidrug- 
resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), and/or had HIV co- 
infection. The eligibility status of each patient was subject to verification by the nurse dedicated 
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to TB patients of each health facility. Based on a patient information document, eligible patients 
were informed about the nature, purpose, potential risks and benefits of the study. Patients 
had the opportunity to decline their participation or to withdraw from the study at any time point. 
Patients who agreed to participate in the study signed a written informed consent. 
Recruitment of new TB cases without HIV co-infection was difficult as a high proportion of TB 
patients are also HIV co-infected in South Africa. In order to meet the sample size in the pre- 
determined time frame, one additional clinic in a neighboring district was included in the study. 
 
 
6.3.2 Study procedures 
 
Eligible participants received a six month standard TB treatment with rifampicin, isoniazid, 
ethambutol and pyrazinamide. This standard treatment was not influenced by the study design. 
HRQOL was evaluated during the treatment course. The data collection regimen to monitor 
changes in HRQOL included five different time points over the six-month treatment period: 
beginning of treatment (baseline) and at follow-up visits after 4, 8, 16 weeks and after six- 
month treatment. Data collection started when TB patients visited the study sites for treatment 
initiation; four HRQOL measures and one socio-demographic questionnaire were applied at 
baseline (treatment start). These four HRQOL measures were re-applied at all follow up visits. 
Data were collected based on completion of paper questionnaires during face-to-face 
interviews conducted by trained field workers. Questionnaires were scanned by the field 
worker for any missing responses during the interviews. 
 
 
6.3.3 Study Materials 
 
The rationale for the selection of HRQOL measures has been described previously (Kastien- 
Hilka et al 2016). Two generic (European Quality of Life 5 Dimensions 5 levels (EQ-5D-5L) 
and Short-Form 12 items (SF-12)), one disease-specific (St. George´s Respiratory 
Questionnaire (SGRQ)) and one condition-specific (Hospital Anxiety and Depression Scale 
(HADS)) HRQOL measures were used. 
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EQ-5D-5L 
EQ-5D-5L (Euroqol) is widely used as a utility index for estimating QALYs in cost-effectiveness 
studies (Euroqol, PROQOLID). It comprises five items/domains (5D) (Mobility, Self Care, Usual 
Activities, Pain/Discomfort, and Anxiety/Depression) with each domain having five levels (5L): 
no problems, slight problems, moderate problems, severe problems, and extreme problems; 
The EQ-5D-5L includes further one vertical visual analogue scale (VAS 20 cm). Index-based 
values (utilities) are calculated from EQ-5D-5L by applying country-specific valuation 
algorithms. No South African specific valuation algorithms were available. Therefore, 
algorithms developed for the UK and for Zimbabwe, the only African country with an available 
algorithm, were used in this study. The EQ-5D-5L utilities range from 0 to 1, with higher scores 
indicating better health. A minimally important difference (MID) is only known for the 3 level 
version of EQ-5D, with a MID of 0.074 (range -0.011 - 0.140) and a MID of 7 for VAS scores 
(Walters, 2005). EQ-5D-5L has an improved sensitivity compared to the 3 level version and its 
MID is also assumed for the 5 level version. 
 
SF-12 
Short-Form 12 (SF-12) is an abbreviated version of SF-36 containing 12 items representing 
eight domains (physical functioning, role physical, bodily pain, general health, vitality, social 
functioning, role emotional, and mental health) (Ware, PROQOLID). Domains are aggregated 
into composite summary scores, Physical Component Score (PCS-12) and Mental Component 
Sore (MCS-12). Scoring ranges from 0 to 100 with greater scores representing better HRQOL. 
A score between 47 and 53 reflects normal scores for both PCS and MCS based on US 
population norms (Maruish, 2009, Atif et al., 2014a). No population norms for South Africa or 
other African countries are available. A MID of at least 3 points has been suggested for the 
SF-36 (Maruish, 2009) and can also be used for SF-12v2 (Maruish ME, 2009). 
 
St. George´s Respiratory Questionnaire 
St. George´s Respiratory Questionnaire (SGRQ) is a disease-specific instrument designed to 
assess  patients  with  respiratory tract  and  immune  system  diseases,  especially asthma, 
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pulmonary diseases, and chronic obstructive disease (Jones, 2009, PROQOLID). SGRQ 
comprises 50 items in three domains (Symptoms, Activity, and Impacts on daily life). Scores 
are scaled from 0 to 100, with higher scores indicating worse HRQOL. A MID for SGRQ is 
defined as an improvement of 4 points in the domain scores and the total score (Jones, 2005). 
 
Hospital Anxiety and Depression Scale 
Hospital Anxiety and Depression Scale (HADS) is a condition-specific instrument applied in 
psychology and psychiatry to detect states of anxiety and depression (El Achhab et al., 2008). 
HADS comprises 14 items in two domains, Anxiety domain and Depression domain. The 
scores of each subscale range from 0-21 (8-10 mild, 11-14 moderate, 15-21 severe). A MID 
for HADS is not available from the developer. A MID of 1.5 points has been estimated for 
chronic obstructive pulmonary disease (COPD), corresponding to a change from baseline of 
20% and informed by both anchor- and distribution-based methods (Puhan et al., 2008). 
 
 
6.3.4 Sample Size 
 
The primary endpoint was defined as change in mean score of PCS-12 between baseline and 
six-month treatment. As SF-12 and SF-36 are comparable measures, sample size 
determination was based on the change in mean score of PCS-36 as reported by Walter 
(Walters, 2004). We assumed a 4.0 point change in PCS-12 mean score (higher than the MID 
of 3 points) between baseline and visit 4 (six-months treatment) (Babikako et al., 2010) (Atif et 
al., 2014a), and a corresponding standard deviation (SD) of 7.0 for the mean score after six- 
months treatment (Atif et al., 2014a), resulting in a standardized effect size of 0.57. Using the 
standardized effect size with a two-sided 5% level of significance and a 95% power yielded in 
an estimated sample size of n = 80 participants. We estimated an attrition rate of 20% resulting 
in a final sample size of n = 96 participants. 
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6.3.5 Ethics 
 
The study adhered to the International Conference on Harmonisation of Technical 
Requirements for Registration  of Pharmaceuticals for Human Use  (ICH) guidelines, the 
Declaration of Helsinki and South African Good Clinical Practice (GCP). The study was 
approved by the institutional review commission of the Swiss Tropical and Public Health 
Institute in Basel, Switzerland. Ethical approval was obtained from the ethical commission of 
North-West and Central Switzerland (EKNZ) and the ethics committee of the University of 
Cape Town. City Health of the City of Cape Town and the Western Cape Government of South 
Africa gave institutional approval of the study. 
 
 
6.3.6 Statistical analysis 
 
Missing interviews were recorded as the absence of the study participant at the appointed 
interview time frame. Missing data were recorded when the interviewed participant did not 
complete HRQOL measures, or only insufficiently, hindering calculation of a domain or total 
score. Significance testing (paired-samples t-test), multivariable analysis and repeated 
measures ANOVA were based on observations that contained all data points required for a 
specific analysis. 
 
All HRQOL responses were transferred to an excel-based database and all measures were 
scored according to each measure´s instructions. 
EQ-5D-5L utility scores were  calculation based on valuation  algorithms for the UK and 
Zimbabwe, applying the EQ-5D calculator (Euroqol). SF-12 component scores PCS-12 and 
MCS-12 as well as SGRQ domain and total score were calculated applying specific scoring 
software provided through the measure´s developer. HADS was scored based on an excel 
worksheet according to manual instructions. 
Interpretation of EQ-5D-5L domain scores and HADS Anxiety and Depression domains were 
both based on categories: EQ-5D-5L on its five levels (no problems, slight problems, moderate 
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problems, severe problems, and extreme problems) and both HADS domains on three levels 
(mild, moderate, severe). The SF-12 component scores and EQ-5D VAS were both interpreted 
based on a range from 0 (worst health) to 100 (best health), the EQ-5D-5L utility index on a 
range from 0 (worst health) to 1 (best health). The SGRQ domains and total score were 
interpreted based on a range between 0 (best health) to 100 (worst health) and compared to 
scores derived from a population with no history of respiratory disease (Jones, 2009). 
Descriptive statistics were applied to socio-demographic data; further to all HRQOL data at 
baseline and at all follow-up visits to understand the HRQOL impairment of TB patients. 
Descriptive statistics were conducted including frequencies (N, N missing, %), central 
tendency (mean, median), and confidence interval (set at 95%). Distribution of data was 
examined by standard deviation (SD), minimum and maximum values, and frequency plots. 
Overall changes in HRQOL between baseline and six-month treatment (visit 4) were calculated 
as frequencies (%). Longitudinal changes were determined by the change in mean scores 
between all follow-up visits and baseline. The change in mean scores was examined by paired- 
samples t-test with a statistical significance (2-tailed) set a priori at P < 0.05. Changes in mean 
scores in the intensive treatment phase (baseline to visit 2) were compared to changes in the 
continuous treatment phase (visit 2 to visit 4) based on paired-samples t-test with a statistical 
significance (2-tailed) set a priori at P < 0.05. The change in mean scores at each time point 
from baseline was also compared to the reported minimally important difference (MID) for each 
measure to understand if the longitudinal changes in HRQOL were clinically meaningful. 
Paired-samples t-test was applied to examine the difference between changes in mean scores 
and MID at a significance level of P< 0.05. 
Differences in HRQOL mean scores among all HRQOL measures over time (baseline and 
follow-up visit 1-4) were examined by repeated measures ANOVA. Bonferroni correction was 
applied to repeated measures ANOVA for multiplicity of tests. 
Responsiveness over time for each HRQOL was measured as an effect size partial eta 
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squared providing information of the effect of time on changes in HRQOL aspects. The time 
effects were based on tests of within-subjects effects. When Mauchly´s test of sphericity was 
not met (significance < 0.05), both partial eta squared and observed power were derived from 
the Greenhouse-Geisser correction. 
The impact of socio-demographic factors including age, gender, educational status and work 
status were elaborated. At baseline univariable analysis was applied to understand which 
factors might be associated with HRQOL, by using a cut off of P = 0.2. Resulting candidate 
factors were further assessed in multivariable models to understand the impact of socio-
demographic factors over time (change from baseline to six month treatment (visit 4)). The 
univariable and multivariable analysis included a general linear model and an analysis of 
variance (ANOVA).  The time effect of socio-demographic factors based on an effect size 
partial eta squared was further included by applying repeated measures ANOVA. Threshold 
values for the effect size were derived from Cohen (Cohen, 1988): 0.1 was interpreted as small, 
0.3 as medium, 0.5 as large and 0.8 as very large. 
 
Robustness of the findings was assessed by sensitivity analyses by excluding HRQOL data 
from visit 3. Further, the assessment of longitudinal changes of HRQOL over time including 
baseline and all follow-up data as described above was repeated by excluding data from visit 
3, which was affected by a very low number of available observations. Results were checked 
for consistency. 
 
 
6.4 Results 
 
In total, 131 eligible patients were recruited and agreed to participate in the study. Overall, 444 
interviews were conducted over the duration of the study with questionnaires completed for 
data analysis. 
From 131 participants who had baseline interviews conducted, 84 (64%) participated in the 
follow-up interview at visit 1, 85 (64%) participated at visit 2, 48 (36%) participated at visit 3 
and 96 (70%) participated at visit 4. Only 20% of participants completed all HRQOL 
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questionnaires at all time points during treatment as per protocol (Table 5). 
Table 5: Overview of interviews taken at each data collection time point per study site. 
 
Data Total 
Collectio Number 
n Point Interview 
s 
Number of interviews 
Study Study Study site Study Study Study Study 
site 1 site 2 3 site 4 site 5 site 6 site 7 
Baseline 131 54 9 18 9 8 13 20 
(treatmen 
t start) 
Visit 1 
(4 weeks 
post 
treatment 
start) 
84 31 8 17 5 6 3 14 
Visit 2 85 34 8 18 2 5 9 9 
(8 weeks 
post 
treatment 
start) 
Visit 3 48 7 10 17 1 1 7 5 
(16 
weeks 
post 
treatment 
start) 
Visit 4 96 41 9 17 3 2 9 15 
(24 
weeks 
post 
treatment 
start) 
Total 444 
During the course of treatment a total of 47, 46, 83, and 35 patients did not participate in 
follow- up interviews 1 to 4, respectively. In the majority of cases the reason for absence of 
participants was unknown. Of those participants who attended an appointment during the 
study period, none refused to participate in the interview. However, four patients were 
unable to participate at follow-up interviews as they had been transferred to a different 
hospital not included in this study and one patient received a custodial sentence. The lowest 
attendance rate to interviews was observed after 16 weeks of treatment (visit 3). The 
reasons why participants did not attend their clinic appointments, and hence the low 
response rate, was unknown. 
In total, nine questionnaires were not completed by patients during the fieldwork. 
Whilst completing the sections on HRQOL measures, two patients did not answer the 
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socio-demographic questionnaire, but all HRQOL measures; these two patients were still 
included in the data analysis. One of each measure was not answered during the data 
collection: SF- 12 at baseline and at visit 1; EQ-5-D-5L at baseline and at visit 4; SGRQ 
at baseline, and HADS visit 1 and visit 2. 
 
 
6.4.1 Description of the study population 
 
Table 6 describes the study population. Of 131 study participants, two participants did not 
provide information on socio-demographic data; 129 participants were included in the 
description of the study population. Study participants who provided socio-demographic data 
(n=129) comprised 64% (n=82) men and 36% (n=47) women, age ranged from 18 years to 80 
years, with the majority of participants being between 20 and 40 years and with a mean age 
of 36 years. The majority of participants were black (90%), living alone (i.e. not married nor co- 
habitation; 82%), and high school education attainment (68%). The majority of the study 
participants (73%) were unemployed, students or pensioners. Only 21% of the study 
participants were aware about existing co-morbidities impacting their health, most of them 
reporting to be diagnosed with other respiratory diseases or diabetes. 
The characteristics of the full study population were similar to the characteristics of those 
patients who provided information at the last visit, after six months of treatment. 
Table 6: Socio-demographic description of study population. 
 
 
 
Socio-demographi c Factors Study populatio n 
N % *N 
missing 
Gender  129  2 
Male 82 63.6 
Female 47 36.4 
Age  129  2 
Mean age 35.8 
Median age 31 
Min 18 
Max 80 
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Age Groups 129  2 
18-30 60 46.5 
31-50 46 35.7 
>51 23 17.8 
Ethnicity 129  2 
black 116 89.9 
other 13 10.1 
Marital status Total 129  2 
single/ never married 103 81.7 
/divorced/separated/widowed   
married/co-habitation 23 18.3 
Education 129  2 
Primary school 30 23.8 
High school 86 68.3 
College or university 10 7.9 
Employment status 128  3 
Employed/Self-employed/own business 34 26.6 
Unemployed/Student/Pensioner 94 73.4 
Co-morbidities 27  104 
Other respiratory diseases 13 48.1 
Diabetes 13 48.1 
Cancer 
Cardio-vascular diseases 1 3.7 
Unknown co-morbidities 
 
6.4.2 HRQOL impairment of TB patients at treatment start 
 
Based on each measure´s score interpretation the HRQOL of the study participants was 
impaired in all physical, mental and psycho-social health domains at treatment start (baseline) 
(Table 7). 
Table 7: Baseline impairment of HRQOL in TB patients at treatment start. 
 
 
HRQOL 
measure 
HRQOL 
domain 
N 
(%) 
Mean score 
(SD) 
95%  Confidence 
Interval 
Median Range N 
mis
sin
g ( 
%) 
Min Max 
SF12 PCS-12 129 35.930 (8.321) 34.477 – 37.376 33.990 16.100 57.090 2 
 MCS-12 129 36.011 (11.487) 34.013 – 38.015 35.840 11.690 68.900 2 
EQ-5D Mobility 129 2.442 (1.117) 2.247 – 2.637 3.000 1.000 5.000 2 
 
 Self Care 129 2.434 (1.131) 2.237 – 2.631 3.000 1.000 5.000 2 
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Usual 
Activities 
129 2.558 (1.224) 2.345 – 2.771 3.000 1.000 5.000 2 
 Pain&Discomf
ort 
129 2.496 (1.098) 2.305 – 2.687 3.000 1.000 5.000 2 
Anxiety&De
pressi on 
129 2.566 (1.224) 2.353 – 2.779 2.000 1.000 5.000 2 
 utility Index 
(UK) 
129 0.505 (0.328) 0.448 – 0.562 0.546 -0.594 1.000 2 
utility Index 
(Zim) 
129 0.620 (0.203) 0.584 – 0.655 0.621 -0.145 0.900 2 
 VAS score 129 54.512 (18.066) 51.364 – 57.659 50.000 10.000 100.000 2 
SGRQ Symptoms 126 41.333 (33.803) 35.349 – 47.317 45.419 0.000 100.000 5 
 Activities 126 70.087 (30.868) 64.622 – 75.522 79.671 0.000 100.00 5 
Impact 126 61.542 (25.638) 57.003 – 66.081 66.798 0.000 100.00 5 
 Total score 126 61.134 (23.045) 57.055 – 65.214 66.366 0.000 92.643 5 
HADS Anxiety 131 11.504 (5.772) 10.506 – 12.502 12.000 0.000 21.000 0 
 Depression 131 12.092 (6.237) 11.014 – 13.170 13.000 0.000 21.000 0 
SF-12: 0 to 100 (= best HRQOL); EQ-5D domains: 1 = no problems, 2 = slight problems, 3 = moderate problems, 4 = 
severe problems, 5 = extreme problems. EQ-5D total index 0 to 1 (best HRQOL); EQ-5D VAS: 0 = worst health to 
100 (= best health); SGRQ 0 to 100 (= worst health); HADS: normal (0-7) mild (8-10) moderate (11-14) severe (15-
21) 
 
 
 
6.4.3 Development of HRQOL during TB treatment 
 
All scores of HRQOL domains improved during the course of standard TB treatment, and over 
the period of the study (Figure 10). These changes were statistically significant. The largest 
improvement was observed in domains relating to mental health (increase in mean score 
between baseline and six month treatment of 59% - 95%), with the highest change observed 
in the HADS Anxiety and Depression domains, followed by improvements in the physical health 
domains and the social health domains . The primary endpoint defined as change in mean 
score of PCS-12 between baseline and six months from treatment initiation (visit 4) showed a 
change of 20 points (from 35.93 to 55.21) which was statistically significant (P <0.005) (Figure 
11). The change in mean score was also greater than the published MID threshold to be 
considered clinically meaningful. 
  
 
 
 
 
 
 
 
 
Figure 10: The development of HRQOL over six-month treatment, presented for each HRQOL measure and its health domains. 
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Figure 11: Histograms of PCS-12 at baseline and after six-month treatment 
 
 
 
 
Figure 11: Histograms of PCS-12 at baseline and after six-month treatment. 
 
The change in HRQOL over time was statistically significant based on average mean scores. 
The change was greater than published MID thresholds for each HRQOL measure and 
thereby clinically meaningful. The MCS-12 mean score showed a greater relative 
improvement by 
+67% over six month treatment than the PCS-12 (+54%). Both component scores changed to 
a value of 55 points for PCS-12 and 60 points for MCS-12 and these values were above U.S. 
population norms (47 points for PCS-12 and 53 points for MCS-12) (Atif et al., 2014a, Maruish, 
2009). All EQ-5D-5L average domain scores changed from an average state of 
“moderate health problems” to a state reporting “no problems” (+57-59%). The total 
index of EQ-5D reflected the same change as was observed on domain level. The total 
index calculated using the UK valuation algorithm changed by +94%. However, the total 
index value based on the Zimbabwe valuation algorithm changed by only +44%. The 
health status of the TB patients measured with the EQ-5D VAS changed by +78%. 
The three SGRQ domains showed the greatest change in the physical symptoms domain with 
 
+90% improvement. Both domains of HADS (anxiety and depression) changed by +95% from 
a state of “moderate problems” to a state of reporting “no problems”. 
The changes in mean scores during the intensive treatment phase were significant and 
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(baseline to visit 2) higher than during the continuous treatment phase (visit 2 to visit 4). The 
changes in mean scores of the SGRQ Activities and Impact domains as well as in the SGRQ 
total score were non-significant during the continuous phase (S1 Table). 
Changes in mean scores increased constantly until six month treatment for SF-12, EQ-5D VAS 
and HADS. The change in EQ-5D and SGRQ mean scores also increased significantly but 
with a peak after 16 weeks of treatment (visit 3) and changes in mean scores decreased until 
six month of treatment. Repeated measures ANOVA confirmed that the overall improvement 
in all HRQOL measures was associated with a statistically significant time effect 
ranging between 58% and 85%, with the highest effect observed on the health status (EQ-
5D VAS) (S2 Table). Sensitivity analysis applied to repeated measure by leaving out data 
from visit 3 confirmed the robustness of the findings 
 
 
6.4.4 The Influence of socio-demographic factors on 
baseline HRQOL and longitudinal changes in HRQOL 
Significant results  from the univariable analysis including the  socio-demographic factors 
gender, age, educational level and work status were further assessed in a multivariable model. 
The univariable analysis showed that HRQOL at baseline was more impacted in older patients 
with low educational background and without work. Age and education were significant factors 
in mental health domains, with younger patients with higher education reporting better HRQOL; 
work status played no major role in the mental health. With exception of MCS-12, gender 
played no role in HRQOL. Only in MCS-12 women reported a lower HRQOL than men. 
The multivariable model confirmed that younger patients (SGRQ Impacts domain, SGRQ 
total score, HADS Anxiety and Depression domains) with higher education (EQ-5D total 
index, HADS Anxiety and Depression domains) and with work (EQ-5D total index, SGRQ 
Symptoms domain) had a better HRQOL at baseline. These effects were only seen at 
baseline for all HRQOL measures (Table 8) and not after six months of treatment. PCS-12 
mean scores at six months were not significantly different for gender, age, educational 
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background and employment status.
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Table 8: Associations between HRQOL and socio-demographic factors at baseline by applying 
a multivariable model. 
 
EQ-5D 
utility 
index 
UK 
EQ-5D SGRQ 
utility Symptoms 
index Zim 
SGRQ 
Impacts 
SGRQ 
total 
HADS 
Anxiety 
HADS 
Depression 
Age 
P* value - 0.047 - 0.046 0.020 0.017 0.029 
18-30 years - 0.655 - 56.959 55.998 11.462 11.179 
31-50 years - 0.615 - 63.373 63.381 11.297 12.703 
>51 years - 0.501 - 75.168 74.813 15.588 15.824 
Education 
P* value 0.015 0.015 - - - 0.010 0.044 
Primary school 0.340 0.516 - - - 14.526 15.158 
High school 0.528 0.629 - - - 11.862 12.154 
College or 
University 
0.745 0.766 - - - 7.286 9.000 
Work Status 
P* value 0.008 0.010 0.020 - - - - 
Employed, self- 
employed, own 
business 
0.669 0.713 26.917 - - - - 
Unemployed, 
student, 
pensioner 
0.444 0.578 46.399 - - - - 
 
 
Results from the repeated measures ANOVA showed no statistically significant effect of 
gender and age on the overall HRQOL improvement. However, education and work status 
showed significant effects. Patients with higher education and with work reported better 
HRQOL. Education (df = 1.000, F = 6.632, P = 0.012, eta = 0.074) and work status (df = 
1.000, F = 7.789, P = 0.007, eta = 0.086) had a statistically significant but small effect on the 
HRQOL improvement with regard to PCS-12 (physical health). Similar effects were 
observed for the EQ5D utility indices (UK valuation algorithm: education df = 1.000, F = 
7.071, P = 0.009, eta = 0.078; work status df = 1.000, F = 7.799, P = 0.006, eta = 
0.085); Zimbabwe valuation algorithm: education df = 1.000, F = 6.821, P = 0.011, eta = 
0.075; work status df = 1.000, F = 7.438, P = 0.008, eta = 0.081). Further, work status 
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showed a statistically significant (df 1.000, F = 7.654, P = 0.007, eta = 0.081) but small effect 
on the overall improvement of the HRQOL domain SGRQ Symptoms (physical health) (S3 
Table). 
 
6.5 Discussion 
 
The increasing prevalence of non-communicable diseases (NCDs) and communicable 
diseases such as TB in South Africa leads to an increased pressure on healthcare 
resources. More importantly, from the patient perspective it also has an impact on the 
general well-being and HRQOL of patients. 
 
This study was designed to evaluate changes in HRQOL in South African patients recently 
diagnosed with TB (without HIV co-infection) during the course of standard TB treatment over 
a six-month period. Two generic HRQOL measures (SF-12 and EQ-5D), a disease-specific 
measure (SGRQ) for respiratory diseases and a condition-specific measure for anxiety and 
depression, the HADS were used to assess HRQOL (Kastien-Hilka, 2016). These four 
HRQOL measure captured relevant health aspects of TB in the physical, mental and 
psychosocial domains. The study population was recruited from the Cape Town district 
Khayelitsha, a socio- economically disadvantaged area. The majority of TB patients were in 
the productive years of their lives. However, more than 70% were not in employment. At the 
start of treatment, HRQOL domains and total scores on all measures indicated significant 
impairment in HRQOL. The results demonstrate that HRQOL improved significantly over 
treatment time, with the greatest improvement observed during the intensive phase of 
treatment and with greatest improvement in mental health domains. 
Socio-demographic predictors for HRQOL at baseline included age, educational background 
and work status. Younger TB patients with a higher education, and who were in 
employment reported better HRQOL at baseline. A significant effect of educational 
background and work status has been reported before (Kastien-Hilka et al., 2016, 
Darvishpoor Kakhki and Masjedi, 2015). It can be assumed that a better education increases 
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the chances for work and financial security which might have a positive effect on HRQOL by 
improved self-care, improved social interactions, less psycho-social distress and less financial 
burden. Gender differences showed no significant effect on most HRQOL domains at 
baseline; only in the MCS-12 women reported a lower HRQOL than men. These effects of 
age, education and work status were not found after six months of treatment. 
Gender and age were no predictors for positive changes in HRQOL over the treatment course. 
A recent study from Louw et al 2016 confirmed our findings of a non-effect of gender and age 
on HRQOL in TB patients after six month treatment in other Provinces in South Africa (Louw 
et al., 2016). However, the same study reported that higher education was significantly 
associated with an improvement in mental health (MCS-12) after six month of treatment. Our 
study confirmed the effect of education on mental health aspects (anxiety and depression) only 
at baseline. 
All changes over treatment time were statistically significant and were also clinically 
meaningful. The greatest improvements in physical health were measured with the respiratory- 
specific measure SGRQ. The primary endpoint defined as overall change in PCS-12 did not 
reflect the greatest improvements. It can be assumed that the Symptoms domain of SGRQ 
captures physical impairment due to TB in more detail and thereby being more sensitive to any 
changes in HRQOL than generic measures such as SF-12 and EQ-5D. 
The study results revealed that the greatest improvement in all HRQOL domains was seen in 
the mental health of TB patients. The condition-specific HADS measure showed a similar 
impact on mental health at treatment start as reported from a study in Pakistan (Husain 
MO, 2008). These results confirm previous findings suggesting that mental health is an 
important aspect in the treatment of TB. About 46-80% of TB patients in South Africa 
report common mental disorders (Westaway, 2001, Naidoo and Mwaba, 2010). This 
psychological distress is associated with physiological TB symptoms, perceived health 
status, adverse events through anti-TB treatment and  treatment outcome  (Peltzer K, 
2012). Furthermore, psychological distress may be caused by social stigmatization (HIV co-
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infection) followed by social isolation during TB treatment and impacted financial situation 
including fear of dying and disease transmission (Peltzer K, 2012, Issa BA, 2009, Hansel 
NN, 2004, Naidoo and Mwaba, 2010, Aamir and Aisha, 2010). Special focus on reduction 
of stigmatization should be given in the management of TB to reduce the psychological 
distress (Cremers et al., 2015). This may suggest that patients perceive a positive outlook 
suffering less from the depression and anxiety associated with TB in South Africa. This again, 
is something that should be considered in the light of non-adherence. Inclusion of 
psychological support and treatment of mental disorders in the management of TB 
should be considered as well as interventions to reduce the stigmatization related to TB 
to improve the overall treatment outcome. 
 
The physical and mental impairment seen in the South African patient population in this study 
is confirmed by studies in other countries applying the same HRQOL measures. The 
generic SF-12 measure indicated at treatment start a similar impairment in both the PCS-12 
and MCS- 12 with a score of 36, presenting defective physical functioning and a high risk for 
depression. A similar HRQOL impairment was reported in a study with TB affected 
immigrants in the UK (Kruijshaar et al., 2010) and from a study in Yemen (Jaber et al., 
2016). Other studies which measured HRQOL by SF-36 or SF-12 in TB patients reported 
higher scores between 40 and 61 and thereby a better HRQOL at treatment start in Canada, 
Uganda, and Malaysia (Babikako et al., 2010, Dion et al., 2004, Guo N, 2008, Marra et al., 
2008, Atif et al., 2014a, Bauer et al., 2015). Measuring the HRQOL in TB with the generic 
measure EQ-5D, our TB patients in South Africa reported a more impaired HRQOL and 
health status than in other countries (Malaysia, the UK, Canada) (Dion et al., 2004, 
Kruijshaar et al., 2010, Awaisu et al., 2012). The same effect was found with the 
respiratory-specific measure SGRQ showing that our study population had a more 
impacted HRQOL than TB patients from Indonesia (Maguire et al., 2009). The SGRQ total 
score still showed some impairment with a score of 14 compared to a value of 5-7 reported 
by people from Spain with no respiratory history (Jones, 2009). 
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The phenomenon of an initial worsening in HRQOL after treatment start reported previously 
could not be confirmed by our observations (Chung and Li, 2013). Our study confirmed that 
the greatest improvement in HRQOL was seen during the intensive phase and this observation 
was reported before (Aggarwal et al., 2013, Awaisu et al., 2012, Balgude and Sontakke, 2012, 
Othman, 2011, Chamla, 2004). It is  expected that monitoring of adherence during this 
treatment phase should be implemented to ensure that patients continue with their medication 
regime as many may perceive this improvement in their HRQOL as a sign of ‘cure’ and 
therefore no need to continue with their medication. 
 
Comparing the results from the EQ-5D VAS and EQ-5D utility index based on value sets 
from UK with value sets from Zimbabwe clearly showed some cultural differences in 
HRQOL changes over time and its interpretation, and highlight the need for specific 
population norms for South Africa. The EQ-5D VAS reached a higher value of 97 than 
that of the general population in the UK of 82.5 and in Zimbabwe of 79.8 (Jelsma, 2003). 
At baseline the utility index derived from the UK value set was by 0.115 points lower than 
the utility index derived from the Zimbabwean value set and this difference was greater 
than the MID for EQ-5D-5L. This is critically important in the context of the increasing 
request for cost-effectiveness analysis (CEA) from health systems in the allocation of 
resources. The EQ-5D is the preferred instrument to estimate population-based utilities for 
the calculation of quality-adjusted life years (QALYs) to provide a cost per QALY outcome in 
CEA. In 2013, the South African Department of Health published the Guidelines for 
Pharmacoeconomic Submissions which requests the use of QALYs for CEA (NDoH, 
2013). The development towards pharmacoeconomic evaluations in South Africa for 
efficient decision making would require data acquisition to establish South African 
population norms for the EQ-5D. 
 
 
6.6 Limitations 
 
This study had several limitations. Our sample size was difficult to reach in one restricted 
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district due to the low number of TB patients without HIV co-infection, as well as due to time 
and resource limitations in this study. In South Africa the high majority of TB patients are HIV 
co-infected; this study did exclude HIV co-infection to understand the isolated TB impact on 
HRQOL. Further, this study did not include a comparison or control group from the general 
population, for time and resource limitations. Our study did not apply a mixed method approach 
and was limited to a quantitative approach; patient perspectives about TB in a South African 
cultural background were not qualitatively assessed. Such data might have enriched the 
quantitative findings for HRQOL in this study. HRQOL was only assessed in a specific district 
of the Western Cape Province with a specific socio-demographic and –economic situation. 
Results from this study may not be generalizable to the rest of the South African population 
which is very diverse. Receiving treatment for their condition may have put an increased 
economic pressure on these participants as they may have been unable to take on work or 
consider their working options due to the travel distance between a health clinic they get the 
treatment from and workplace, but also due to the disease induced worsening of their physical 
condition (Dias et al., 2013, Chang B, 2004, Hansel NN, 2004). 
Additionally, there is an increased risk of tuberculosis when diagnosed with diabetes 
(Ottermann, 2013), therefore we expected diabetes as a major co-morbidity in our TB patients. 
We included questions about NCDs in our study, however it was apparent that only a small 
portion of TB patients were aware of any co-morbidity they may have, including diabetes. We 
assume that other health issues are unknown to a majority of TB patients have. These 
unknown co-morbidities are assumed to have an additional impact on the HRQOL in 
TB patients at baseline which we could not distinguish. 
 
 
6.7 Conclusions 
 
TB negatively impacts the HRQOL of patients, with specific impairment reported in physical, 
mental and psycho-social health aspects, however with treatment HRQOL improves 
significantly. Different aspects of health (HRQOL domains) are impacted differently and it 
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would appear that the rate of improvement in each domain may also be different. HRQOL 
reveals different outcomes depending on the type of measure applied and depending on the 
cultural background and the study setting, making comparison of HRQOL outcomes 
difficult. Generic HRQOL PROs may not adequately capture all relevant aspects of TB, 
and thus a disease-specific HRQOL measure is required. This study also demonstrates the 
need for an integrative understanding of TB with HRQOL as core element to inform gaps 
in current TB management. Improvements in the management of TB following an integrative 
patient-centred approach will contribute towards meeting the UN SDG3 target and will 
support the End TB strategy of the WHO. 
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7.1 Abstract 
 
Background: Health-related quality of life (HRQOL) and adherence to treatment have 
implications for patient management and care. Tuberculosis (TB) and its treatment present 
a major public health concern in the South African health care system. This study aimed 
to evaluate the association between HRQOL and adherence in TB patients in South Africa. 
Methods: Four self-reported HRQOL and one self-reported adherence measures were used 
in an observational longitudinal multicentre study during six-month standard TB treatment. The 
relationship between both concepts was examined in 131 patients using Spearman´s rho 
correlations and linear regression models. 
Results: HRQOL improved over six-month TB treatment, whereas adherence mean scores 
stayed constant with participants attaining a medium average level. Associations between 
HRQOL and adherence were mainly weak and included a positive relationship with 
improvements in anxiety and depression, pain and discomfort, and psycho-social 
health aspects. 
Conclusion: This study has clearly demonstrated that management of TB patients must 
address their specific mental and psycho-social needs, besides adequate drug treatment. 
An integrative patient-centred approach will contribute towards supporting the Sustainability 
Development Goal 3 target and the End TB strategy. 
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7.2 Introduction 
 
According to the World Health Organization (WHO), health is a multi-dimensional construct 
and comprises physical, mental and social health domains (WHO, 1948). Health-related quality 
of life (HRQOL) can be measured using patient-reported outcome (PRO) measures, which 
take into account these different domains of health. Non-adherence to treatment has a 
negative impact on HRQOL and other measures of health care and outcomes including clinical 
effectiveness, morbidity, medical and psycho-social complications and health care costs (direct 
and indirect costs) (Cramer, 2008, WHO, 2003). The WHO has defined inadequate adherence 
to medication as a major problem in the management of chronic diseases (WHO, 
2003). According to WHO, increased medication adherence could have a greater impact on 
the health of a population than any improvement in specific medical treatments (WHO, 
2003). Both adherence and HRQOL are important indicators for the effectiveness and 
treatment success of therapeutic interventions (Cote, 2003). However, the association 
between HRQOL and adherence to treatment has rarely been studied in some chronic 
conditions including tuberculosis (TB). 
TB places a significant burden on the health systems of countries where this condition is not 
controlled. South Africa, which has the highest prevalence and incidence rates of all 22 high- 
burden TB countries worldwide (WHO, 2015c), has committed a significant portion of its health 
budget to expand early detection and treatment of TB (Christian, 2016). Aside from 
the financial burden on the South African health budget, TB also places a considerable 
burden on the patient, significantly impacting the physical, emotional, psycho-social as 
well as economical domains of health (Kastien-Hilka et al., 2016). These same domains are 
known to impact medication adherence (WHO, 2003). Standard TB treatment is available 
in South Africa, including supervised monitoring and adherence checks by the introduction 
of Direct Observed Treatment (DOT). 
Cote et al and Saleem et al propose a model whereby HRQOL is an ultimate outcome while 
adherence is seen as an intermediate outcome (process variable). This model follows that any 
impact of a therapeutic intervention is revealed by a change in adherence first, followed by a 
change in HRQOL (Cote, 2003, Saleem, 2012). However, the relationship between these 
two concepts is complicated by the fact that HRQOL may also directly influence adherence 
(Agh, 2015). A systematic review by Munro et al identified two underlying mechanisms 
for the association between well-being and adherence, specific to TB treatment (Munro S, 
2007). In this alternative model, the first mechanism relates to TB patients prematurely 
stopping their treatment because they fell better, with patients perceiving the improvement in 
well-being as a cure of TB. On the other hand, the second observed mechanism refers to 
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patients stopping treatment when they experience no improvement or a worsening in their 
health status and well- being, i.e. the medication was not working (Munro S, 2007, WHO, 
2003). This alternative model would imply that a change in HRQOL appears first, and is 
followed by a change in adherence behaviour. 
The aim of this research was to evaluate the relationship between patient-reported HRQOL 
and adherence in pulmonary TB in South Africa using a longitudinal study design. The study 
provides information on the longitudinal changes in HRQOL and adherence during six-month 
treatment. The evaluation of both concepts over time allows identifying which health aspects 
of TB have an influence on adherence and which health domains are affected by non- 
adherence. 
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7.3 Methods 
 
A detailed description of the study design and methodology has previously been 
published (Kastien-Hilka, 2016). Briefly, the study used an observational longitudinal 
design including repeated measures of HRQOL. 
 
 
7.3.1 Patient population and participant recruitment 
 
Study participants were recruited between November 2014 and May 2015 at six selected 
primary health care clinics with the highest TB caseloads per month in Cape Town. Four of 
these facilities are run by the local government, and two by the provincial government; all are 
located in the Khayelitsha sub-district of the Cape Town Metro district. This sub-district has the 
highest TB burden in Cape Town, based on latest 2012 survey data provided by the Western 
Cape Province. Recruitment of new TB cases without HIV co-infection was difficult, as a high 
proportion of TB patients are HIV co-infected in South Africa. In order to meet the sample 
size in the pre-determined time frame, one additional clinic in the neighboring district Delft 
was included in the study. 
The study population comprised of patients newly diagnosed with active pulmonary TB who 
were 18 years of age or older. Patients were excluded if they were diagnosed with multidrug- 
resistant TB (MDR-TB), extensively drug-resistant TB (XDR-TB), and/or had HIV co-
infection. The eligibility status of each patient was subject to verification by the nurse 
dedicated to TB patients at each health facility. 
 
 
7.3.2 Study procedures 
 
Eligible participants received their regular six-month standard of care TB treatment with 
rifampicin, isoniazid, ethambutol and pyrazinamide. Self-reported HRQOL and adherence 
were documented at the following time points during the six-month treatment period: at 
beginning of treatment (baseline, HRQOL only) and at follow-up visits (4, 8, 16 weeks and after 
six-month treatment). At the same time points sputum smear results were collected in order to 
monitor treatment success. Data collection started when TB patients visited the study sites for 
treatment initiation; four HRQOL measures and one socio-demographic questionnaire were 
applied at baseline (treatment start). These four HRQOL measures were re-applied together 
with a self-reported adherence measure at all follow up visits. Data were collected using paper 
questionnaires during face-to-face interviews conducted by trained field workers. 
Questionnaires were scanned by the field worker for any missing responses during 
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the interviews. Sputum smear results for each participating patient were provided through 
the study sites nurses. 
 
 
7.3.3 Study material 
 
The rationale for the selection of HRQOL measures and adherence measure has 
been described previously (Kastien-Hilka, 2016). Two generic (EQ5D-5L and SF-12), one 
disease- specific (SGRQ) and one  condition-specific (HADS) HRQOL measures  were 
chosen. A detailed description of each HRQOL measure is available in the supplement 
material. As self- reported adherence measure the Morisky Medication Adherence Scale 8 
items (MMAS-8) was selected (Krousel-Wood, 2009, Morisky and DiMatteo, 2011, Morisky, 
2008a). The scale is a generic measure assessing long-term chronic and infectious medical 
regimens is reliable and valid and has been applied in TB before (Lam and Fresco, 2015, 
McInerney et al., 2007, Corless et al., 2009, Stirratt et al., 2015). The MMAS has shown to 
be sensitive to identify low adherence and is a simple scale to identify and monitor 
adherence (Morisky, 2008b). The MMAS-8 scale ranges from 0 to 8.0; total scores are 
interpreted in the following way: low adherence <6.0, medium adherence 6.0 – 8.0, and 
high adherence =8.0. 
 
 
7.3.4 Statistical analysis 
 
All statistical analyses were conducted using IBM SPSS Version 23®. Statistical analysis of 
the HRQOL measures and changes over treatment time has been described elsewhere. 
Descriptive analyses were applied to socio-demographic data and sputum smear results; and 
all adherence data at all follow-up visits 1-4 to understand the longitudinal development of 
adherence during  six month treatment. Descriptive analyses included frequencies (N, N 
missing, %), central tendency (mean, median), and confidence interval (set at 95%). 
Distribution of data was examined by standard deviation (SD), minimum and maximum values, 
and frequency plots. 
Longitudinal changes in adherence were examined by the change in mean scores between 
follow-up visit 1 and follow-up visits 2, 3, and 4. The change in mean scores was assessed by 
paired-samples t-test with a statistical significance (2-tailed) set a priori at P < 0.05. Differences 
in adherence mean scores over time were also examined by repeated measures ANOVA. 
Bonferroni correction was applied .to account for multiple testing. The effect size partial eta 
squared provides information of the effect of time on changes in adherence. The time effects 
were based on tests of within-subjects effects. When Mauchly´s test of sphericity was not met 
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(significance < 0.05), both partial eta squared and observed power were derived from the 
Greenhouse-Geisser correction. The impact of socio-demographic factors including gender, 
age, educational background and work status were assessed by applying multivariate analysis 
with adherence at visit 1 and visit 4 as dependent variable. 
Associations between mean scores of HRQOL and adherence were examined using a step- 
wise method. First, descriptive, HRQOL and adherence measures were scrutinized for 
a possible relationship. Second, Spearman´s rho correlation coefficients were calculated 
between HRQOL domains and total mean scores on the one hand and adherences 
mean scores, on the other hand at all time points. In addition, correlations were applied to 
HRQOL and adherence and sputum smear results. Further, Spearman´s rho correlation 
coefficients were examined between changes in HRQOL mean scores (between baseline 
and visit 2; between baseline and visit 4) and adherence mean scores at visit 4. The 
strength of correlations was categorised as follows: 0-0.1 = no correlation, 0.1-0.3 = weak 
correlation, 0.3- 
0.5 = moderate correlation and 0.5-1.0 = strong correlation (Cohen, 1988). In a third step, 
a linear regression model (univariate analysis, multivariate analysis and repeated 
measures ANOVA) was used to examine the associations over time and to examine which 
domain-based associations from the correlation analysis are confirmed by the regression 
model. Multivariate analysis was performed for changes in mean scores of HRQOL between 
baseline and visit 2 and adherence mean score at visit 2; and for changes in mean scores 
of HRQOL between baseline and visit 4 and adherence mean scores at visit 4. Changes in 
HRQOL were treated as dependent variable and adherence scores visit 2 and visit 4 were 
explanatory, fixed factors in the multivariate model. Differences in HRQOL mean scores 
between baseline and visit 4 and differences in mean adherence scores between visit 1 and 
visit 4 were examined by a two factorial repeated measures ANOVA, treating both HRQOL 
and adherence as dependent variables. Bonferroni correction was applied. A repeated 
measures ANOVA was conducted with HRQOL as dependent variable and adherence was 
inserted as fixed factor to examine the effect of time on HRQOL changes by categorizing 
adherence as good, medium or low adherence. Furthermore, univariate analysis was 
applied changes in HRQOL mean scores during the intensive treatment phase (Baseline to 
visit 2) and during the continuous treatment phase (visit 2 to visit 4) with adherence as a 
categorical variable (good, medium, low) and a fixed factor at the end of each treatment 
phase (visit 2 and visit 4). Partial eta squared (η2) was applied as effect size to observe the 
effect of adherence on changes in HRQOL mean scores.  
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7.4 Results 
 
 
7.4.1 Development of HRQOL over treatment time 
 
Baseline scores indicated significant impairment in overall HRQOL and domains. Socio- 
demographic determinants associated with baseline HRQOL were age, education and work 
status, where older, less educated and unemployed (or not working) patients report poorer 
HRQOL. Gender showed no significant effect on HRQOL. 
All HRQOL domains and total scores improved over six-month of TB treatment, with highest 
improvement during the intensive treatment phase (first 8 weeks of treatment). These changes 
were statistically significant, and based on the thresholds set by minimal important difference 
(MID) for each measure, were also clinically meaningful. The greatest improvement in HRQOL 
was observed in mental health domain, such as anxiety and depression. 
 
 
7.4.2 Development of adherence over treatment time 
 
Table 9 and figure 12 present self-reported adherence from 4 weeks (visit 1) to six months 
(visit 4) of standard TB treatment. The mean scores of adherence were in the range of medium 
adherence for the complete treatment time. Mean score for adherence at 4 weeks (visit 1) and 
6 months (visit 4) were identical. Paired samples t-test confirmed that changes between visit 1 
and visit 2, 3 and visit 4 were not statistically significant (2-tailed). Repeated measures ANOVA 
confirmed these findings, and treatment time had no significant effect on the adherence 
behaviour (P= 0.116, partial eta squared = 0.084). 
Based on the adherence grading of MMAS-8, the majority of TB patients reported a good 
adherence at all time points during treatment (74% - 89%). This good level of adherence 
remained unchanged in most patients (79%) throughout the study period. However, 
approximately 21% of patients classified as a good adherer at visit 1 changed their adherence 
behaviour to medium and low adherence after six months. In the group of patients with medium 
and low adherence, 46% improved their adherence to good adherence behaviour after six 
month of treatment. 
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Table 9: Development of adherence over treatment time based on average mean scores 
in adherence at each data collection point over six month TB treatment. 
 
 
 
Time 
 
Mean (SD), N 
 
CI95% 
 
Range 
Good 
adherence 
mean score 
% 
Medium 
adherence 
mean score 
% 
Low 
adherence 
mean score 
% 
Visit 1 7.400 (1.474) (7.076-7.716) 8.000 6.734 2.917 
 84 8 73.8 19.0 7.1 
Visit 2 7.622 (1.053) (7.394-7,851) 8.000 6.800 3.417 
 84 8 78.6 17.9 3.6 
Visit 3 7.800 (0.671) (7.601-7.995) 8.000 6.833 5.000 
 47 3.5 89.4 6.4 4.3 
Visit 4 7.400 (1.503) (7.089-7.701) 8.000 6.789 3.361 
 95 7 76.8 13.7 9.5 
Good adherence = 8, medium adherence = 6-8, low adherence < 6 
 
 
 
 
 
 
Figure 12: Development of adherence over six month TB treatment, based on average 
mean scores. 
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Age, gender and work status showed no impact on the adherence at visit 1 and visit 4. Only 
education had a statistically significant influence on the adherence at visit 4 (η2= 0.129 P= 
0.016). At six-month treatment a lower educational background led to better adherence scores 
than a higher education. 
 
 
Associations between HRQOL and sputum smear results and between adherence to 
medication and sputum smear results were not examined since routinely collection of sputum 
smear results for each participating patient was only possible in few cases. Only one of 
the seven study sites applied sputum smear testing during the course of treatment, but 
only in single cases and not regularly when patients came to the clinics on a monthly basis. 
 
 
7.4.3 Association between HRQOL and adherence over 
treatment time 
HRQOL improved significantly over the treatment time, while mean adherence scores 
remained constant at a medium adherence level. The most pronounced correlation indicated 
a moderate and positive association between adherence in the first 4 weeks and EQ-
5D Anxiety/Depression at six-month treatment (r = -0.430 p< 0.001). The same positive but 
weak relationship was observed between adherence in the first 4 weeks and EQ-5D utility 
index (both UK and Zim based) at six-month treatment (r = 0.364, p= 0.003). At six-month 
treatment a weak but positive relationship between Symptoms and Activities domains 
(SGRQ) and adherence was observed (r = -0.297 p= 0.004; r = -0.317 p= 0.002). 
Spearman´s rho correlation was also calculated for overall changes in HRQOL mean scores 
(baseline to visit 4) and adherence at six-month of treatment. Statistically significant, weak 
correlations were observed between the overall improvement of the HADS Anxiety (r= 0.226 
P= 0.026), EQ-5D Pain/Discomfort (r= 0.232 P= 0.026), SGRQ Impacts (r= 0.291 P= 
0.005) 
and SGRQ total scores (r= 0.226 P= 0.014) and adherence at six-month treatment. All 
relationships showed that an improvement in HRQOL between baseline and visit 4 was 
positively associated with adherence. 
The multivariate model confirmed some of these findings. It showed positive, statistically 
significant but weak associations between overall improvements in the EQ-5D Pain/Discomfort 
domain (η2 = 0.098 P= 0.041), SGRQ Activities domain (η2= 0.110 P= 0.026), SGRQ Impacts 
domain (η2= 0.131 P= 0.011) and SGRQ total score (η2= 0.135 P= 0.013) and adherence at 
visit 4. The association between HRQOL domains and adherence was responsible for 10% - 
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14% of the variance in the HRQOL domains. In addition, an association between improvement 
of SGRQ total score (η2= 0.102 P= 0.039) in the first 8 weeks of treatment and adherence at 
visit 4 was found, which accounted for 11% of the variance of HRQOL improvement. Patients 
with good adherence had a greater change in HRQOL than patients with medium and low 
adherence. For the SGRQ Activities and Impacts domains as well as for the SGRQ total score, 
a worsening was observed for medium adherers. 
The positive associations between overall improvements in the EQ-5D Pain/Discomfort 
domain (η2= 0.071 P= 0.038), SGRQ Impacts domain (η2= 0.088 P= 0.015) and SGRQ total 
score (η2= 0.077 P= 0.031) and adherence at six-month treatment from the multivariate model 
were further confirmed by statistically significant results from repeated measures ANOVA. 
The association between HRQOL improvements and different levels of adherence was 
assessed by comparing the intensive and the continuous treatment phases. No significant 
relationships between HRQOL and adherence levels were found during the intensive treatment 
phase. The associations found from Spearman´s rho correlation, multivariate model and 
repeated measures ANOVA were confirmed for the continuous treatment phase. During the 
continuous treatment phase there were significant and positive associations between HRQOL 
and adherence, with an effect size of 10% to 15% related to the EQ-5D Pain/Discomfort 
domain (η2= 0.103, P= 0.032), EQ-5D VAS (η2 = 0.156 P= 0.004), SGRQ Activities (η2= 0.123, 
P= 0.015) and Impact domains (η2= 0.124 P= 0.014). Good adherers reported a greater 
change in HRQOL than low adherers. Medium adherers showed a worsening in HRQOL during 
the continuous treatment phase in the domains SGRQ Impacts and Activities (Table 10). 
Table 10: Associations between HRQOL and adherence during the intensive and continuous 
treatment phases based on linear regression models for three HRQOL domains. 
 
HRQOL Spearman´s Spearman´s Univariate 
rho  correlation rho  correlation Model 
at 6 month (changes in 
η2(Sig) 
treatment HRQOL) 
 
r (Sig) r (Sig) 
Multivariate 
Model 
η2(Sig) 
Repeated 
measures 
ANOVA 
η2(Sig) 
EQ-5D Pain/Discomfort  0.232 0.103 0.098 0.071 
  (P= 0.026 (P= 0.032) (P= 0.041) (P= 0.038) 
SGRQ Activities -0.317  0.123 0.110 
 (P= 0.002)  (P= 0.015) (P= 0.026) 
SGRQ Impacts  0.291 0.124 0.131 0.088 
  (P= 0.005) (P= 0.014) (P= 0.011) (P= 0.015) 
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7.5 Discussion 
 
HRQOL and adherence to medication are two distinct concepts that are thought to be 
interrelated and require consideration, in the interest of optimal management of the patient. 
Both concepts are impacted by a number of factors including disease-related, mental health, 
psycho-social-related, socio-demographic and socio-economic factors (Kastien-Hilka et al., 
2016). TB has a negative impact on many domains of HRQOL including the physical, mental, 
psycho-social and economic domains. Adherence to TB treatment is essential for successful 
treatment and cure of the patient; and adherence may be impacted by the patients’ perception 
of their HRQOL. Adherence is still a major health issue in South Africa, even though direct 
observed treatment (DOT) for ensuring adherence has been implemented. 
 
The present study sought to evaluate the association between HRQOL and adherence in TB 
patients in South Africa. There are several key findings. First, while HRQOL improved in all 
domains, adherence behavior was constant, with adherence of most patients being classified 
as medium during the course of six-month standard treatment. About 76% were good adherers 
and 24% were non-adherers. Another study reported a similar finding with 26% TB patients in 
Southern Africa being non-adherent (Theron et al., 2015). Second, gender, age and work 
status had no effect on the adherence over treatment time. Only education showed a significant 
effect on adherence at six-month treatment, with patients with lower education reporting better 
adherence. Patients with higher education had a lower adherence at six month of treatment. 
 
Third, this study showed statistically significant, but mainly weak associations between 
HRQOL and adherence. Generally, there were positive associations between adherence 
during the first four weeks of treatment and good HRQOL in terms of lower levels of anxiety 
and depression and overall HRQOL (utility) at six-month treatment. This would suggest that 
higher levels of adherence may positively influence the improvements in psychological 
distress. Our study did not find associations between HRQOL at treatment start and adherence 
over treatment time. However, other studies reported that an impaired HRQOL in at treatment 
start negatively impacts adherence in patients with chronic obstructive pulmonary disease 
(COPD) (Agh, 2015). 
 
Psychological distress, including anxiety and depression are reported to be prevalent in TB 
*Significance level <0.05; HRQOL: health-related quality of life; effect size partial eta squared (η2); EQ-5D: EuroQol 
Questionnaire; SGRQ: St. George´s Respiratory Questionnaire 
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patients (Theron et al., 2015). While good adherence to treatment improved anxiety and 
depression, depression at treatment start may be a trigger for non- adherence although our 
study did not find this reciprocal relationship between HRQOL and adherence. Theron et al 
assessed psychological distress in TB patients in Southern Africa and observed a significant 
relationship between higher levels of TB-related psychological distress and non-adherence 
(Theron et al., 2015). 
 
The results of the present study revealed an effect of treatment time on the overall 
improvement in HRQOL, specifically significant positive associations between lower levels of 
pain, discomfort and psycho-social factors related to TB and higher overall adherence during 
the continuous treatment phase. Our study findings about the associations between HRQOL 
and adherence were confirmed to be present only during eight to 24 weeks of treatment rather 
than during the first eight weeks of treatment (intensive phase). 
 
Very few studies have assessed the association between HRQOL and adherence in other 
diseases so far. Similar to the present study, only a weak to negligible association between 
HRQOL and adherence could be demonstrated. Various HRQOL PRO measures have been 
applied, mainly generic instruments such as RAND-12, SF-12, HUI2 and HUI 3 (Cote, 2003) 
and EQ-5D (Saleem, 2012, Agh, 2015), but also the respiratory-specific SGRQ (Agh, 2015) 
and psychological measure Kessler-10 (Theron et al., 2015). The methods for adherence 
monitoring included self-reported measures such as MMAS (Cote, 2003, Agh, 2015) and The 
Drug Attitude Inventory (DAI-10) (Saleem, 2012), electronic monitoring and DOTS clinic cards 
for TB adherence monitoring (Theron et al., 2015). Our study applied a similar concept of 
generic, disease- and condition-specific HRQOL measures and a self-reported adherence tool 
and confirmed the weak associations reported in other studies by our findings. Our study 
combined generic with disease- and condition specific HRQOL measures to ensure that all 
possible relevant HRQOL domains were captured. These different types of PRO measures 
capture different aspects of health and this might influence the association with adherence. 
Generic measures such as SF-12 and EQ-5D might not be sensitive enough to examine 
associations to adherence. We only found weak associations between the single item of the 
generic EQ-5D measuring pain and discomfort and adherence. The respiratory-specific 
HRQOL measure SGRQ showed significant association with adherence, specifically in the 
psycho-social domains of health measured in this PRO. 
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7.6 Limitations 
 
Our study has several limitations. We used a self-reported measure of adherence. This 
may have impacted the reliability of the observed relationship between HRQOL and 
adherence. An ideal adherence measure would assess overall adherence to medication 
including initiation, persistence, implementation and discontinuation. However, such a 
measure does not exist; therefore a multi-measure approach should be considered where 
direct and indirect adherence measures are combined (Fairman, 2000). Direct measures 
such as drug determination in biological fluids or direct patient observation are often 
regarded as being the most reliable and accurate. However, individual changes in drug 
metabolism and multidrug intake affect monitoring of plasma levels, and patient observation 
is limited to inpatient settings and clinical trials (Fairman, 2000, Nguyen et al., 2014, Lam and 
Fresco, 2015). Indirect measures comprise medication monitoring (such as pill counting) 
and self-reported measures; however, medication monitoring is cost intensive and self-
reported measures may be less reliable due to patient recall, underreported non-adherence 
and memory bias issues (Fairman, 2000, Lam and Fresco, 2015, Stirratt et al., 2015). 
Each adherence measure has its advantages and disadvantages (Lam and Fresco, 
2015). Direct Observed Treatment (DOT) has been introduced for supervised treatment 
monitoring in South Africa to ensure adherence to treatment. A self-reported measure is 
best applicable to the study environment and study settings as it is cost-effective, with a 
minimum burden to the patient, easy to administer and flexible in timing and mode of 
administration. Self-reported adherence measures have additional advantages; they inform 
about non-adherence before adverse clinical outcomes develop and about adherence 
determinants such as psychosocial factors (Stirratt et al., 2015). Our study was limited by 
missing clinical data for treatment monitoring. Sputum smear results were not tested on a 
regular basis in the clinics during the course of treatment and a clinical parameter for 
monitoring the effectiveness of TB treatment was not available to draw associations 
between clinical parameter in TB and HRQOL and adherence development. 
 
 
7.7 Conclusion 
 
Very few studies have evaluated the association between different HRQOL aspects 
and adherence to treatment before. Adherence to medication is a major public health 
concern and is a crucial step toward improving health outcomes and lowering health 
care costs. Non- adherence impacts HRQOL and both concepts are interrelated. In 
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South Africa DOT is established to ensure adherence to TB treatment, however this 
only works when patients attend the clinic for their treatment. Even though DOT has been 
established in South Africa, TB prevalence and incidence rates are still high in South 
Africa. Our study showed that a reciprocal relationship exists between adherence and 
HRQOL in TB in a South African setting. However, this relationship was very weak and 
limited to pain, discomfort and psycho-social aspects related to TB. HRQOL is affected by 
a number of different factors and not limited to medication adherence; this might explain the 
weak associations found. This study has clearly demonstrated that management of TB 
patients must address their specific mental and psycho- social needs, besides adequate 
drug treatment. Such integrative patient-centred approach should result in an 
improvement in the quality of life of these patients and will contribute towards supporting 
the UN SDG3 target and the End TB strategy of the WHO. 
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8. Discussion 
 
 
8.1 Tuberculosis in South Africa 
 
Although tuberculosis (TB) has existed for thousands of years and effective treatment 
is available, it is still a major public health concern worldwide. One third of the world 
population is infected with mycobacterium tuberculosis, having a latent TB infection, and 
10.4 million people fell ill from TB in 2015 (WHO, 2016). About 1.8 million persons died from 
TB, including 400,000 cases with HIV co-infection. In international comparison, the 
incidence rate is one of the highest in South Africa, with 834 new cases per 100,000 
population and a total of 454,000 official cases in 2015 (WHO, 2016). More than 1% of the 
South African population are affected by TB in their lives and 80% are estimated to have a 
latent TB which carries considerable risk of progression to active TB (TBfacts.org). The TB-
specific mortality rate was 133 per 100,000 population in South Africa in 2015 (WHO, 
2016). With a significant burden of diseases (infectious diseases, non-communicable 
diseases, perinatal and maternal disorders, and injury-related disorders), the South 
African society experiences increased pressure on its scarce healthcare resources 
(Mayosi et al., 2009). At the patient level, TB has a significant negative impact on the 
health-related quality of life and general well-being (Kastien-Hilka et al., 2016). 
The work presented here is well embedded in the United Nations (UN) third Sustainable 
Development Goal (SDG) which aims to ensure healthy lives and promote well-being at all 
ages, including the end to the epidemic of TB (WHO, 2015b). The World Health Organization 
(WHO) has claimed that patient involvement in their healthcare is a social, economic and 
technical necessity (Doward et al., 2010). Examining the patient perspective on disease 
applying patient-reported outcomes (PROs) allows for a better understanding of the burden of 
TB and the impact of TB treatment in an integrative manner, and provides information beyond 
biomedical and clinical parameters (Deshpande, 2011, Doward et al., 2010, Acquadro C, 
2003b). Health-related quality of life (HRQOL) is a PRO-specific concept which includes 
physical, mental and social health domains. Given that the treatment of TB involves a lengthy 
process of medication over time, it is surprising that to date very few studies have followed 
changes in HRQOL longitudinally over time in TB patient populations. More importantly, no 
longitudinal study has assessed HRQOL over time in South Africa. 
HRQOL is associated with medication adherence (Agh, 2015, Chung and Li, 2013, Cote, 2003, 
Saleem, 2012, Theron et al., 2015). Both concepts may influence each other in a reciprocal 
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relationship (Cote, 2003, Saleem, 2012, Munro S, 2007). While research about the association 
between HRQOL and adherence in TB is lacking, such information may help to 
optimize treatment programs, understand the limitations in TB control, aid the development 
of targeted interventions and improving the health status of high-burden TB populations. 
 
 
8.2 Summary of study methodology 
 
The overall aim of this doctorate thesis research program was to understand the impact of TB 
on South African patients with a patient-centred approach. This approach focused on HRQOL 
and adherence to standard TB treatment. A systematic review was conducted to generate an 
evidence base  for the development and  performance  of a  longitudinal study evaluating 
HRQOL, medication adherence, and the association of both in new TB cases (older than 18 
years) without HIV co-infection in South Africa. The study was conducted in seven health 
clinics with dedicated TB units in Khayelitsha and Delft, two sub-districts in Cape Town. Two 
generic (SF-12 and EQ-5D-5L), one respiratory-specific (SGRQ) and one condition-specific 
(HADS) PROs for HRQOL evaluation were applied over a treatment period of six months. The 
study thereby followed the recommendation to combine generic and disease-specific 
measures to capture all relevant health aspects in TB and to deliver complementary 
information (eunethta, 2013). All HRQOL measures have been validated in TB populations: 
SF-12 , EQ-5D-5L (Dion et al., 2004), SGRQ (Pasipanodya et al., 2007a), and HADS (Duko, 
2015). According to the respective manuals, all four measures have been validated 
linguistically for English for South Africa. Adherence was measured with the indirect self- 
reported measure Morisky Medication Adherence Scale (MMAS-8). MMAS-8 has been 
validated in a number of different study populations, diseases and languages, including 
pulmonary TB patients (Mkopi, 2014). Linguistic validation of MMAS-8 has been performed for 
English for South Africa (De Klerk, 2003). All study sites confirmed prior to the start of the study 
that TB patients of the clinics are fluent in English. Therefore, no other translations were 
performed. PRO outcomes are often requested by regulatory bodies and these regulatory 
authorities require validation  of applied instruments  in  a population similar to the  study 
population. The present study followed this approach to the extent possible and applied PRO 
instruments which had previously been validated in TB populations and in the South African 
population. 
The data collection process, role and responsibilities as well as the training of interviewers is 
described in a Standard Operating Procedure (SOP) (see Appendix supplementary 
material chapter 5). Interviewers recruited participants, performed the interviews, reviewed 
each questionnaire for missing items, and followed up each participant. 
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8.3 Summary of findings 
 
To briefly summarize the findings of this doctorate research program, our systematic review 
showed that TB impacts HRQOL negatively and that similar factors also impact medication 
adherence. However only a small number of studies assessed HRQOL in TB over the course 
of treatment and no longitudinal study has been conducted in South Africa. Information on the 
impact of TB on the patient from a patient perspective is very limited for the South 
African situation. The present longitudinal study enrolled 131 participants in total. The majority 
were in their productive age between 20 and 40 years (mean age 36 years), of black ethnicity, 
received high school education and were without a job engagement. Our study outcomes 
showed an overall negative impact of TB on patients' HRQOL Younger patients with higher 
education and being in a work engagement reported a better HRQOL. Education and 
work status were identified as socio-demographic predictors showing a significant 
association with HRQOL at the beginning of TB treatment while age was a predictor on only a 
single mental health domain. 
We observed greater impairment in the psychological and psycho-social aspects of health than 
in physical health, at treatment start. The greatest impairment and greatest improvement over 
time among all health aspects in TB were seen for mental health, particular depression and 
anxiety. Overall, HRQOL improved significantly and with meaningful changes over the course 
of six-month treatment. The biggest improvements in HRQOL were seen during the first eight 
weeks of treatment (intensive phase). 
While HRQOL improved over the course of treatment, the average mean score in adherence 
was constantly on a medium adherer level for six months. About 76% of the study TB patients 
reported a good adherence while 24% reported to be non-adherent (medium and low adherer). 
Education was the only socio-demographic predictor for adherence in our study, showing TB 
patients with a lower education reporting a better adherence in South Africa. 
The association between HRQOL and medication adherence was examined based on HRQOL 
and adherence data which were collected at the same time points (4, 8, 16 weeks and six 
months post-treatment start). A positive weak association between overall improvements 
(changes in mean scores between treatment start and six months of treatment) in HRQOL and 
adherence at treatment start was observed. Good adherence at treatment start had a positive 
impact on the overall improvement in mental health and psycho-social health aspects after six 
months of treatment. These associations were only confirmed for the continuous treatment 
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phase (remaining 16 weeks of treatment with isoniazid and rifampicin). No associations 
between HRQOL and adherence were found during the intensive treatment phase (first 
8 weeks of treatment with all four oral antibiotic drugs). 
8.4 Comparison with published literature and 
related considerations 
Several of our findings were also reported by other authors. Our observations support and 
confirm that gender and age as socio-demographic factors have no impact on HRQOL in TB 
patients, as was just recently reported for a different South African population (Louw et al., 
2016). A greater impairment in psychological and psycho-social health aspects compared to 
physical health was also found by others (Aggarwal et al., 2013, Bauer et al., 2013, Ralph et 
al., 2013, Awaisu et al., 2012, Balgude and Sontakke, 2012, Louw et al., 2012, Othman, 2011, 
Guo et al., 2009, Guo N, 2008, Chamla, 2004). The improvements in HRQOL were greater 
during the intensive phase than during the continuous phase of TB treatment as confirmed by 
others (Bauer et al., 2013, Othman, 2011). As we did not follow-up patients beyond 6 months 
and beyond treatment completion, if morbidity still existed due to TB after treatment completion 
could not be verified. Morbidity after treatment completion may exist due to anatomic and 
functional changes of the lung at treatment  completion although the person was 
microbiologically cured and this was found by others (Ralph et al., 2013, Pasipanodya et al., 
2007b, Weis and Pasipanodya, 2010, Muniyandi et al., 2007). As reported elsewhere 
previously (Awaisu et al., 2012, Guo et al., 2009, Chang B, 2004, Hansel NN, 2004), TB also 
has a negative impact on physical health. The respiratory measure SGRQ measured the 
greatest improvements in physical health (Symptoms domain) and seemed to capture these 
health aspects with higher sensitivity compared to the two generic measures SF-12 and EQ- 
5D-5L. It is most likely that the impaired physical functioning was closely related to 
the development of fatigue, adverse drug events, and quantity of drug pills and treatment 
duration (Chang B, 2004, Hansel NN, 2004). 
An additional analysis of the mental health domains of the HRQOL measures was conducted 
but not included in the manuscripts forming the main part of this thesis. It has been included 
here to support the interpretation of our findings. This analysis comprised the visual 
presentation of improvements in mental health domains (MCS-12, EQ-5D-5L 
Anxiety/Depression, HADS Anxiety, and HADS Depression) over the course of six months 
treatment based on single patient scores rather than on mean scores. The mean scores might 
mask the variability and subjectivity reported by the single patient. This additional analysis 
showed that the impairment in mental health was very variable within the study population at 
the beginning of treatment, while the mental health status reported after six-month of treatment 
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showed substantially less variation (figure 13). 
 
 
 
 
 
Figure 13: Improvements in mental health measured by SF-12, EQ-5D-5L and HADS over 
six-month TB treatment, presented as change in single patient scores 
 
 
Our findings about impaired mental health in TB patients are in line with other reports stating 
that about 46-80% of TB patients in South Africa have mental disorders (Westaway, 2001, 
Naidoo and Mwaba, 2010), with depression and anxiety being the most frequently reported 
ones. Such psychiatric co-morbidity may be linked to psycho-social aspects related to TB, most 
commonly stigmatization and social isolation, which all may increase the distress of physical 
illness and may also impact the adherence to medication. There may be a connotation of TB 
with HIV/AIDS, particularly in South Africa, where more than 70% of all HIV/AIDS cases suffer 
also from TB. This may lead to stigma and disruption of social interaction with others, resulting 
in social isolation (Dhuria et al., 2009, Naidoo and Mwaba, 2010, Van Rie et al., 2008). Such 
stigmatization and social isolation might also apply to our TB patients. Inability to work due to 
TB symptoms and its infectious nature may lead to a decrease in income or even a total loss 
of income (Hansel NN, 2004, Dias et al., 2013) and increases the psychological pressure on 
the patient. Financial constraints due to the socio-economic situation of most TB patients in 
South Africa but also the severity of TB often lead to the situation that patients are unable 
to travel to the next clinic to seek TB treatment. TB patients from this study reported 
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frequently being too sick to come to the clinic or being too sick to take their medication 
according to treatment instructions. The overall improvements in mental health over six-
month treatment may be related to the overall improvement in physical and psycho-social 
aspects related to TB. Although rarely mentioned in the literature it should be mentioned 
here that a psycho- stimulating effect was observed under isoniazid TB treatment during 
clinical trials in 1953 in the U.S. (Healy, 1996). Until today this effect has not been 
confirmed and our study did not investigate in this effect further. 
The study intended to collect sputum smear results for all participating patients during the 
treatment course in order to understand how changes in sputum smear results may be 
associated with changes in HRQOL and adherence. However, only in a minority of TB cases 
(19 patients, 14.5% of the study population) the clinics collected data on sputum smears. This 
was a common practice in all clinics. Some clinics applied X-rays to some patients for 
diagnostic testing. Sputum smear results are expressed as number of bacilli and range from 0 
(no bacterial found) to +3. For the 19 patients with sputum smear data collected, overall 
HRQOL improved while sputum smear results showed an unchanged value of +3 confirming 
the presence of bacilli. As the number of patients with sputum results was very small and the 
values for sputum remained unchanged over the treatment period, we decided not to use the 
clinical data for investigation of any associations between sputum, HRQOL and adherence. 
Medication adherence is a key factor for treatment success (NDoH, 2014). TB patients being 
non-adherent to TB treatment expose other non-infected people to the risk of spreading free 
TB bacteria and this may result in physical disability, drug resistance, relapse and risk of death 
in the community and in increased healthcare costs (NDoH, 2014, Chirwa T, 2013, Cramm 
JM, 2010, Husain MO, 2008). Our expectations were to observe a good adherence at 
the beginning of the treatment and a deterioration of adherence alongside 
improvements in HRQOL. However, the mean score of adherence was constantly on a 
medium adherer level for six months, with patients reporting a lower education showing 
better adherence. In South Africa non-adherence to TB treatment is reported to be related 
to poverty, HIV co-infection, stigmatization, an unsupportive social and work environment, 
and feelings of helplessness and hopelessness, limited transport to the clinics, and limited 
food access (Naidoo P, 2009). That good adherence may be associated with both lower 
and higher levels of education was reported in different diseases (Jin, 2008). A higher 
education might support a better understanding of the disease and its treatment and might 
therefore lead to a better adherence. However, it might also apply that a less educated patient 
might trust the advice of the physician more and thereby may have a better adherence (Jin, 
2008). 
A systematic review on adherence to TB treatment (Munro S, 2007) reported two underlying 
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patterns: TB patients become non-adherent when they either experienced an improved well- 
being and perceived this as cure from TB or when they experienced no improvement or even 
a worsening in  well-being. The positive  weak associations found between  HRQOL and 
adherence in our study might be because generic PRO measures such as SF-12 and EQ-5D- 
5L are  not sensitive  enough to  capture  all changes in  HRQOL  in TB and thereby 
the association to adherence may be observed as weak; or other factors not captured in this 
study such as other socio-demographic or psycho-social aspects influence the association 
between HRQOL and adherence. Or the association between HRQOL and adherence might 
be indeed as weak as observed in our study. The positive associations were only found 
during the continuous treatment phase, and not during the intensive treatment phase. 
This finding suggests that it is particularly important to identify and understand drivers of 
adherence to TB treatment and how adherence can be supported during the continuous 
treatment phase. Based on different statistical methods applied (correlations and linear 
regression models considering the temporal sequence of observations) to investigate the 
association between HRQOL and adherence the study confirmed an, albeit weak, positive 
relationship between aspects of pain and discomfort measured by EQ-5D-5L and psycho-
social health aspects measured by SGRQ, and adherence, with HRQOL being the driver for 
adherence. These findings may indicate that TB management should also focus on any 
impairment in mental and psycho-social health in TB patients and that the association 
between HRQOL and adherence should be considered as essential part of the TB 
management. However, based on the weak associations found and considering limited 
sample size and missing data, we cannot exclude the possibility that the associations 
found were merely due to chance. 
 
 
8.5 Generalizability of study findings 
 
Our study showed in which way and to which extent TB impacts patients in South Africa, from 
a patient perspective including physical, mental and psycho-social health aspects. These 
findings support the bio-psycho-social health model which was introduced by George Engel in 
the 1970s. George Engel highlighted that a patient´s suffering can only be understood when a 
disease is observed in its biological, psychological and social dimensions (Borrell-Carrio et al., 
2004). Contrary to the biomedical health model which regards the patient as an object by 
separating the body and mind in a dualistic way (Hatala, 2012, Borrell-Carrio et al., 2004), the 
bio-psycho-social health model follows a humanistic and integrative approach. Biological, 
psychological and social factors are implicated in different stages of a pathogenesis and health 
aetiology (Hatala, 2012). In addition, our study outcomes indicated how the different 
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dimensions of health included in the bio-psycho-social health model are interlinked with the 
medication adherence, particularly with mental and psycho-social aspects (Adwok, 2012). The 
impairment found in HRQOL at treatment start and the improvement in HRQOL during the 
course of TB treatment was reported by a number of other studies in different countries as 
reported in our systematic review (Kastien-Hilka et al., 2016). However, the selection 
of different HRQOL measures and mode of application might lead to different HRQOL 
scores. The socio-demographic background might also impact the HRQOL outcomes. 
Thereby, our HRQOL data may not be generalizable to other study populations. The same 
may apply to outcomes generated with the self-reported adherence measure. The 
positive weak associations found in our study between HRQOL and adherence may not be 
generalizable to other populations. The number of available literature on associations 
between HRQOL and adherence to medication is very little and reported results are 
contradictory. 
Our study methodology may be generalizable to other studies following a patient-centred 
approach by applying PRO measures in other TB studies and even in other diseases. The 
methodology for PRO selection and thereupon the rationale for endpoint model and 
sample size determination are applicable to other outcomes research studies. 
 
 
8.6 Future research agenda 
 
This study identified a need for further research and recommendations for a future research 
agenda are briefly discussed here. Our dataset may allow further statistical analysis by 
exploring underlying patterns for adherence and non-adherence in TB. Such exploratory 
statistical analysis may provide a deeper understanding of adherence patterns in TB and of 
the association between HRQOL and adherence. It may inform TB management programs 
to improve the healthcare service. 
Furthermore, our dataset allows for the calculation of QALYs based on utilities calculated from 
EQ-5D. Combined with the identification of costs, these QALYs can be applied in comparative 
studies to allow cost-effectiveness analysis (CEA). In 2013, the South African Department of 
Health published the Guidelines for Pharmacoeconomic Submissions which requests the 
use of QALYs for CEA (NDoH, 2013). However, preference-based utilities need to be 
estimated on basis of valuation algorithms (value sets) derived from general population 
studies. Such value sets are available for some countries but not for South Africa. Our 
study estimated the utilities for patients on TB standard treatment using the UK and on the 
Zimbabwean value sets. The resulting utilities differed and showed that based on the UK 
value set, the HRQOL of our patients during TB treatment improved by 94%, while based on 
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the Zimbabwean value set the improvement was only 44%. This difference may have an 
impact on the calculation of QALYs and on CEA outcomes. This in turn may impact the 
allocation of resources when making decisions within the National Health Insurance in 
South Africa. The National Department of Health South Africa (NDoH) requests in their 
National Pharmacoeconomic Guideline the calculation of QALYs when performing a CEA. 
If the NDoH decides for EQ-5D as preferred utility measure, then a study research on 
generating a value set for South Africa would be needed. Our study outcomes were 
presented and discussed with the NDoH during a joint workshop in October 2016 
(Fundisa, 2016). The need for HRQOL instruments specific for South Africa related to TB 
as well as other common diseases (e.g., diabetes) will be a matter of further discussion with 
the NDoH. 
Our dataset may support the development of a TB-specific HRQOL measure which is still 
lacking. A detailed analysis of the dataset on an item-by-item basis might evaluate which items 
reflect the patient´s perspective in TB more than others. It might be that some items were 
answered more often than others or some items were only answered very little or not at all, as 
they might not reflect the relevance for the patient with regard to TB. Such analysis would 
require to be supported by in-depth interviews of TB patients in order to select relevant 
elements for a TB-specific measure. 
In addition to TB, South Africa is facing the double burden of TB with HIV co-infection and of 
MDR-TB. Therefore, a study combining generic and disease- or condition-specific 
HRQOL measures evaluating HRQOL in TB patients with HIV co-infection and in patients 
with MDR- TB will complete the understanding of the impact of TB on patients living in 
South Africa. A similar approach should be applied to understand the impact of TB on 
children, although PRO studies in children are a specific challenge and child-friendly PROs 
are required. In this context, it will be advisable to consider the development and 
validation of a TB-specific HRQOL measure for South Africa which can be applied in other 
countries after its validation. 
Furthermore, the evaluation of HRQOL allows the identification of added benefits of new TB 
treatment options planning to access the South African market. If a new healthcare product in 
TB may show a greater improvement in HRQOL compared to standard TB care, this extra gain 
in HRQOL may be defined as an added benefit. This added benefit may enable the healthcare 
system to recognize relevant innovations and to distinguish against any me-too healthcare 
products. As a number of new TB drugs, vaccines and diagnostic tools are in late clinical stage 
development and will enter the market soon, South Africa needs to make decisions which 
products are best for the patient and most cost-effective for the healthcare system. Our study 
methodology may advice  on  how a comparative  study with new technologies might be 
130  
designed and which issues might develop. Information on HRQOL should support the 
identification of sustainable products. 
TB impacts a person beyond their microbiological infection and related disease symptoms. TB 
affects several dimensions  in  the health-related  life of a person and can  have societal 
consequences due to its psycho-social impact. Future research may investigate if the 
implementation of psychological support throughout the course of treatment might not 
only ensure an integrative approach to treatment but also assist with an improvement 
in the adherence to treatment and thereby treatment success. Such study should consider 
the socio- demographic environment of the patients when optimizing the TB management in 
community and public health programmes for South Africa. Outcomes from such research 
may further discuss if and how psycho-social support should be considered to be included in 
the National TB guideline. Further, the study outcome may inform health policy makers 
with regard to initiatives to improve medication adherence to TB treatment in the South 
African public health system. Further research would then be required to discuss how the 
knowledge about psycho- social health issues related to TB may be included in the training 
of healthcare providers in South Africa. And integration of screening for mental and 
psychological disorders in TB patients might help to improve adherence to TB treatment. 
 
 
8.7 Limitations 
 
This PhD research has several limitations. The preparatory systematic review on HRQOL and 
adherence applied mixed methods by combining literature from qualitative and quantitative 
studies and did not include solely randomized controlled trials for quantitative analysis. This 
may be viewed as a limitation. However, the mixed-methods approach ensured capturing all 
relevant information on the topic. Publication bias may be present in the systematic review but 
we selected peer-reviewed literature from three different databases and included grey 
literature to minimise publication bias. We did not include unpublished information and studies 
published in a different language than English. 
The longitudinal study also faced several limitations. Time and resource constraints as well as 
the fact that a high number of TB patients are HIV co-infected did impact the 
recruitment process. Based on HIV tests applied during the TB diagnostic procedure before 
treatment start, this study did exclude HIV co-infection to understand the isolated TB 
impact on HRQOL. Whether the participating TB patients developed HIV during the 
treatment was not tested. HIV co-infection impacts HRQOL further and unknown HIV co-
infection during treatment might have influenced our outcomes. 
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Further, we could not include a comparison or control group from the general population, due 
to limited time and resources. Single group studies are often claimed to be non-informative 
without a comparator group. However, longitudinal studies as ours can be a source of relevant 
information by making before-after comparisons and observing change over time. 
Our longitudinal study was limited to a quantitative approach; patient perspectives about TB 
in a South African cultural background were not qualitatively assessed. Such data might 
have enriched the quantitative findings on HRQOL in this study. HRQOL was only 
assessed in a specific district of the Western Cape Province with a specific socio-
demographic and – economic situation. 
Additionally, there is an increased risk of tuberculosis in patients with co-morbidities, however 
only a small portion of TB patients were aware of any co-morbidity they may have had, such 
as e.g. diabetes. In a  majority of cases  the study participants were unable to provide 
information on co-morbidities and we assume that other health issues were unknown to the 
majority of them. These unknown co-morbidities might have had an additional impact on the 
HRQOL in TB patients at baseline which we could not distinguish. 
 
Although all applied HRQOL measures and the MMAS-8 had been previously validated in TB 
populations and linguistically validated for English for South Africa, study populations may 
differ by their socio-demographic and socio-economic background. The populations of the 
validation studies may not have been similar to our study population in all socio-demographic 
and socio-economic aspects. This may be reflected in our study outcomes. 
 
The use of a self-reported measure of adherence may have impacted the reliability of the 
observed relationship between HRQOL and adherence. A self-reported measure may be 
less reliable due to patient recall, underreported non-adherence and memory bias issue. An 
ideal adherence measure would assess overall adherence to medication including 
initiation, persistence, implementation and discontinuation, but such a measure does not 
exist. Optimally, a multi-measure approach should be considered where direct and 
indirect adherence measures are combined (Fairman, 2000). Since Direct Observed 
Treatment (DOT) has been introduced for supervised treatment monitoring in South Africa to 
ensure adherence to treatment, we applied a self-reported measure to DOT as it was 
cost-effective and best applicable to the study environment and study settings, with a 
minimum burden to the patient, easy to administer and flexible in timing and mode of 
administration. Adverse events are known to impact medication adherence negatively. One 
item of the MMAS-8 asks: “Have you ever cut back or stopped taking your medication 
without telling your doctor, because you felt worse when you took it?”While the MMAS-8 
does not measure adverse events, this item may allude to possible adverse events. The 
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same item might theoretically bias the association between HRQOL and medication 
adherence examined in the present study due to a limited degree of overlap between 
concepts. MMAS-8 includes two items with a short recall period (“Thinking over the past 
two weeks, were there any days when you did not take your TB medicine?” and “Did you 
take your TB medicine yesterday?”). However, the recall period of the two items is different 
and the overall recall period of the MMAS-8 is not clearly defined. 
 
PRO measures reflect the subjective perspective of the patient. However, there might be 
a temptation to 'please the doctor' when answering questions. Social desirability is always 
a concern in any study using subjective outcomes. It might also have had an impact on 
the outcomes of this study. In addition, although interviewers were not allowed to 
interpret the applied PRO measures as per the SOP, a certain degree of interpretation may 
have occurred and impacted or biased our study results. Our study was limited by missing 
sputum smear results for treatment monitoring. Sputum smear results were not tested on a 
regular basis in the clinics during the course of treatment and a clinical parameter for 
monitoring the effectiveness of TB treatment was not available to draw associations 
between clinical parameters in TB and the development of HRQOL and adherence. 
 
 
9. Conclusions 
 
The relevance and importance of HRQOL assessments is growing and HRQOL has 
become an important tool for the understanding of health outcomes adopting a 
patient-centered approach to care and treatment. This work demonstrates the need for an 
integrative understanding of TB with HRQOL as core element to understand gaps in current 
TB management. This study has demonstrated that management of TB patients should 
address their specific mental and psycho-social needs, besides adequate drug treatment and 
that these specific needs may be associated with adherence to medication, although weak. 
The adoption of the bio-psycho-social health model into the health system of South Africa may 
help to reduce the burden of TB and of other communicable and non-communicable 
diseases. Considering the application of PROs and their results in the decision-making 
process in the healthcare system of South Africa, with a particular focus on HRQOL, 
may support an integrative understanding of the burden of disease for the South African 
population from the perspective of patient, the end-client and end-consumer within the 
system. Such integrative patient-centred approach should result in an improvement in the 
health-related quality of life of these patients and will contribute towards supporting the UN 
SDG3 target and the End TB strategy of the WHO. Furthermore, information on PROs is 
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introduced to the South African healthcare system now and there is a need for validated local 
PRO data for pharmacoeconomic assessments to inform the healthcare system efficiently. 
HRQOL allows identification of the value for money principle which will be the driver for 
future healthcare spending in the public sector. Lastly, both the private and public sector 
view pharmacoeconomics as an important part of rational use and decision-making 
process in the South African healthcare system to ensure availability and accessibility of 
affordable essential medicines. 
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Appendix 
 
Supplementary material to Chapter 2.1 
 
 
Figure 1: Literature search strategy conducted in Pubmed to formulate research objectives. 
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Supplementary material to Chapter 4 
 
Search strategy for identification and selection of relevant studies 
A systematic and comprehensive literature search was performed in PubMed, EMBASE and 
PsychINFO, with the last search conducted on 22 February 2015. Search terms applied 
included tuberculosis, health related quality of life, HRQOL, quality of life, South Africa, patient- 
reported outcomes, outcome assessment, life quality, well-being, adherence, non-adherence, 
and compliance. All search terms were combined differently and applied to each database, as 
shown in table 1: 
Table 1: Combination of search terms. Search terms were combined differently 16 times and 
applied to the databases PubMed, EMBASE and PsychINFO. 
 
Search Term combinations applied to Pubmed, EMBASE and PsychINFO 
Tuberculosis AND health related quality of life 
Tuberculosis AND HRQOL 
South Africa AND health related quality of life 
Tuberculosis AND South Africa AND health related quality of life 
Tuberculosis AND patient-reported outcomes 
Patient-reported outcomes AND South Africa 
Tuberculosis AND patient-reported outcomes AND South Africa 
Tuberculosis AND well-being AND outcome assessment AND life quality 
Pulmonary Tuberculosis AND adherence AND South Africa 
Tuberculosis AND adherence AND health-related quality of life 
Tuberculosis AND non-adherence AND quality of life 
Non-adherence AND health-related quality of life 
Non-adherence AND health-related quality of life AND tuberculosis 
Non-adherence AND health-related quality of life AND South Africa 
Tuberculosis AND compliance AND quality of life 
Tuberculosis AND compliance AND quality of life AND South Africa 
 
Each search term combination was applied to the database separately and resulted in “initial 
hits”. Initial hits were then screened by title and abstract with regard to search terms and 
selected articles resulted in “Hits by abstract and title”. Articles were excluded if they were not 
related to the pre-defined search terms or were published in a language other than English. 
From the selected articles, duplicates were removed and resulted in “Hits after removal of 
duplicates”. 
The following figures 1-3 present each search term combination with its related initial hits and 
number of articles after review by title and abstract and removal of duplicates, for each 
database.
145  
 
 
Figure 1: Search strategy in Pubmed. 
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Figure 2: Search Strategy in EMBASE. 
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Figure 3: Search Strategy in PsychINFO. 
 
Our literature search in PubMed, EMBASE and PsychINFO yielded 988 initial hits; after 
screening by title and abstract and after removal of duplicates, 61 articles remained. Addition 
of three WHO reports, two guidelines from Department of Health South Africa and one article 
identified by hand search of citations resulted in 67 eligible articles for this systematic review. 
One article was excluded, yielding 66 eligible full-text articles (Figure 4). A detailed description 
of the literature search is available in the Appendix. The 66 articles comprised 22 cross- 
sectional studies, 17 longitudinal studies, 7 (systematic) reviews, 8 qualitative studies and 12 
articles including editorials, comments and letters. Nine studies were performed in South Africa 
(four HRQOL and five medication adherence studies; Table 4). All final 66 articles underwent 
extraction of information about HRQOL and adherence in TB. The 17 identified 
longitudinal studies were potentially eligible for separate data extraction; 11 of them 
actually met the eligibility criteria for separate data extraction, while 6 studies were excluded 
as eligibility criteria were not met (Table 3). Application of the STROBE quality of 
reporting checklist to the 11 longitudinal studies resulted in a median score of 7 for 
HRQOL studies, with scores ranging from 5 to 11 out of 16 (the greater the score the higher 
the quality of reporting). The adherence study had a score of 10 (Table 3). 
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Figure 4: Literature search process in the databases PubMed, EMBASE and 
PsychINFO; additional articles were obtained from World Health Organization and 
Department of Health Republic of South Africa. 
All final 66 articles were uploaded to EndNote X7 version 3.1. Table 2 presents all 66 
identified articles included in this systematic review. 
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Table 2: Articles finally included in the systematic review 
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Articles finally included in the systematic review (cont.) 
 
Reference Study Design Comment 
Husain et al2008: The relationship between anxiety, depression and illness perception in 
tuberculosis patients in Pakistan 
 
cross-sectional  
Issa et al 2009: Depression comorbidity among patients with tuberculosis in a university 
teaching hospital outpatient clinic in Nigeria. 
cross-sectional  
Kittikraisak et al 2012: Health related quality of life among patients with tuberculosis and 
HIV in Thailand. 
 
cross-sectional  
Kruijshaar et al 2010: Health status of UK patients with active tuberculosis longitudinal  Louw et al 2012: Quality of life among tuberculosis (TB), TB retreatment and/or TB-HIV co- 
infected primary public health care patients in three districts in South Africa. 
 
cross-sectional  
Lutge et al 2013: Economic support to improve tuberculosis treatment outcomes in South 
Africa: a pragmatic cluster-randomized controlled trial.  longitudinal  
Lutge et al 2012: Material incentives and enablers in the management of tuberculosis. 
Cochrane Database Syst Rev. 18;1:CD007952 
Cochrane systematic 
review  
Maguire et al 2009: Pulmonary tuberculosis, impaired lung function, disability and quality of 
life in a high-burden setting. 
 
longitudinal  
Mamani et al 2014: Assessment of Health-related Quality of Life among Patients with 
Tuberculosis in Hamadan, Western Iran 
 
longitudinal  
Marra et al 2004: Factors influencing quality of life in patients with active tuberculosis. qualitative study  Marra et al 2008: Health-related quality of life trajectories among adults with tuberculosis: 
differences between latent and active infection. 
 
longitudinal  
Masumoto et al 2014: Factors associated with health-related quality of life among 
pulmonary tuberculosis patients in Manila, the Philippines. 
 
corss-sectional  
McInerney et al 2007: Characteristics of anti-tuberculosis medication adherence in South 
Africa. 
cross-sectional  
Miller et al 2009: Personal and societal health quality lost to tuberculosis.PLoS One. 
2009;4(4):e5080  cost-effectiveness study  
Muniyandi et al 2007: Evaluation of post-treatment health-related quality of life (HRQoL) 
among tuberculosis patients 
 
cross-sectional  
Munro et al 2007: Patient Adherence to Tuberculosis Treatment: A Systematic Review of 
Qualitative Research 
systematic review of 
qualitative research  
Naidoo and Mwaba 2010: Helplessness, depression, and social support among people 
being treated for tuberculosis in South Africa. 
 
qualitative study  
Naidoo et al 2009: Exploring tuberculosis patients' adherence to treatment regimens and 
prevention programs at a public health site. 
 
qualitative study  
Othman et al 2011: Health related quality of life of pulmonary and extrapulmonary 
tuberculosis patients in Yemen. 5:4(547-553) 
cross-sectional, 
instrument validation  
Pasipanodya et al 2007: Using the St. George Respiratory Questionnaire to ascertain 
health quality in persons with treated pulmonary tuberculosis. 
cross-sectional, 
instrument validation  
Pasipanodya et al (2007) Pulmonary Impairment after Tuberculosis. Chest 131;6:1817- 
1824. 
 
cross-sectional  
Peltzer et al 2013: Prevalence of post-traumatic stress symptoms and associated factors 
in tuberculosis (TB), TB retreatment and/or TB-HIV co-infected primary public health-care 
patients in three districts in South Africa. 
 
 
cross-sectional 
 
Peltzer et al 2012: Prevalence of psychological distress and associated factors in 
tuberculosis patients in public primary care clinics in South Africa. 
 
cross-sectional  
Rajeswari et al 2005: Perceptions of tuberculosis patients 
about their physical, mental and social well-being: A field report from south India. 
longitudinal  
Ralph et al 2013: High Morbidity during Treatment and Residual Pulmonary Disability in 
Pulmonary Tuberculosis: Under-Recognised Phenomena 
 
longitudinal  
Rowe et al 2005: Adherence to TB preventive therapy for HIV-positive patients in rural 
South Africa: implications for antiretroviral delivery in resource-poor settings? 
 
qualitative study 
taken&from&McInerny&et 
al&2007 
 
Van Rie et al 2008: Measuring stigma associated with tuberculosis and HIV/AIDS in 
southern Thailand: exploratory and confirmatory factor analyses of two new scales. 
cross-sectional  
Volmink and Garner 2007: Directly observed therapy for treating tuberculosis. Cochrane systematic review  
Weis and Pasipanodya 2010: Measuring health-related quality of life in tuberculosis: a 
systemic review--response. 
 
response  
WHO (World Health Organization) 2013: Global Tuberculosis Report 2013.  WHO report accessed&from&WHO website 
 
WHO (World Health Organization) 2012: South Africa Tuberculosis Profile.  WHO country profile accessed&from&WHO website 
WHO (World Health Organization) 2003: Adherence To Long-Term Therapies – Evidence 
for Action.  WHO report 
accessed&from&WHO 
website 
 
Yin et al 2012: Development and validation of a Tuberculosis Mediaction Adherence Scale 
cross-sectional, 
instrument development 
and validation 
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Quality of reporting check list for longitudinal studies 
 
Table 3: Quality of reporting of longitudinal studies in HRQOL and medication adherence in 
PTB according to STROBE Statement and Bauer et al (2013). 
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Table 4: Studies on HRQOL and medication adherence performed in South Africa. From 
all eligible articles included in the systematic review nine articles reported research performed 
on HRQOL and adherence in South Africa. 
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Supplementary material chapter 5 
Table 1: Studies included in the development of study design. 
 
 
 
Studies applying PRO instruments in TB 
 
 
Study Type 
 
 
Country 
 
 
Adeyeye et al 2014 (Adeyeye et al., 2014) 
 
 
cross-sectional 
 
 
Nigeria 
 
 
Aggarwal et al 2013 (Aggarwal et al., 2013) 
 
 
longitudinal 
 
 
India 
 
 
Atif et al 2014 (Atif et al., 2014b) 
 
 
cross-sectional 
 
 
Malaysia 
 
 
Atif et al 2014 (Atif et al., 2014a) 
 
 
longitudinal 
 
 
Malaysia 
 
 
Atif et al 2013 (Atif et al., 2013) 
 
 
cross-sectional 
 
 
Malaysia 
 
 
Awaisu et al 2012 (Awaisu et al., 2012) 
 
 
cross-sectional 
 
 
Malaysia 
 
 
Babikako et al 2010 (Babikako et al., 2010) 
 
 
cross-sectional 
 
 
Uganda 
 
 
Balgude et al 2012 (Balgude and Sontakke, 2012) 
 
 
longitudinal 
 
 
India 
 
 
Bauer et al 2013 (Bauer et al., 2013) 
 
 
systematic review 
 
 
NA 
 
 
Chamla 2004 (Chamla, 2004) 
 
 
longitudinal 
 
 
China 
 
 
Chung et al 2012 (Chung et al., 2012) 
 
 
longitudinal 
 
 
Taiwan 
 
 
Corless et al 2009 (Corless et al., 2009) 
 
 
cross-sectional 
 
 
South Africa 
 
 
Dhingra and Rajpal 2005 (Dhingra and Rajpal, 2005) 
 
 
longitudinal 
 
 
India 
 
 
Dhuria et al 2009 (Dhuria et al., 2009) 
 
 
longitudinal 
 
 
India 
 
 
Dion et al 2004 (Dion et al., 2004) 
 
 
cross-sectional 
 
 
Canada 
 
 
Dujaili et al 2015 (Dujaili et al., 2015) 
 
 
longitudinal 
 
 
Iraq 
 
 
Guo et al 2009 (Guo et al., 2009) 
 
 
systematic review 
 
 
NA 
 
 
Guo et al 2008 (Guo N, 2008) 
 
 
cross-sectional 
 
 
Canada 
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Husain et al 2008 (Husain MO, 2008) 
 
 
cross-sectional 
 
 
Pakistan 
 
 
Issa et al 2009 (Bauer et al., 2013) 
 
 
cross-sectional 
 
 
Nigeria 
 
 
Kittikraisak et al 2012 (Kittikraisak et al., 2012) 
 
 
cross-sectional 
 
 
Thailand 
 
 
Kruijshaar et al 2010 (Kruijshaar et al., 2010) 
 
 
longitudinal 
 
 
UK 
 
 
Louw et al 2012 (Louw et al., 2012) 
 
 
cross-sectional 
 
 
South Africa 
 
 
Maguire et al 2009 (Maguire et al., 2009) 
 
 
longitudinal 
 
 
Indonesia 
 
 
Mamani et al 2014 (Mamani et al., 2014) 
 
 
longitudinal 
 
 
Western Iran 
 
 
Marra et al 2008 (Marra et al., 2008) 
 
 
longitudinal 
 
 
Canada 
 
 
Masumoto et al 2014 (Masumoto et al., 2014) 
 
 
cross-sectional 
 
 
Philippines 
 
 
McInerney et al 2007  (McInerney et al., 2007) 
 
 
cross-sectional 
 
 
South Africa 
 
 
Muniyandi et al 2007 (Muniyandi et al., 2007) 
 
 
cross-sectional 
 
 
India 
 
 
Naidoo and Mwaba 2010 (Naidoo and Mwaba, 2010) 
 
 
qualitative 
 
 
South Africa 
 
 
Othman et al 2011 (Othman, 2011) 
 
 
cross-sectional 
 
 
Yemen 
 
 
Pasipanodya et al 2007 (Pasipanodya et al., 2007a) 
 
 
cross-sectional 
 
 
USA 
 
 
Pasipanodya et al 2007 B (Pasipanodya et al., 2007b) 
 
 
cross-sectional 
 
 
USA 
 
 
Peltzer et al 2013 (Peltzer et al., 2013) 
 
 
cross-sectional 
 
 
South Africa 
 
 
Peltzer et al 2012 (Peltzer K, 2012) 
 
 
cross-sectional 
 
 
South Africa 
 
 
Rajeswari et al 2005 (Rajeswari et al., 2005) 
 
 
longitudinal 
 
 
India 
 
 
Ralph et al 2013 (Ralph et al., 2013) 
 
 
longitudinal 
 
 
Indonesia 
 
 
Yin et al 2012 (Yin et al., 2012) 
 
 
cross-sectional 
 
 
China 
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Table 2: HRQOL measures identified and extracted from studies included. 
 
PRO measures applied in assessment of 
HRQOL 
Number of single 
studies identified 
Countries 
Short-Form-36 (SF-36) 18 Uganda,  Canada,  China, South 
  Africa,  UK,  India,  Western  Iran, 
  Malaysia, USA, India 
World Health Organization´s Quality of Life 5 India, Taiwan, Nigeria 
- BREF (WHOQOL-BREF)   
EuroQoL (EQ-5D) 4 Canada, UK, Thailand, Malaysia 
Beck Depression Inventory (BDI) 4 South Africa, Turkey, Canada 
Kessler-10 4 South Africa, Ethiopia 
St.  George´s  Respiratory  Questionnaire 4 USA, Indonesia 
(SGRQ)   
Standard Gamble (SG) 3 Canada, UK, Turkey 
Visual Analogue Scale (VAS) 3 Canada, Thailand 
General Health Questionnaire 12 (GHQ-12) 2 Turkey, Nigeria 
Mood  Adjective  Check  List  Short  Form 2 Sweden 
(MACL   
Severe Respiratory Insufficiency 2 Spain, Germany 
Questionnaire (SRI)   
SF-6D utility score 2 Canada 
Sickness Impact Profile (SIP) 2 Sweden 
State-Trait Anxiety Inventory Short Form 2 UK, Turkey 
(STAI-6)   
Center for Epidemiologic Studies 2 UK, USA 
Depression Scale (CES-D)   
Duke Health Profile (DUKE) 2 Colombia, Philippines 
DR-12 2 India, Yemen 
Hospital  Anxiety  and  Depression  Scale 1 Pakistan 
(HADS)   
Short-Form 12 (SF-12) 1 South Africa 
Beck  Depression  Inventory  (BDI)  Short 1 South Africa 
Form   
Brief Disability Questionnaire (BDQ) 1 Turkey 
Dysfunctional Analysis Questionnaire 1 India 
(DAQ)   
Health Utilities Index 2 (HUI 2) 1 Canada 
Health Utilities Index 3 (HUI 3) 1 Canada 
Life Satisfaction Index Z 1 China 
Mental Health Index (MHI-5) 1 USA 
Modified Version of SF-36 1 India 
Modified St. Georges Respiratory 1 Indonesia 
Questionnaire   
Present State Examination (PSE) 1 Nigeria 
Rosenberg Self-Esteem Scale (RSE) 1 South Africa 
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Self-Rating Anxiety Scale (SAS) 1 China 
Sheehan Disability Scale (SDS) 1 China 
Social Support Rating Scale (SSRS) 1 China 
Symptoms Check List (SCL-90) 1 China 
Voice Handicap Index-10 (VHI-10) 1 Turkey 
Quality of Life Questionnaire (QLQ) 1 Turkey 
Short-Form 8 (SF-8) 1 Philippines 
Medical Research Council (MRC) dyspnea 1 Philippines 
scale   
Primary Care PTSD screen 1 South Africa 
World Health Organization´s Quality of Life 1 Ethiopia 
- HIV (WHOQOL-HIV)   
The  Functional  Assessment  of  Chronic 1 Iraq 
Illness Therapy-Tuberculosis (FACIT-TB)   
Illness Perception Questionnaire (IPQ) 1 Pakistan 
Patient Health Questionnaire (PHQ-9) 1 Nigeria 
 
Table 3: Adherence measures identified and extracted from published studies included 
 
PRO measures applied in adherence Number of studies 
assessment 
Country 
Morisky Medication Adherence Scale 2 South Africa 
(MMAS)   
Perceived Nonadherence Scale (ACTG) 1 South Africa 
TB medication adherence scale (TBMAS) 1 China 
 
Table 4: presents 17 instruments for HRQOL assessment in the indications pulmonary, 
respiratory and psychological diseases and linguistically validated for English in South Africa, 
accessed from PROQOLID database. 
 
PRO HRQOL measures Pathology/Disease 
Baseline and Transition Dyspnea Indexes (BDI-TDI) Pulmonary Disease, Chronic Obstructive ,Respiratory 
 Tract Diseases 
Clinical COPD Questionnaire (CCQ) Pulmonary Disease, Chronic Obstructive ,Respiratory 
 Tract Diseases 
Chronic  Respiratory  Disease  Questionnaire  Self- Pulmonary Disease, Chronic Obstructive ,Respiratory 
Administered Standardized (CRQ-SAS) Tract Diseases 
Inhaled Corticosteroid Questionnaire (ICQ) Pulmonary Disease, Chronic Obstructive ,Respiratory 
 Tract Diseases 
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St George’s Respiratory Questionnaire (SGRQ) Pulmonary Disease, Chronic Obstructive ,Respiratory 
Tract Diseases 
Asthma Control Diary (ACD) Respiratory Tract Diseases 
Asthma Control Questionnaire (ACQ) Respiratory Tract Diseases 
Asthma Control Test (ACT) Respiratory Tract Diseases 
Asthma Quality of Life Questionnaire (AQLQ) Respiratory Tract Diseases 
Community-Acquired Pneumonia Symptom Respiratory Tract Diseases 
questionnaire (CAP-Sym)  
EORTC Quality of Life Questionnaire - Lung Cancer Respiratory Tract Diseases 
Module (EORTC-QLQ LC13)  
Geriatric Depression Scale (GDS) Psychiatry/Psychology 
Hospital Anxiety and Depression scale (HADS) Psychiatry/Psychology 
Inventory of Depressive Symptomatology (IDS-SR and Psychiatry/Psychology 
IDS-C)  
Montgomery-Asberg Depression Rating Scale Psychiatry/Psychology 
(MADRS)  
Quick   Inventory   of   Depressive   Symptomatology Psychiatry/Psychology 
(QIDS-SR and QIDS-C)  
Quality of Life in Depression Scale (QLDS) Psychiatry/Psychology 
 
Description of Selected HRQOL and Adherence PROMs 
 
The following section provides a description of the PROMs applied to evaluate HRQOL and 
medication adherence in TB. Information was derived from PROQOLID database 
(PROQOLID) for EQ-5D, SF-12v2, SGRQ and HADS and from the developer of MMAS 
Prof Morisky for the MMAS instrument. 
 
EQ-5D-5L (provided through EuroQol) 
 
EQ-5D (Euroqol) assesses health outcomes and is widely used as a utility index for estimating 
QALYs in cost-effectiveness studies. EQ-5D comprises 5 domains/items 
• Mobility 
• Self-care 
• Usual activities 
• Pain/discomfort 
• Anxiety/depression 
and one vertical visual analogue scale (VAS 20 cm). Each item allows five levels of severity of 
response ranging from ‘no problems’ to´ extreme problems’. Higher scores indicate better 
HRQOL. The VAS records the respondent’s self-rated health on a 20 cm vertical, 
visual analogue scale with endpoints labelled ‘the best health you can imagine’ and ‘the worst 
health you can imagine’. This information is used as quantitative measure of health as 
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judged by the individual respondents. Index-based values (utilities) are calculated from EQ-
5D-5L by deriving values from country-specific value sets. Such value-sets for EQ-5D-5L 
are currently under development. A crosswalk between the 5L and 3L of EQ-5D is 
available for 10 countries, including Zimbabwe as only African country. Value sets for 
South Africa are not available for any version of EQ-5D. The completion time for EQ-5D 
takes a few minutes. Reliability, validity and ability to detect change are approved 
(PROQOLID) A minimal important difference (MID) for EQ-5D-3L is approved with Mean 
MID = 0.074 (range -0.011 - 0.140) and MID = 7 for VAS scores (Walters, 2005). 
 
Short-Form 12 (SF-12) (Author Ware John E, provided through Quality Metrics) 
 
SF-12 is an abbreviated version of SF-36 containing 12 items over 8 domains: 
• Physical functioning (PF) with 2 items 
• Role physical (RP) with 2 items 
• Bodily pain (BP) with 1 item 
• General health (GH) with 1 item 
• Vitality (VT) with 1 item 
• Social functioning (SF) with 1 item 
• Role emotional (RE) with 2 items 
• Mental health (MH) with 2 items 
Domains can be aggregated into composite summary scores for physical and mental 
state, referred to as Physical Component Score (PCS-12) and Mental Component Sore 
(MCS-12). PCS-12 includes PF, RP, BP, and GH domains, MCS-12 include VT, SF, RE and 
MH domains. Scoring ranges from 0 to 100; greater scores represent better HRQOL. The 
completion time for SF-12v2 is 2 minutes. Reliability, validity and ability to detect 
change are approved (PROQOLID). A minimal important difference for SF-12v2 is not 
defined; however a minimum meaningful difference for SF-36 is mentioned as > 3 point 
change (Maruish, 2009). SF-36 and SF-12v2 are comparable in their outcomes and a 
minimum meaningful difference of > 3 points can be considered for SF-12v2 (Maruish ME, 
2009). 
 
 
 
St. George´s Respiratory Questionnaire (SGRQ) (Author Jones Paul W, 
provided through The St. George's University of London Medical School) 
A disease-specific instrument designed to assess patients with respiratory tract diseases and 
immune system diseases, especially asthma, pulmonary diseases, and chronic obstructive 
disease. SGRQ comprises 50 items over 3 domains (symptoms, activity, and impacts on daily 
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life) over two parts. Part I covers symptoms (several scales) and Part II covers activity and 
impacts on daily life (dichotomous true/false) except the last question (4-point Likert scale). 
The Symptom Component Score is calculated from questions 1-8, the Activity Component 
Score is calculated from questions 11 and 15, and the Impacts Component Score is calculated 
from questions 9-10, 12-14, and 16-17. Scores are scaled from 0 to 100, with higher 
scores indicating worse HRQOL. The completion time for SGRQ is 10 minutes. Reliability, 
validity and ability to detect change are approved (PROQOLID). A minimal important 
difference (MID) for SGRQ is defined as improvement of 4 points on the separate 
domains and the total score (Jones, 2005). 
 
 
 
Hospital Anxiety and Depression Scale (HADS) (Authors Snaith RP and 
Zigmond AS, provided through GL Assessment) 
HADS is an instrument applied in psychology/psychiatry to detect states of anxiety and 
depression.  HADS comprises 14 items over 2 dimensions 
• Anxiety with 7 items 
• Depression with 7 items 
Scores for each item range from 0 to 3, with higher scores indicating worse HRQOL (i.e. more 
anxiety and depression). The anxiety subscale scoring ranges from 0-21 (8-10 mild anxiety, 
11-14 moderate anxiety, 15-21 severe anxiety). The completion time for HADS is 2-5 minutes. 
Reliability, validity and ability to detect change are approved (PROQOLID). A minimal 
important difference (MID) for HADS has not been evaluated. A MID was observed for 
COPD with a value of 1.5 points corresponding to a change from baseline of 20% and 
informed by both anchor- and distribution-based methods (Puhan et al., 2008). 
 
 
 
Morisky Medication Adherence Scale (MMAS-8) (Author Morisky DE) 
 
MMAS-8 is being used in the assessment of self-reported medication  taking behaviour 
(Krousel-Wood, 2009, Morisky and DiMatteo, 2011, Morisky, 2008a). The scale is a generic 
measure assessing long-term chronic and infectious medical regimens, such as high blood 
pressure, diabetes, tuberculosis, HIV, elevated serum lipids, osteoporosis, immuno- 
suppressant medication. It is a reliable and valid indicator to assess self-reported medication- 
taking behaviour, including several levels of criterion related validity (blood pressure control, 
HgA1c) discriminant validity (social desirability) and persistence using pharmacy fills as a 
criterion. MMAS has a high sensitivity of 93% to identify low adherence and is a simple scale 
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to identify and monitor adherence (Morisky, 2008b). The MMAS-8 scale ranges from 0 to 
8.0; total scores are interpreted in the following way: 
• Low adherence <6.0 
• Medium adherence 6.0 – 8.0 
• High adherence =8.0 
 
Use of the ©MMAS is protected by US copyright laws. Permission for use is required. A license 
agreement is available from: Donald E. Morisky, ScD, ScM, MSPH, Professor, Department of 
Community Health Sciences, UCLA School of Public Health, 650 Charles E. Young Drive 
South, Los Angeles, CA 90095-1772. 
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Standard Operating Procedure (SOP) for application of 
questionnaires evaluating the health-related quality of life and 
medication adherence in pulmonary tuberculosis 
 
1. Purpose and Scope 
• The present SOP provides an overview of the procedures that take place 
during application of questionnaires evaluating the health-related quality of life 
(HRQOL) and medication adherence in patients newly diagnosed with pulmonary 
tuberculosis. The SOP refers to the research study entitled health-related quality of life 
and its association to medication adherence in pulmonary tuberculosis in South 
Africa – an integrated patient-centred outcomes approach (protocol version 
1.4/25.08.2014). 
• The applied questionnaires are objective means of collecting information about 
TB patient´s HRQOL and medication adherence behavior. In the present research 
study they are used as independent research instruments. 
• There are no strict reporting criteria for questionnaire;based research projects, when 
compared with the conduct of randomized trials. In order, therefore, to prevent 
methodological errors and to promote the collection of high quality data a 
process should be followed to ensure that questionnaire;based research and data 
collection is well;designed, well;managed, non;discriminatory and reduces potential 
bias, with a view to contributing to a generalizable evidence base. 
• This SOP is relevant for all research team members involved in the data 
collection process and application of questionnaires evaluating HRQOL and 
medication adherence in pulmonary TB patients. It is important that all study 
personnel fully understand and comply with this SOP. 
 
2. Definitions 
This section provides a short explanation of terminology used in this SOP. 
 
 
Terminology 
 
Explanation 
Face-to-face In-person administration of a questionnaire by a trained interviewer 
administration  
Health-related quality of life The value assigned to duration of life as modified by the impairments, 
 functional states, perceptions, and social opportunities that are influenced by 
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disease, injury, treatment, or policy. Measurement of health-related quality 
of life addresses the various dimensions of health and well-being 
Measure Questionnaires designed for use with a particular patient group 
Medication adherence Patient behaviour with regard to the prescribed interval, dose, and dosing 
 regimen as well as quality of how medication is taken and is expressed as 
 percentage of total number of doses taken or therapy days available 
Patient-reported outcome Any report of the status of a patient’s health condition that comes directly 
 from the patient, without interpretation of the patient’s response by a clinician 
 or anyone else 
Self-administered Respondents  read  and  answer  the  questions  by  themselves,  without 
 assistance. The respondent completes the questionnaire herself or himself 
 according to written or oral instructions 
 
3. Abbreviations 
 
 
HRQOL Health-related quality of 
life PRO patient-reported outcome 
TB Tuberculosis 
 
4. Roles and Responsibilities 
• This SOP applies to research team members of the present research study, who 
are involved in the data collection process including the application of 
questionnaires evaluating HRQOL and medication adherence 
• Research team members directly involved in the data collection process comprise: 
o Main researcher 
o Principal investigators (research supervisors) 
o Research assistant 
o Assisting field worker 
 
5. Data Protection and Confidentiality 
• The collection and processing of personal or sensitive data is governed by local law of 
South Africa 
• In the majority of cases where sensitive personal data are being collected, explicit 
consent is necessary. For consent to be explicit, individuals must have a full 
understanding of what their data will be used for and they must ‘opt in.’ A patient 
information and informed consent document is handed out to the patient and the 
informed  consent  has  to  be  signed  after  agreement  to  participate.  The  
patientinformation remains with the patient; the signed informed consent is collected 
and remains with the research team 
• Personally sensitive data include, but are not limited to, socio-demographic 
data, physical and mental health, social behaviour, and clinical data in the context to 
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anti-TB drug treatment monitoring 
• Personally sensitive data are protected by anonymization of each patient participating. 
A unique identifier code is assigned by the investigator to each study participant. This 
subject identification (SID) code protects the subject’s identity and confidentiality in the 
research file. SID is used in lieu of the subject’s name on all research documents 
that go to the sponsor or outside of the institution where the patient is treated 
• The subject identification (SID) code is additionally collected on a subject identification 
code list. The SID code list exists for each study site facility and comprises the 
SID code for each patient enrolled into the study at the specific study site and 
links the patient SID code to the medical record number of the patient at the clinic. 
Since one research team member is dedicated to one health facility, the SID code 
list per clinic remains with the respective research team member during the time of 
recruitment. After recruitment the SID code list is handed over to the main researcher. 
During recruitment the field worker has to show the SID code list to the main 
researcher or to the research assistant on a weekly basis. 
 
6. Questionnaires and Study Material 
The questionnaires applied in the present research study comprise 
• Four different HRQOL measures: 
o Short Form 12 (SF-12) 
o EuroQol 5 Dimensions (EQ-5D-5L) 
o St. George´s Respiratory Questionnaire (SGRQ) 
o Hospital Anxiety and Depression Scale (HADS) 
• One adherence medication measure: 
o Morisky Medication Adherence Scale 8 items (MMAS-8) 
• One questionnaire for assessing socio-demographic characteristics 
 
 
All questionnaires are PRO measures which are paper-based and self-administered, thereby 
providing subjective information from the patient directly. All questionnaires are closed which 
means each item is answered by ticking the most applicable predetermined answer. 
 
Further study material comprises 
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• Patient Information and Informed Consent 
• Subject Identification Code List 
• Monitoring Sheet 
 
The patient information is a document that explains the study research in a more 
common language. This document is designed for the patient to take it home for his or her 
reference. The informed consent is a one-pager available in English and Xhosa and has to 
be signed by the patient if he or she confirms to participate in the study. The informed 
consent has to be collected and handed over to the main researcher or principal 
investigator. The monitoring sheet is a one-pager assigned for each participating patient. 
This sheet is a constant part of the patient research folder and is used for every visit 
you interact with the patient. The monitoring sheet contains information about facility 
name and study site log number, patient code (SID code), patient study group, treatment 
start, expected follow-up visits (based on treatment start), and sputum smear results at all 
visits where questionnaires are applied. 
 
7. Procedures 
 
7.1 Eligible participants 
• The purpose of application of questionnaires is to evaluate the HRQOL and 
medication adherence of pulmonary TB patients during anti-TB treatment comprising 
four different antibiotic drugs over 6 month. 
• Patients eligible for the research study are older than 18 years, are newly diagnosed 
with pulmonary TB and will start standard drug treatment for their first time; and who 
have no HIV co-infection and no multi-drug resistant (MDR) TB. 
• Eligible patients belong either to a group of patients receiving complete treatment under 
supervision in the health clinic – thereafter called” clinic group”; or eligible patients 
belong to a group of patients receiving their treatment in their community and visiting 
the health clinic on predefined visits for diagnostic monitoring and drug collection 
– thereafter called “community group” 
• All eligible patients participating (clinic group and community group) fill out four different 
HRQOL questionnaires and one socio-demographic questionnaire at baseline (visit 0) 
• All eligible patients participating (clinic group and community group) fill out four different 
HRQOL questionnaires and one medication adherence questionnaire at visit 1 (after 
4 weeks of treatment), visit 2 (after 8 weeks of treatment and changing from intensive 
to continuous phase), visit 3 (after 16 weeks of treatment), and visit 4 (after 24 
weeks treatment and end of treatment). 
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7.2 Data collection process 
• Data collection comprises a time frame of 6 month of anti-TB drug treatment comprising 
four different antibiotics for each eligible participant, starting with treatment start, 
thereafter called baseline, and finalizing with end of treatment 
• Data are collected at five different time points (baseline, visits 1,2,3,4) for eligible 
participants from the clinic group and at a minimum of three different time 
points (baseline, visit 2, visit 4) from eligible participants from the community group 
• The five data collection points are defined as in the following table: 
 
 
Data Collection Time Point 
 
Description 
Visit 0 begin of treatment which is start of the intensive phase and baseline (BL) 
Visit 1 after 1 month of treatment and middle of the intensive phase 
Visit 2 after 2 month of treatment and switch from intensive to continuation phase 
Visit 3 after 4 month of treatment which is in the middle of the continuation phase 
Visit 4 after 6 month of treatment which is end of treatment (EOT) 
 
 
• At baseline socio-demographic characteristics are collected 
• At baseline and at visits 1, 2, 3, and 4 HRQOL data are collected 
• At visit 2 (change from intensive to continuous phase) and visit 4 (end of 
treatment) medication adherence data are collected 
• The  administration  of  all  questionnaires  for  data  collection  is  assigned  to  
pre- determined research team members 
 
Data collection at baseline has a time window of three days, meaning data can be 
collected within first three days of treatment start. All follow-up visits have a time window of 
one week. 
 
7.3 Data Collection and Questionnaire Administration 
Step-wise process at Baseline: 
 
Step 1: A nurse informs you via SMS or by calling that the clinic has identified an eligible 
patient; the nurse provides you with the date the respective patient is 
visiting the clinic. You have to be at the clinic at the same date. 
Step 2: A nurse refers you to the eligible patient. Before you talk to the patient, ask 
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the nurse to hand out a safety mask for you. You have to wear a safety 
mask all the time you talk to patients for your own health safety. 
 
Step 3: Introduce the study to the eligible patient by using the patient 
information document; mention that participants are receiving a token in form 
of a voucher from us  after completion of each  visit. After he or she has  
confirmed  to participate in the study, hand out the patient information to the 
patient for their reference. 
 
Step 4: Get the informed consent form signed by the patient and collect the 
informed consent for our reference. 
 
Step 5: Use the SID code list (a separate document) and write down a patient 
unique SID code; the SID coding for patients is linked to the study site log 
number. Study site log numbers are the following: 
 
Study Site Log Number Study Site Name 
1-HRQOLTB Khayelitsha Site B 
2-HRQOLTB Michael Mapongwana Hospital 
3-HRQOLTB Town 2 Clinic 
4-HRQOLTB Kuyasa Clinic 
5-HRQOLTB Matthew Goniwe Clinic 
6-HRQOLTB Nolungile Clinic 
 
The unique patient SID code is composed of the study site log number plus a 
consecutive numbering; the following is an example of a consecutive numbering for 
Khayelitsha site B: 
1-HRQOLTB_001 
1-HRQOLTB_002 
1-HRQOLTB_003 
 
 
Step 6: Use the SID code list to write down the medical record number of the 
patient which the study site has assigned to the patient in the TB registry 
book. 
 
Step 7: Use the monitoring sheet (a separate document) to write down 
• Facility name and study site log number 
• Patient code (SID code) 
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• Patient study group (clinic group or community group) 
• Date of treatment start 
• Confirm  if  participant  has  received  a  voucher  after  
questionnaire completion or not with YES or NO 
• Sputum smear result at baseline/treatment start 
Ask the nurse to provide you with the date of treatment start which is 
written down in the TB registry book and with the sputum smear result before 
treatment. 
 
Step 8: Start with the baseline interviews by applying the document “Questionnaires at 
baseline”. Apply the questionnaires to the patient while he or she is waiting 
for seeing the doctor and /or waiting for treatment/diagnostic results. 
 
The questionnaires are originally designed for self-administration and the 
patient should complete the questionnaires without the help of others (e.g. site 
staff, family, friends, etc.). If the patient is not illiterate the patient should 
has the choice of completing the questionnaires by their own. 
The only exception: if the patient is blind or illiterate the questionnaires may be 
read to the patient verbatim, but the reader must not aid in the interpretation 
of questions or in the selection of answers. 
All questionnaires should be completed before any other site activities, i.e. 
before seeing the physician, any tests or treatment, receive results of tests, etc. 
 
Step 9: Explain shortly the significance and relevance of the questionnaires to the participant; 
remind participants that we are asking them to complete these 
questionnaires because we are interested in hearing directly from them how 
they are doing; this will help motivate participants to comply with data 
collection. 
 
Step 10: If the patient self-completes the questionnaires make sure the patient 
understands how to fill out the questionnaires and make sure they can be 
completed in privacy. Inform the patient that the information is confidential. 
 
Step 11: The person responsible for questionnaires (assigned research team members) should 
retrieve the completed forms. Check that all questions have been answered 
and that only one answer is recorded for each question. 
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If a participant has questions or is unable to complete the questionnaires by himself/ herself: 
• Remind him/her there are no right or wrong answers 
• Remind him/her to choose the answer that most reflects what is true for them 
• Do NOT reword, interpret or paraphrase questions or response options 
• Do NOT  suggest answers  or  help  a patient select  an  answer  under 
any circumstances 
 
Step-wise process for follow-up visits: 
 
Step 1:  Use the monitoring sheet (a separate document) to write down: 
• Visit date according to clinic or community group 
• Confirm  if  participant  has  received  a  voucher  after  
questionnaire completion or not with YES or NO 
• Sputum smear result according to the visit date 
 
Step 2: Apply the questionnaires to the patient while he or she is waiting for seeing the doctor 
and /or waiting for treatment/diagnostic results. 
The questionnaires are originally designed for self-administration and the 
patient should complete the questionnaires without the help of others (e.g. site 
staff, family, friends, etc.). If the patient is not illiterate the patient should 
has the choice of completing the questionnaires by their own. 
The only exception: if the patient is blind or illiterate the questionnaires may be 
read to the patient verbatim, but the reader must not aid in the interpretation 
of questions or in the selection of answers. 
All questionnaires should be completed before any other site activities, i.e. 
before seeing the physician, any tests or treatment, receive results of tests, etc. 
 
Step 3: Explain shortly the significance and relevance of the questionnaires to the participant; 
remind participants that we are asking them to complete these 
questionnaires because we are interested in hearing directly from them how 
they are doing; this will help motivate participants to comply with data 
collection. 
 
Step 4: If the patient self-completes the questionnaires make sure the patient understands 
how to fill out the questionnaires and make sure they can be completed 
in privacy. Inform the patient that the information is confidential. 
Step 5: The person responsible for questionnaires (assigned research team members) should 
retrieve the completed forms. Check that all questions have been answered 
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and that only one answer is recorded for each question. 
If a participant has questions or is unable to complete the questionnaires by himself/ herself: 
• Remind him/her there are no right or wrong answers 
• Remind him/her to choose the answer that most reflects what is true for them 
• Do NOT reword, interpret or paraphrase questions or response options 
• Do NOT  suggest answers  or  help  a patient select  an  answer  under 
any circumstances 
 
7.4 Missing Data 
• Quickly review the completed questionnaires to look for missing or multiple 
responses to a question 
• Patients should be approached as quickly as possible if any responses are missing or 
are marked incorrectly and asked to complete all questions and/or clarify 
responses where more than one response has been given 
• PRO data cannot be queried at a later date 
• Missing  questionnaires  and  missing  questions  should  be minimized  as  much  
as possible 
• If there is much missing data we will not be able to meaningfully interpret the PRO data 
 
8. Related Documents 
• PhD proposal version 1.4/25.08.2014 
• Questionnaires version 1.2/15.08.2014 
• Patient Information and Informed Consent version 1.2/11.08.2014 
• Monitoring Sheet version 1.0/15.10.2014 
• Subject Identification Code List version 1.0/15.10.2014 
170  
Supplementary material to chapters 5, 6, and 7 
Patient-reported outcome (PRO) 
measures SF-12 
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EQ-5D-5L 
 
Under each heading, please tick the ONE box that best describes your health TODAY 
 
MOBILITY 
I have no problems in walking about ! 
I have slight problems in walking about ! 
I have moderate problems in walking about ! 
I have severe problems in walking about ! 
I am unable to walk about ! 
SELF-CARE 
I have no problems washing or dressing myself ! 
I have slight problems washing or dressing myself
 
! I have moderate problems washing or dressing myself
 
! I have severe problems washing or dressing myself
 
! 
I am unable to wash or dress myself ! 
USUAL ACTIVITIES (e.g. work, study, housework, 
family or leisure activities) 
I have no problems doing my usual activities ! 
I have slight problems doing my usual activities ! 
I have moderate problems doing my usual activities ! 
I have severe problems doing my usual activities ! 
I am unable to do my usual activities ! 
PAIN / DISCOMFORT 
I have no pain or discomfort ! 
I have slight pain or discomfort ! 
I have moderate pain or discomfort ! 
I have severe pain or discomfort ! 
I have extreme pain or discomfort ! 
ANXIETY / DEPRESSION 
I am not anxious or depressed ! 
I am slightly anxious or depressed ! 
I am moderately anxious or depressed ! 
I am severely anxious or depressed ! 
I am extremely anxious or depressed ! 
 
 
South Africa (English) © 2012 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group 
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• We would like to know how good or bad your health is TODAY. 
• This scale is numbered from 0 to 100. 
 
• 100 means the best health you can imagine. 0 means the worst health you can imagine. 
• Mark an X on the scale to indicate how your health is TODAY. 
• Now, please write the number you marked on the scale in the box below. 
 
The best health 
you can imagine 
100 
 
95 
 
90 
 
85 
 
80 
 
75 
 
70 
 
65 
 
60 
 
55 
 
50 
YOUR HEALTH TODAY  = 
45 
 
 
40 
 
35 
 
30 
 
25 
 
20 
 
15 
 
10 
 
5 
 
0 
 
The worst health 
you can imagine 
 
South Africa (English) © 2012 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group 
175  
St. George´s Respiratory Questionnaire (SGRQ) 
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178  
 
 
179  
 
 
180  
 
St. George's Respiratory Questionnaire 
 
 
 
 
 
 
 
 
 
 
 
 
 
South Africa I English version 6 
"'Past 3 months" version 
 
 
Here i.s a list of other ac6vities that your chest trouble may prevent you doing. (You do not have 
to tick (V) these, they areju.st toremind you of ways in which your breathlessness may affect 
you): 
 
Goingfor v1Slks or wsl}(ingthe dog 
Doing things at home or inthe garden 
Sexual infercoorse 
Goingout to ctiurch.pub,clubor place of entertainment 
Goingoutin bad weather or Wlto smoky rooms 
Visiting family or friends or playingwith children 
 
 
 
 
Please write down any other important acti'vities that yow chest trouble may stop you doing: 
 
 
 
 
 
 
 
 
 
Please tick {"') only one box which you think best describes how your chest affects you: 
 
It does not stop me doinganything Iwouldlike to do  D 
Itstops m-e doing oneor two things Iwouldlike to do    D   
If stops me doing most of the thingsI\YOuld ike to do    D  tt 
stops me doing everythingI\YOuld ike to do    D 
Thank you for completing this questionnaire. Before you finjsh Vl'OUld you please check tosee thatyou 
have answered all  the ques6cns. 
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Hospital Anxiety and Depression Scale (HADS) 
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Morisky Medication Adherence Scale (MMAS-8) 
 
You indicated that you are taking medication for your (identify health concern,  
such as “high blood pressure”). Individuals have identified several issues regarding 
their medication-taking behavior and we are interested in your experiences. There 
is no right or wrong answer. Please answer each question based on your personal 
experience with your [health concern] medication. 
(Please check your response below) 
 No=1 Yes=0 
1. Do you sometimes forget to take your tuberculosis pills?   
2. People sometimes miss taking their medications for reasons other 
than forgetting. Thinking over the past two weeks, were there any 
days when you did not take your tuberculosis medicine? 
  
3. Have you ever cut back or stopped taking your medication without 
telling your doctor, because you felt worse when you took it? 
  
4. When you travel or leave home, do you sometimes forget to bring 
along your tuberculosis medication? 
  
5. Did you take your tuberculosis medicine yesterday?   
6. When you feel like your tuberculosis is under control, do you 
sometimes stop taking your medicine? 
  
7. Taking medication everyday is a real inconvenience for some 
people. Do you ever feel hassled about sticking to your tuberculosis 
treatment plan? 
  
 
8. How often do you have difficulty remembering to take all your medications? 
(Please circle your response below) 
Never/Rarely…………………………………… ... 4 
Once in a 
while……………………………………3 
Sometimes……………………………………… ... 2 
Usually…………………………………………….1 
All the 
time………………………………………..0 
 
 
Coding Instructions for the ©Morisky Medication Adherence Scale (8-Item) 
 
You will need to reverse the code response in a positive direction for item number 5 and 
standardize the code for item 8 (0-4), resulting  in a scale from low adherence to 
high adherence. Item 8 is divided by 4 when calculating a summated score. This 
procedure standardizes the 5-point Likert scale. The total scale has a range of 0 to 8.0. The 
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eight-item compliance scale had an alpha reliability of 0.83 (n= 1367) among patients 
diagnosed with essential hypertension attending an outpatient clinic of a large teaching 
hospital.  We have used a 75% completion criterion for establishing eligibility. The median 
value of all missing items would be substituted for the missing item for individuals meeting 
the eligibility criterion. 
 
 
Re-codes:  
If Item5 = 0 Item5r = 1 (high adherence) 
If Item8=4 Item8r = 1 (highest adherence) 
If Item8=3 Item8r = .75 (high adherence) 
If Item8=2 Item8r = .50 (moderate adherence) 
If Item8=1 Item8r = .25 (low adherence) 
If Item8=0 Item8r = 0 (lowest adherence) 
Adherence Level Percent 
 
Low Adherence (< 6) 
 
32.1 
Medium Adherence (6 to <8) 52.0 
High Adherence (= 8) 15.9 
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Supplementary material chapter 6 
S1 Table. Changes in HRQOL in the intensive and continuous treatment phase. 
 
 
HRQOL Treatment Phase N (pairwise) Change in mean P value 
PCS-12 Intensive phase 83 11.785 < 0.05 
Continuous phase 65 7.991 < 0.05 
MCS-12 Intensive phase 83 17.708 < 0.05 
Continuous phase 67 6.644 < 0.05 
EQ-5D total index UK Intensive phase 84 0.365 < 0.05 
Continuous phase 67 0.152 < 0.05 
EQ-5D total index Zimbabwe Intensive phase 84 0.213 < 0.05 
Continuous phase 67 0.083 < 0.05 
EQ-5D VAS Intensive phase 85 24.482 < 0.05 
Continuous phase 69 18.681 < 0.05 
SGRQ Symptoms Intensive phase 80 26.602 < 0.05 
Continuous phase 68 11.505 0.002 
SGRQ Activities Intensive phase 84 46.481 < 0.05 
Continuous phase 69 9.442 0.527 
SGRQ Impacts Intensive phase 84 46.953 < 0.05 
Continuous phase 70 4.246 0.767 
SGRQ total score Intensive phase 81 32.070 < 0.05 
Continuous phase 68 14.546 0.487 
HADS Anxiety Intensive phase 85 7.600 < 0.05 
Continuous phase 68 3.82 < 0.05 
HADS Depression Intensive phase 85 7.071 < 0.05 
Continuous phase 68 4.779 < 0.05 
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S2 Table. Overall treatment time effect on HRQOL (test of within-subjects effects). 
 
Sensitivity  Analysis  baseline,  8  weeks  and  24 
weeks treatment 
HRQOL N  
P < 0.05 
Partial 
eta 
squared 
Observed 
power 
HRQOL N  
P < 0.05 
Partial 
eta 
squared 
Observed 
power 
PCS-12 26 <0.05 0.686 1.000 PCS-12 65 < 0.05 0.748 1.000 
MCS-12 27 <0.05 0.698 1.000 MCS-12 67 < 0.05 0.691 1.000 
EQ5D 
total 
index UK 
27 <0.05 0.619 1.000 EQ5D 
total 
index UK 
66 < 0.05 0.621 1.000 
EQ5D 
total 
index 
Zimbabw 
e 
27 <0.05 0.596 1.000 EQ5D 
total 
index 
Zimbabw 
e 
66 < 0.05 0.588 1.000 
EQ5D 
VAS 
28 <0.05 0.845 1.000 EQ5D 
VAS 
69 < 0.05 0.808 1.000 
SGRQ 
Symptom 
s 
23 <0.05 0.582 1.000 SGRQ 
Sympto 
ms 
65 < 0.05 0.425 1.000 
SGRQ 
Activities 
28 0.286 0.043 0.192 SGRQ 
Activities 
68 0.001 0.143 0.933 
SGRQ 
Impacts 
28 0.231 0.053 0.226 SGRQ 
Impacts 
69 0.002 0.126 0.887 
SGRQ 
total 
score 
24 0.494 0.030 0.157 SGRQ 
total 
score 
65 0.057 0.047 0.538 
HADS 
Anxiety 
27 <0.05 0.653 1.000 HADS 
Anxiety 
68 <0.05 0.664 1.000 
HADS 
Depressio 
n 
27 <0.05 0.604 1.000 HADS 
Depressi 
on 
68 <0.05 0.642 1.000 
Greenhouse-Geisser Test was applied as sphericity was not assumed (p < 0.05) 
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S3 Table. Effects of socio-demographic factors on overall HRQOL improvement. 
 
 
HRQOL Source Df F P value 
(*Sig < 
0.05) 
Partial eta 
squared 
PCS-12 PCS-12 x gender 1.000 1.047 0.309 0.012 
PCS-12 x Age Groups 1.000 0.082 0.775 0.001 
PCS-12 x Education 1.000 6.632 0.012* 0.074 
PCS-12 x Work Status 1.000 7.789 0.007* 0.086 
MCS-12 MCS-12 x gender 1.000 1.949 0.166 0.022 
MCS-12 x Age Groups 1.000 0.000 0.999 0.000 
MCS-12 x Education 1.000 0.880 0.351 0.010 
MCS-12 x Work Status 1.000 1.341 0.250 0.015 
EQ5D total index UK EQ5DindexUK x gender 1.000 0.484 0.488 0.006 
EQ5DindexUK x Age Grou ps 1.000 1.537 0.219 0.018 
EQ5DindexUK x Education 1.000 7.071 0.009* 0.078 
EQ5DindexUK x Work Stat us 1.000 7.799 0.006* 0.085 
EQ5D total 
Zimbabwe 
index EQ5DindexZim x gender 1.000 0.263 0.609 0.003 
EQ5DindexZim x Age Groups 1.000 1.696 0.196 0.020 
EQ5DindexZim x Education 1.000 6.821 0.011* 0.075 
EQ5DindexZim x Work Sta tus 1.000 7.438 0.008* 0.081 
EQ5D VAS EQ5D VAS x gender 1.000 0.190 0.664 0.002 
EQ5D VAS x Age Groups 1.000 1.467 0.229 0.017 
EQ5D VAS x Education 1.000 3.098 0.082 0.034 
EQ5D VAS x Work Status 1.000 1.878 0.174 0.021 
SGRQ Symptoms SGRQ Symptoms x gende r 1.000 0.217 0.642 0.003 
SGRQ Symptoms x Age G roups 1.000 3.325 0.072 0.038 
SGRQ Symptoms x Educa tion 1.000 0.004 0.950 0.000 
SGRQ Symptoms x Work Status 1.000 7.654 0.007* 0.083 
SGRQ Activities SGRQ Activities x gender 1.000 0.435 0.511 0.005 
SGRQ Activities x Age Gro ups 1.000 0.364 0.548 0.004 
SGRQ Activities x Education 1.000 1.929 0.169 0.022 
SGRQ Activities x Work St atus 1.000 0.202 0.655 0.002 
SGRQ Impacts SGRQ Impacts x gender 1.000 0.702 0.404 0.008 
SGRQ Impacts x Age Grou ps 1.000 0.462 0.498 0.005 
SGRQ Impacts x Education 1.000 1.889 0.173 0.021 
SGRQ Impacts x Work Sta tus 1.000 0.638 0.427 0.007 
SGRQ total score SGRQ total score x gender 1.000 0.669 0.416 0.008 
SGRQ total score x Age Gr oups 1.000 0.461 0.499 0.006 
SGRQ total score x Educat ion 1.000 2.271 0.136 0.027 
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 SGRQ total score x Work Status 1.000 0.280 0.598 0.003 
HADS Anxiety HADS Anxiety x gender 1.000 0.470 0.495 0.006 
HADS Anxiety x Age Groups 1.000 1.396 0.241 0.016 
HADS Anxiety x Education 1.000 3.881 0.052 0.044 
HADS Anxiety x Work Status 1.000 0.794 0.375 0.009 
HADS Depression HADS Depression x gender 1.000 0.302 0.584 0.004 
HADS Depression x Age Groups 1.000 3.499 0.065 0.040 
HADS Depression x Education 1.000 2.377 0.127 0.027 
HADS Depression x Work Status 1.000 0.321 0.572 0.004 
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